The role of the NFKB signalling pathway in the inflamed intestine by Jones, Edward Roland
    
 
  
 
Title The role of the NFқB signaling pathway in 
the inflamed intestine 
Name  Edward R. Jones 
 
 
 
 
 
 
This is a digitised version of a dissertation submitted to the University of 
Bedfordshire.  
It is available to view only.  
This item is subject to copyright. 
 
 
 
 
 
 
 
 
-

The role of the NFKB Signalling Pathway in the Inflamed 
Intestine 
By 
Edward Rowland Jones BSc 
A Thesis submitted to the University of Luton 
for the degree of Doctor of Philosophy 
Department of Sports Exercise and Biomedical Sciences, 

Faculty of Health and Social Science, The University of Luton 

Park Square, Luton 

Bedfordshire, LV 1 3JU 

July 2002 
PARK SQ. LI3RA.RY 
UNIVERSITY OF 
LurON 
I 
g;a 
Abstract 
The nuclear factor kappa B (NFKB) signalling pathway is essential in the 
establishment and propagation of inflammation in the intestine. An increased number 
of cells, predominantly of the macrophage and intestinal epithelial cell (IEC) type, 
are known to contain the active form of the NF1d3-p65 subunit in inflamed and non­
inflamed intestinal tissue from Crahn's disease (CD) patients, though this remains to 
be confirmed. However the stimuli that induce NFKB activation in IECs and the 
mechanism of NFKB activation in macrophages, are only poorly understood. As 
such, this thesis has investigated the NFKB signalling pathway and its role in 
intestinal inflammation. 
Increased levels of NFKB DNA-binding activity and inhibitor kappa B alpha (IKBa) 
protein levels were found in both inflamed and non-inflamed intestinal tissue from 
CD patients. However, Bcl-3 levels did not significantly change. 
In HeLa Ohio cells, a human mucosal epithelial cell line, interleukin-l ~ (IL-l ~), 
lipopolysaccharide (LPS) and Phorbol 12-myritate I3-acetate (PMA) were shown to 
induce NFKB activation. However, when these same stimuli were used in another 
human IEC line, Caco-2, little NFKB-mediated gene expression was observed unless 
a combination of stimuli, IL-l~, LPS and tumour necrosis factor alpha (TNFa), was 
used. In RAW 264.7 cells, a murine macrophage cell line, LPS-stimulated NFKB­
mediated NO production was shown to involve protein kinase C epsilon (PKCc). 
Subsequently, PKC€ protein levels were also shown to be up-regulated in inflamed 
intestinal tissue from TNBS-treated rats. This was associated with increased NFlcB 
activation and IKBa protein levels, increases that were absent in non~inflamed tissue 
11 
from TNBS-treated rats. In addition, IKB~ and Bcl-3 protein levels did not differ 
between inflamed and non-inflamed tissues, although they did vary with intestinal 
region. 
In conclusion, this study shows that abnormal NFKB activation and IKBa expression 
occurs in CD, and also suggests increased NFKB activation IKBa expression can co­
exist within inflamed intestinal tissue. In addition, the IEC line Caco-2 is shown to 
be relatively unresponsive to NFKB activation. In the macrophage cell line, RAW 
264.7, PKC£ is involved in NFKB-mediated gene expression, and PKC£ protein 
levels are increased in the inflamed, TNBS-treated, intestine. 
-
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Chapter 1 
1.1 The Alimentary Canal 
1. 1.1 Gross structure and function. 
Humans require continued nourishment for their existence. To this end a highly 
specialised system for the assimilation of energy and materials essential for life 
has evolved known as the alimentary canal (Allison et al., 1998). This is 
essentially a tube that nms from the mouth to the anus (Fig 1.1) forming a 
continuous interface between the external environment and the bodies circulatory 
system. It has a basic structure (Fig 1.2) that varies only minimally along its 
length. 
oral cavity 
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duodenum 
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Figure 1.1 The Alimentary Canal 
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Figure 1.2 Representation of the alimentary canal wall. 
The Small Intestine 
The small intestine is the region of the alimentary canal in which the majority of 
digestion and absorption occurs. It is -3m long in vivo with a diameter of 4 cm 
and is arbitrarily divided into 3 parts, the duodenum, the jejunum and the ileum 
(Allison et ai., 1998). 
The small intestine accomplishes the majority of absorption that occurs in the gut. 
Roughly 90% of total ingested water is absorbed by the small intestine and the 
majority of the fat content of a meal is also absorbed here. To fulfil this function 
the small intestine has a highly adapted structure. Its mucosa has a huge surface 
area estimated at 700m2 that is derived from folding that causes the luminal 
surface to appear wrinkled. The mucosa has many finger like projections 
protruding from it named villi. These villi range in height from 0.5-0.8 mm and 
are found throughout the small intestine and into the upper part of the large 
intestine. These protrusions are structurally supported by the lamina propria and 
contain a high density of both blood capillaries and lacteais, vessels of the 
lymphatic system that are responsible for the transport of the majority of absorbed 
fluids and lipids from the small intestine. 
Whilst the small intestine primarily has an absorptive function, under certain 
conditions, such as inflammation, this function becomes inverted. For example, 
the presence of a bacterial toxin in the small intestine can cause large amounts of 
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isotonic liquid to be secreted so that the contents of the bowel are flushed out, 
causing diarrhoea. 
The Large Intestine 
The large intestine begins at the ileocecal junction and includes the caecum (and 
its appendix), the ascending colon, transcending colon, descending colon, sigmoid 
colon, rectum and anal passage. Although it is named the large intestine it is in 
fact only 125cm long in vivo and its width decreases from 8.5cm in diameter at 
the proximal, caecal end, to 2.5cm in the sigmoid colon (Allison et al., 1998). 
Of the 1.5 litres of water and electrolytes that escape the small intestine each day, 
upwards of 95% are absorbed by the large intestine. Also, the residual food 
elements and dietary fibre that still remain in the chyme, are converted by the 
endogenous microflora of the large intestine into substances of calorific value 
such as small chain fatty acids e.g. butyrate. These short chain fatty acids are then 
utilised by the colonic epithelial cells as a principal source of energy. These 
microflora also produce the essential vitamins K, biotin, and folic acid. Very little 
digestion is accomplished by the large intestine itself. 
1. 1.2 Cellular structure and function 
The wall of the alimentary canal has the same basic structure throughout. It 
consists of 4 major regions, serosa, muscularis externa, submucosa and mucosa 
(Fig 1.2). The serosa is the outer most layer and consists of a simple squamous 
epithelium (mesothelium) that rests on connective tissue (Allison et al., 1998). 
Within the serosa the muscularis extern a can be found. This has two further 
subdivisions, the circular and longitudinal muscle layers. These both consist of 
smooth muscle with the only difference being the orientation of the muscle fibres. 
The two opposed muscle layers are separated by a connective tissue septum, 
which contains the myenteric plexus and parasympathetic ganglion cells thereby 
coupling the electrical activity of the two layers. 
The next layer is the submucosa, which is a layer of loose connective tissue 
containing larger blood vessels, lymphatics, ganglion cells, and nerve fibres of the 
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myenteric plexus. On the luminal side of the submucosa, the mucosa can be 
found. The mucosa can be subdivided into two further classifications, the lamina 
propria and the epithelium. 
The lamina propria consists mainly of connective tissue, which provides support 
for the epithelial lining allowing the formation of both the crypts and the villi. 
Extracellular connective tissue is present including collagen and elastic fibres. The 
most prevalent cell types to be found here in normal humans are lymphocytes, 
plasma cells and macrophages indicating an important immunological role for the 
lamina propria. In addition, eosinophiis, mast cells, fibroblasts, small 
unmyelinated nerve celis, blood and lymph vessels are all present in the lamina 
propria. The basal surface of the epithelial cells rests immediately on the blood 
and lymph vessels that transport the absorbed nutrients away to other regions of 
the body. The endothelial cells of these blood vessels (but not the lymphatics) are 
specially adapted to this purpose having fenestrations (pores) which are orientated 
toward the epithelium, substantially increasing the permeability of the endothelial 
cell wall. 
The epithelium is separated from the lamina propria by a basement membrane 
consisting of a thin basal lamina and a deeper layer of reticular fibres and 
glycoprotein connective tissue. It is punctuated by gaps that allow the passage of 
macromolecules as well as diapedising leukocytes. 
The epithelium itself is only one cell thick and contains a variety of highly 
specialised cell types. These cell types include absorptive cells, undifferentiated 
crypt cells, goblet cells, paneth celis, M cells, and caveloated cells. Since this is 
the site at which the majority of damage to the luminal wall is accrued, a 
mechanism of rapid cell turnover operates to minimise the presence of damaged 
cells. As such, epithelial cells of the alimentary canal have an average life of only 
4-7 days after which time they slough off into the lumen to be digested or 
excreted. Breakdown of the intestinal epithelia barrier can allow the pro­
ini1ammatory contents of the lumen into the lamina propria (Jones et al., 1995; 
Jobin and Sartor, 2000). The intestinal epithelium therefore, has a pivotal role in 
inflammatory responses in the intestine. 
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1.2 Inflammation 
An immune response manifests itself in a state of inflammation and occurs in 
response to infection, antigen challenge, or physical damage. The cardinal signs of 
redness, swelling, heat, immobilisation and pain define an inflammatory response 
and are the result of the underlying mechanisms of the immune response involved 
i.e. the attraction of leukocytes and soluble mediators of immunity to the 
inflammatory site. The function of this immune response is to remove the causes 
of the inflammation along with any damaged tissue thereby allowing the healing 
process to begin. 
Once an inflammatory stimulus is present, the cells exposed quickly begin to 
secrete inflammatory mediators that propagate three main events. Firstly, 
vasoactive compounds e.g. histamine, 5-hydroxytryptamine (5HT-serotonin), and 
platelet activating factor (PAF), increase the blood supply to the area, aiding an 
accuIl1:ulation of immune components at the site. Secondly, these same vasoactive 
compounds stimulate the retraction of endothelial cells thereby increasing 
capillary permeability. This permits the penetration of large serum proteins e.g. 
proenzymes and antibodies, into the tissues at the site of inflammation. Thirdly, 
chemotactic agents e.g. neutrophil chemotactic factor (NCF), macrophage 
inflammatory protein 1 ~ (MIP-l ~), and interferon-inducible protein 10 (IP-lO) 
promote the inundation of the area by leukocytes, initially with neutrophils and 
later monocytes and lymphocytes (Sinigaglia and Ambrosio, 2000). 
The newly arrived leukocytes clear the damaged tissue and inflammatory stimuli 
(e.g. an infectious or noxious agent), and for this they possess a number of 
specialised functions. Neutrophils are phagocytic and envelop their targets for 
digestion by an array of enzymes e.g. proteases, lipases, acid hydrolases, and 
super oxide dismutase. Neutrophils also secrete pro-inflammatory molecules, 
particularly cytokines, which help propagate the inflammation. 
Monocytes, attracted by the secretions of the neutrophils, become stimulated by 
interferon-y OFN-y) at the site of inflammation and mature into macrophages. 
These macrophages, like neutrophils, are phagocytic and also have the ability to 
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present their ingested antigens in combination with the major histocompatibility 
complex II (MHC II). This complex is then used by T lymphocytes for immune 
surveillance since most T cells are unable to detect antigen unless it is presented 
to them in complex with MHC II. Macrophages can also produce large amounts of 
the pro-inflammatory cytokines interleukin-l (IL-l; Dinarello, 1996) and tumour 
necrosis factor-a (TNF-a; Schreiber, 1998) that are pivotal in propagating the 
inflammatory response. 
Lymphocytes are the last major cell type to arrive at a site of inflammation but are 
potentially the most effective/specific. There is a short (approximately two days) 
lag between the initiation of an inflammatory response and the point at which 
lymphocyte activity becomes efficacious since lymphocytes must adapt to the 
antigens that are present (Janeway et aI., 1999). 
Lymphocytes can be subdivided into three groups, T helper (T H) ceUs, T cytotoxic 
lymphocytes (CTLs) and B cells. B cells produce antibodies, which are 
glycoproteins that can specificaUy bind an antigen. Antibody binding can lead to 
the immobilisation of the antigen, and or its opsonisation, marking it for 
destruction by one of the phagocytic cells or through the complement cascade. T H 
cells, on the other hand, orchestrate the immune response through their production 
of cytokines that modulate the activities of other cells, whilst, CTLs destroy the 
body's own cells, either when they are damaged, or infected (e.g. virally). 
If the cause of inflammation persists, lasting over weeks, months, or even years, a 
state of chronic inflammation develops. Here the inflammatory response may be 
directed towards auto-antigens, commensal organisms, or cryptic infections. This 
can lead to the establishment of prolonged inflammation since these antigen 
sources are not easily removed. Such inappropriate inflammatory responses cause 
serious tissue damage leading to pain and discomfort, and are characteristic of 
diseases such as Crohn's disease (CD), rheumatoid arthritis eRA), asthma, and 
multiple sclerosis (MS; Janeway et ai., 1999). 
Activation of the immune system during an inflammatory response, a 
circumstance common throughout life, leads to the activation and proliferation of 
leukocytes. However, the immune system remains at a relatively constant size 
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throughout life. This is in part due to the limited life span (approximately 10 days) 
of the majority of leukocytes, and in part to two active mechanisms that limit 
leukocyte numbers and activity. These mechanisms are FaslFasL induced 
apoptosis, known as activation induced cell death (AICD), and cytokine 
deprivation induced cell death. AICD not only restricts lymphocyte proliferation 
upon exposure to massive antigen levels during periods of intense host infection, 
but also suppresses self-reactive lymphocytes and hence, is involved in the 
maintenance of peripheral tolerance. 
The drawback with AICD is that it is dependent upon T cell TCR binding, an 
occurrence less frequent after the resolution of an inflammatory response. Thus, 
the mechanism of cytokine deprivation induced cell death exists to reduce 
lymphocyte cell numbers after the resolution of inflammation. Lymphocytes are 
dependent on the presence of cytokines (e.g. IL-2, IL-4, IL-7, and IL-15) to 
maintain their survival through the up-regUlation of anti-apoptotic proteins such as 
Bcl-2 (Akbar et aI., 1997). When an inflammatory response resolves, the 
expression of these cytokines is down-regulated leading to the apoptosis of these 
lymphocytes. 
1.2.1 Gut Associated lymphoid tissue (GAL T) 
Under the heading of mucosal associated lymphoid tissue (MALT), which 
includes the urogenitary tract, airways and alimentary canal, comes the sub­
grouping of gut associated lymphoid tissue (GALT). GALT includes any 
organised lymphoid tissue in the gut, which ranges from intra-epithelial 
lymphocytes and lamina propria leukocytes to Peyer's patches (Kagnoff, 1981). 
The key role that GALT plays in the adult immune system is demonstrated by its 
status as the major lymphopoietic organ in adults (Allison et al., 1998). In fact it 
may even be a source of T cells as thymic function declines with age. The GALT 
is also the primary site from which effector cells disperse to the other MALT 
regions (Dunkley et at., 1995). One implication of this is that tolerance acquired 
to an oral antigen can be transferred from the gut to the rest of the MALT e.g. the 
lung. 
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The GALT is therefore key in the establishment and maintenance of oral 
tolerance, a state of immune anergy or active suppression (Janeway et al., 1999; 
Male et ai., 1996). A facet of this role is the high rate of apoptosis that occurs in 
the GALT, which is involved in the screening of auto-reactive! hyper-reactive 
lymphocytes. 
The full repertoire of leukocyte cell types may be found at GALT sites. However, 
the relative proportions of these cell types may differ from other MALT sites 
reflecting the unique demands posed in the GALT compared to other areas of the 
body. For example, lymphocytes found in the mucosal layer of the GALT are 
predominantly CD8+ cytotoxic cells whilst CD4 helper T cells are more dominant 
in the submucosa. Also, up to 60% of the T cells in the intestine are of the y'6 type 
compared to 20% at other sites in the body (Male et ai., 1996). These yoT cells are 
activated rapidly in response to immunogenic substances due to their ability to 
recognise soluble antigen (Janeway et aI, 1999). 
An important facet of GALT lymphocyte population is the high number of plasma 
cells present and the resulting high antibody production capability. In fact, 
antibody secretion is a continuous process in the GALT with 5-15g of secretory 
immunoglobulin A (sIgA) being secreted each day. Production of IgB, which is 
involved in immediate hypersensitivity reactions that are necessary for anti­
parasitic defence, is also proportionally higher in the GALT than the rest of the 
body demonstrating the increased risk of parasitic attack posed at the GALT 
surfaces. 
The GALT also contains Intra-epithelial lymphocytes (IELs) and, as their name 
suggests, these lymphocytes are found between epithelial cells in the gut mucosal 
wall. IELs are present at a ratio of roughly 1:7 with enterocytes. The majority of 
IELs are CD8+ y'6CTLs although other T cell types, B cells and NK cells may also 
be IELs (Kagnoff, 1981). Whilst IELs are not directly exposed to the luminal 
contents due to their positioning behind the tight junction complex of adjacent 
epithelial cells, they are exposed and can respond to unprocessed soluble antigen, 
an important functional distinction from their lymphocyte relative, the a.8T cells. 
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Lymphocytes are not only found interspersed in the epithelium, but they are also 
found in non-encapsulated lymphoid aggregates in the lamina propria. The 
presence of these aggregates represents a simple illustration of the need for the 
close proximity of lymphocytes for effective immune functioning i.e. during TH 
cell stimulation of CTLs. 
Another example of the need for lymphocytes to be clustered can be found in 
Peyer's patches (PP's) the function of which is the immune sampling of the 
luminal contents. PP's were first observed by Konrad Peyer more then 300 years 
ago and are the major lymphoid structure of the small intestine (Kagnoff, 1981). 
Located in the mucosa they are most predominant in the ileum becoming sparser 
toward the appendix. 
Contained within PP's are roughly equal numbers of Band CD4+ T lymphocytes 
along with a smaller number of macrophages (CD68+) (Farstad et at., 1994). 
Within the PP epithelium are a variable number of M cells, named after their 
characteristic shape, which phagocytose antigens from the intestinal lumen 
(Owen, 1999), and partially process them (Allan et al., 1993) before presenting 
them to the leukocytes underneath (Pringault, 1999). Peyer's patches are 
increasingly believed to play an important role in the maintenance of oral 
tolerance and immunity, and as such, have a key role in the immune system of the 
intestine. 
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1.3 Inflammatory Bowel Disease 
1.3.1 Grohn's Disease 
Crohn's disease (CD) is an Inflammatory Bowel Disease (IBD), the world-wide 
incidence rate for which is roughly 6 per lOs population (Parkes et ai., 1997). This 
rate has been steadily rising over the past half century (Hugot et al., 1999) 
although the reasons for this increase remain unknown. 
The symptoms of CD range from diarrhoea and abdominal pain to severe 
ulceration, bleeding, highly impaired nutrient uptake, and in the worst cases, 
death. These symptoms are caused by a chronic inflammatory response that is 
either inappropriately initiated or prolonged (Fiocchi, 1999) a theory supported by 
the partial success of glucocorticoids, which are known immuno-suppressants, in 
the treatment of IBD. As yet treatment for CD is ineffective and targeted toward 
the suppression of the chronic inflammatory symptoms whilst neither prevention 
nor cure is possible as the aetiology of CD remains unknown. 
Inflammatory processes in CD result in the formation of ulcerations, primarily in 
the terminal ileum and proximal colon and lessening toward the rectum, though 
these ulcerations may occur anywhere along the alimentary canal (Crohn et ai., 
1932). Typically, inflammation in CD involves the entire thickness of the bowel 
wall (transmural) and is of a chronic type that is patchy and discontinuous in 
nature. A paving stone pattern is often created through the alternation of necrosis, 
fissures, ulcers, apthoid lesions, fistula, granuloma and intact mucosal areas 
(Schreiber, 2000). This can lead to a distortion in the circumferal shape of the 
bowel which, in severe cases, can lead to the development of pseudodiverticula 
(an out pushing of the intestinal tissue) that can obstruct the intestine. 
Most patients with CD will experience a periodic flaring of the symptoms, which 
can be controlled by medications, and the patient brought into remission. Such 
medications include salicylate preparations, antidiarrheal and antispasmodics, 
corticosteroids, antibiotics, and immuno-suppressants e.g. 6-mercaptopurine (6­
MP; Korelitz and Present, 1985), however none of these medications are able to 
maintain remission. 
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Dietary changes and supplements are also recommended (Powell et ai., 1999) and 
include decreasing fibre intake, or switching to a liquid diet or intravenous 
nutrition. Patients with advanced disease causing persistent bowel obstruction, 
abscess, and fistulae may require surgery involving the removal of large sections 
of the intestine. The base of the ileum may then be attached either directly to the 
rectum (lleoanal anastomosis) or to a pouch located externally that collects 
draining waste (Protocolectomy). 
In CD, Gill obvious T helper cell 1 (THI) phenotype exists with increased IL-12 
(Parronchi et al., 1997) and IFNI' levels as well as decreased IL-4 and IL-5 levels 
(Fuss et at., 1996). 
1.3.2 Ulcerative Colitis 
Ulcerative colitis (UC) differs from CD in a number of ways. It usually begins in 
the rectum, spreads to the large bowel and terminates at Bauhins valve, rarely 
effecting the small intestine. Like CD a chronic inflammation occurs however, 
only the luminal surface of the intestinal wall is involved with inflammation rarely 
penetrating past the submucosal level. Also, the T H profile of UC is less clear with 
lamina propria T cells being found to secrete increased amounts of IL-5 with 
decreased IL-4 and normal IL-2 and IFN-y levels (Fuss et aI., 1996). 
The chronic inflammation which occurs in DC results in the death and subsequent 
loss of the intestinal epithelial layer allowing ulcers to form that cause the 
appearance of contact bleeding. Also, the transition from inflamed to normal 
mucosa is continuous and takes place at the microscope level. Severe UC also has 
an associated increased risk of cancer, due in part to damage caused by the severe 
chronic inflammation and also the aberrations in glycoconjugate sulphation that 
have been observed in the disease. 
Treatment for UC is, like CD, limited. The major medication type administered is 
Sulfasalazine whilst those patients that do not react well to this drug are treated 
with 5-ASA (both are anti-inflammatory). In severe cases patients are given 
corticosteriods that are more potent anti-inflammatory drugs e.g. predenisone, or 
hydrocortisone, and if this fails surgery is carried out (a treatment required in 
approximately 25% of patients). 
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1.3.3 History of IBD 
In considering the aetiology of IBD, modern causes are often cited due to the 
seminal papers of erohn et al., (1932) and Wilks & Moxon (1875) which are 
relatively recent. However, in reality, possible descriptions of IBD can be found 
as far back as Greek literature indicating that an aspect of modern living need not 
be the sole cause of IBD. 
In 640BC the aptly named Soranus of Ephesus described a bloody flux 
reminiscent of Ulcerative colitis. Similar symptoms were also described by 
Hippocrates of Cos (460-377BC) and later by Aretaeus of Cappadocia (170AD). 
Untreated, there was a high mortality rate associated with these symptoms. 
In the 17th century Louis XIII's personal physician described a non-specific 
enteritis upon post mortem of a 34 year old man (Bernier et al., 1981). He 
recorded inflamed and ulcerated terminal ileum and colon with enlarged 
mesenteric lymph nodes making CD the likely cause of death. More famously 
Mozart who lived from 1770-1827, is believed to have been a sufferer of CD as he 
exhibited certain telltale symptoms including diarrhoea, dehydration, prostration, 
anorexia and abdominal colic (Kubba and Young, 1996). 
In 1859 a Dr Smethurst was found guilty of the murder of his mistress Isabella 
Banks by the administration of unknown poison! Sir Samuel Wilks expressed his 
opinion in court, that the ulcerated bowel of Miss Banks was caused by an 
abortifacient supposedly administered by Dr Smethurst. The autopsy report was as 
follows: "The intestines lay in a coil adherent by a thin layer of lymph indicative 
of recent inflammation; the ileum was inflamed for three feet from the ileocaecal 
valve though otherwise the small intestine looked normal. The large intestine was 
ulcerated from end to end. Tuberculosis was excluded". Dr Smethurst would have 
been hung if it weren't for the intervention of Sir Benjamin Brodie, Surgeon to St 
George's Hospital, whom informed the home secretary that there was not 
"absolute and complete evidence of guilt". Dr Smethurst, now saved from the 
noose, could have been the first person hung as a result of mistaken belief that he 
was the cause CD! 
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1.3.4 Evidence for abnormalities In non-inflamed regions of the CD 
intestine 
Whilst the majority of work completed on CD has focused on the inflamed areas, 
abnormalities also exist in the non-inflamed regions of intestine in CD sufferers. 
A number of lines of evidence point towards a heightened immune activation in 
CD with macroscopically non-inflamed regions of mucosa characterised by 
evidence of granulomas and granulomatous vasculitis (Wakefield et ai., 1991). 
Increased levels of proinflammatory cytokines are also present (Reimund et at., 
1996). Furthermore, whilst epithelial cells in the normal intestine are able to 
selectively stimulate CD8+ suppressor T cells through their MHC II HLA-DR 
expression, in histologically inflamed and non-inflamed CD tissue CD4+ T cells 
are stimulated instead (Mayer and Eisenhardt, 1990). Evidence also exists for a 
universal skew in T cell receptor subunits that may indicate the presence of a 
superantigen in CD (Ogawa et al., 1997). The non-inflamed CD intestine also 
displays an increased capacity for reactive oxygen species (ROI) production and 
protein carbonyls (Lih-Brody et ai., 1996), and increased expression of vasoactive 
intestinal polypeptide (VIP) occurs within nerves of the inflamed and non­
inflamed mucosa (Bishop et al., 1980). 
Increased intestinal permeability to ovalbumin has also been observed in non­
inflamed regions of the intestine in CD patients (Soderholm et aI., 1999). The 
increased intestinal permeability that this result implies would likely lead to a 
higher antigenic load in the mucosa causing immune activation (Hollander, 1999). 
Abnormal intestinal permeability has also been reported in relatives of CD 
patients (Hollander et al., 1986 & May et al., 1993) strongly suggesting a genetic 
component to the disease. 
1.3.5 The genetics of CD 
The cause of many of these abnormalities may lie in a genetic susceptibility and 
various lines of evidence point towards the role for genetics in the aetiology of 
CD. In Ashkenazi Jews there is a two to four fold increase in the prevalence of 
CD, whilst in Afro-Caribbeans this rate is decreased (McConnell and Vadheirm, 
1992). Also, relatives of patients with CD are at increased risk of developing CD 
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(Probert et ai., 1993 & Satsangi et aI., 1994) whilst in monozygotic twins, 
prevalence is 10 fold higher as compared to dizygotes (Tysk, et ai., 1998). Indeed, 
the inheritance of CD has been calculated to be higher than that of schizophrenia 
or asthma and roughly equivalent to that of insulin-dependent diabetes mellitus 
(Parkes et aI., 1997). To date a number if genetic linkage sites have been 
identified with CD and these include the various candidate genes (Table 1.1) for 
lED (Parkes et al., 1997). 
Table 1.1 Candidate genes linked with IBD 
Chromosome 	 Gene product 
16 	 IL-4 receptor 

CD 11 integrin cluster 

E-cadherin 

NOD2 

12 	 IFNy 

mtegrin B7 

ERBB3 

7 	 EGFR 

HGF 

MUC3 

3 	 GNAI2 

HMLHI 

FHIT 

Recently the IBDI gene locus has been refined to reveal mutations in the NOD2 
gene on chromosome-16 that are associated with CD (Hampe et ai., 200 1; Hugot 
et al., 2001 & Ogura et ai., 2001a). These mutations, which consist of a 
frameshift, insertion or substitution, have implications for NFKB activation in the 
bowel discussed in greater detail later (chapter 3 and 7). 
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The inheritance patterns of CD do not follow a Mendalian pattern, a fact that may 
be partly due to the multi-factorial nature of the disease (Parkes et aI., 1997). 
However, this may also be due to a role of epigenetics in the disease (Petronis & 
Petroniene, 2000). Epigeneitc traits are mediated via heritable modification of 
DNA such as methylation which often cause changes in chromatin structure. The 
epigenetic traits of CD include; maternal transmission (Akolkar et aI., 1997), 
differences in genetic anticipation based on parental transmission (Polito et al., 
1996 & Heresbach et al., 1998), discordance of monozygotic twins (Petronis and 
Petroni ene, 2000), and abnormal regulation/ expression of cytokine genes (Louis 
et al., 1996 & Funakoshi et ai., 1998). 
In summary, ever mounting evidence indicates that genetic predisposition's may 
playa role in CD. However, whilst the majority of research carried out to date on 
the aetiology and patho-physiology of CD has focused on the inflamed tissue, this 
has been hampered by the large scale changes in gene expression and signal 
transduction pathway activity normally associated with an inflammatory response. 
It seems likely that the cause(s) of CD exists throughout the bowel and not just in 
the overtly inflamed tissue. Changes/aberrations in the non-inflamed CD intestinal 
tissue may therefore predate or predetermine the subsequent development of 
chronic inflammation. 
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1.4 Intracellular Signalling Cascades 
Intracellular signalling cascades exist to transmit a signal at the cell surface, such 
as the recognition of a cytokine by the cell-surface cytokine receptor, to the 
interior of the cell, and in particular, the cell nucleus where a change in gene 
expression can be enabled. Thus, intracellular signalling cascades such as the 
mitogen activated protein kinase (MAPK) cascade and the nuclear factor kappaB 
(NFKB) signal cascade, are vital in mediating cellular responses, such as the 
responses that occur during an inflammatory response. 
1.4.1 MAPKs 
The first MAPKs, p42 (Sturgill et ai., 1988) and p44 (Sanghera et a!., 1990), were 
discovered through their activation by mitogens. When it was later discovered that 
mitogens are not the only stimuli capable of inducing their activation they were 
renamed extra cellular regulated kinase-l (ERKl) and ERK2. However, the 
MAPK nomenclature is still used to describe this family of highly homologous 
kinases that now includes ERKs, c-jun N-terminal kinases (JNKs also known as 
Stress activated protein kinases SAPKs) and p38 MAPKs. 
1.4.2 p38 MAPK 
Also known as reactivating kinase (RK), Mpk2, and cytokine-suppressant anti­
inflammatory drug (CSAID)-binding protein (CSBP), the p38 family of MAP 
kinases is activated by stress signals. The first mammalian p38 MAPK was 
identified in murine pre-B cells in complex with a transfected CD14 in 
macrophages after stimulation with lipopolysaccharide (LPS; Han et ai., 1994). 
The p38 MAPK family are 38kDa proteins very similar to the yeast gene product 
HOG 1 (Brewster et ai., 1993), the activity of which is stimulated by osmotic 
shock. The multiple p38 MAPK family members are now known to include p38, 
p38~2, p38y and SAPK4 (Kumar et ai., 1997) and require activation via 
phosphorylation by MAPK kinases (MKKs) e.g. MKK3 and MKK6, that act upon 
the sequence Thr-Gly-Tyr (Fig 1.3; Fanger et aI., 1997). 
One of the reasons for the broad ranging effects of the p38 MAPK family is their 
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ability to modify the activity of a number of transcription factors. So far the 
transcription factors known to be targets of p38 MAPK include; ATF-2 (Fig 1.3; 
Raingeaud et al., 1995), CHOP (Wang and Ron, 1996), monocyte enhanced factor 
2C (MEF2C; Han et al., 1997), and NFKB (Berghe et ai., 1998; Jean et ai., 2000). 
As well as acting on transcription factors the p38 MAPK family is also known to 
phosphorylate a number of other kinases including MAPKAP (Beyaert, 1996) and 
MAPK interacting kinase (Mnkl) (Waskiewicz et al., 1997), although the exact 
function of these kinases is not clearly defined. 
(Stimuli) (Stimuli ) (Stimuli) 
.. 
Ras Rac,.Cdc42 ? 
~ ? (PAK65) 
MAPKAPKl ATF-2 
HSP 27 " gene expression 
Figure 1.3 p38 activation pathway 
1.4.3 ERKs 
Extracellular regulated kinases (ERKs) are broad specificity, proline directed 
SerlThr kinases that are important in the regulation of cell growth, differentiation 
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tpl-2 MEKK~ 
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and protection against apoptosis. So far ERKl, 2, 3, and 5 have been identified 
and cloned (Su and Karin, 1996), and more are likely to follow. 
The ERK family signal cascades are often tightly regulated by other signalling 
pathways, frequently in a tissue dependent manner (Su and Karin, 1996). ERKs 
may be activated by cytokines through the action of JAKs (Fig 1.4) with most 
ligands that activate JAK-STATs also activating the ERK pathway (Winston and 
Hunter, 1996). The role of ERKs in this situation is to modulate the activity of 
STATs (Winston and Hunter, 1996). Other ERK substrates include Rsk, Elkl 
(pelch, 1996), TeF (ternary complex factor), and c-jun (Karin and Hunter, 1995). 
SI;Uli Styli 
JAKs 
" Ras ~ 
Raf ~4o$ 
MEKs
., 
ERKs 
+~~ 
SRF STATs etc. 
Figure 1.4 ERK activation pathways 
1.4.4 JNK (c-jun N-terminal kinases) 
Also known as stress activated protein kinases (SAPKs), the JNK family is found 
exclusively in eukaryotic cells. They are involved in the regulation of cytokine 
induced cellular differentiation, apoptosis and growth arrest (Coroneos et aI., 
1996; Woodgett et ai., 1996; Davis, 2000). The JNK family consists of at least 
three p46 and p54 isoforms (JNKl, JNK2, JNK3) that are activated upon exposure 
of the cell to stress events (Woodgett et aI., 1996; Davis, 2000). Strong activation 
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of the JNK family is observed after TNFa stimulation (Fig 1.5), UV irradiation, 
treatment with certain translational inhibitors such as anisomycin, exposure to IL­
l, co-stimulating acti vation of T cells, ischemia reperfusion, exposure to 
alkylating agents and mitomycin C (Su and Karin, 1996; Woodgett et ai., 1996). 
11 cdc42 "-.. 
CDI20a~.. c-Ra\. ... PAK~ MEKK ~ SEK~ JNK 
(TNEx receptor) (MKK4) (SAPK)"ill" 
Racll2 
Figure 1.5 TNFa. stimulated JNK activation. 
1.4.5 Adapter proteins 
Functional MAPK cascades appear to require adapter proteins that are necessary 
to hold the MAPK, MEK and MEKK enzymes together, organising them into a 
functional unit (Elion, 1998). Adapter proteins such as MEK partner 1 (MP 1; 
Schaeffer et ai., 1998) and JNK interacting-protine (lIPl; Whitemarsh et ai., 
1998) provide the cascades with insulation from the effects of other MAPK 
cascade constituents. The adapter proteins are therefore capable of controlling, to 
some extent, the response in anyone cell, to a given stimulus. 
1.4.6 JAK-STAT signalling pathway 
The Janus family of protein tyrosine kinases (JAK) - Signal Transducers and 
Acti vators of transcription (STAT) signalling pathway is activated through 
cytokine-mediated receptor activation (Ihle, 1995). Cytokines all signal through a 
related set of receptors. These receptors have no intrinsic kinase activity and 
therefore require JAKs for much of their receptor function (Thle, 1995). 
The JAK family is currently known to include JAKs 1, 2, and 3 as well as Tyk2 
(Briscoe et ai., 1994). They are cytoplasmic proteins that directly interact with 
their associated receptors upon receptor aggregation. The primary purpose of the 
receptor ligand is to aggregate and hence bring together a concomitant homo or 
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hetero-typic aggregation of JAKs. The JAKs subsequently phosphorylate their 
receptors as well as a variety of cellular substrates including STATs, and the p85 
subunit of phosphatidyl-inositol-3-kinase (PI3K), as well as phospholipase-Crl 
(PLCy-l) (Yasukawa et ai., 2000; We, 1995; Briscoe et al., 1994). 
STATs 
JAKs are essential for STAT activation. These transcription factors are recruited 
to the JAK receptor complex where they become phosphorylated on a Tyr residue 
in their carboxyl region. This is necessary and sufficient for STAT dimerisation 
and the formation of a high affinity binding site for DNA (target sequence 
TTNCNNNAA), at the same time as inducing rapid translocation of STATs to the 
nucleus (Thle, 1995 & 1996). 
Virtually all cytokines appear to activate one or more STAT in a highly specific 
manner, and once activated, they are capable of mediating a number of functional 
(non-mitogenic) processes (Table 1.2) and are typically anti-proliferative (lhle, 
1995; Yasukawa et ai., 2000). 
Table 1.2 STAT functions 
Function Mediated Genes Targeted 
IFN-regulated genes Immunoglobulin class switching 
anti-viral responses MHCII 
acute phase genes Immunoglobulin 
Interestingly an ERK phosphorylation site has been found within STATla that 
affects its ability to activate transcription, but not DNA binding activity (Winston 
and Hunter, 1996). This suggests a role for ERKs in STAT activation (Fig 1.6). 
Evolutionary conservation of this ERK binding domain is striking due to the 
general lack of consensus generally shown in the rest of the carboxyl domain. 
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Mutation of the ERK phosphorylation site, S727, in this domain, leads to a three­
fold reduction in STATla mediated induction of endogenous IFNy-inducible I 
genes (Thle, 1996). 
~JAK 
Receptor "A. ~ .......... STAT+gene expression 

Ras.., Rat... MEK ~ ERK 
Figure 1.6 JAK-STAT activation pathway 
1.4.7 PKC 
The protein kinase C (PKC) family of related enzymes has a role to play in many 
cell signalling cascades. The PKC family can be subdivided into three groups 
based on differences in structure and cofactor requirement (Jaken, 1996). The 
classic PKC (cPKC) isoforms, which include PKC a, ~I, ~II and y, require Ca2+, 
diacylglycerol (DAG), and phosphatidylserine (PS) for optimal activity. The 
novel PKC (nPKC) isoforms, which include S, t, 11, and 8, still require DAG and 
PS for activation but no longer need Ca2+. The atypical PKC (aPKC) isoforms ~, 
t and A bind PS but are insensitive to DAG and Ca2+. However, despite 
differences in activating stimuli there is a large overlap in substrate specificity. 
PKC function and activity are therefore largely regulated in vivo by tissue specific 
expression, intracellular localisation and by binding to specific targeting proteins 
(Mochly-Rosen et al., 1991; Jaken, 1996; Oka et at., 1997; Mayne and Murray, 
1998; Wu et al., 2000). 
The PKC isoforms have a multitude of cellular substrates and have been shown to 
be involved in a wide range of biological processes including, proliferation, 
differentiation, and apoptosis (Kazanietz, 2002), as well as immune and 
neurological processes (Mellor and Parker, 1998; Castrillo et at., 200 1). The PKC 
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family has also been shown to be a key mediator of growth factor, hormone, and 
neurotransmitter actions (Kazanietz, 2002). 
One of the reasons for the broad ranging implications of PKC activation may be 
the fact that transcription factors are one of their targets. Indeed the PKC family is 
involved in IL-l ~-stimulated NFKB activation in DLD-l enterocytes (Wilson et 
ai., 1999), NFKB activation in T cells (Steffan et aI., 1995), and LPS-stimulated 
NFKB activation in alveolar macrophages (Greenberg et al., 1998). Also, in RAW 
cells, LPS has previously been shown to activate NF1d3 through PKC (Chen et aI., 
1998a; St-Denis et aI., 1998). However, whilst a role for PKC in these processes 
is not questioned, the isoform(s) involved is still debated (Baeuerle and Henkel, 
1994; Chen et al., 1998a; St-Denis et al., 1998). 
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1.5 Nuclear Factor kappa B 
1.5.1 Background 
The name, nuclear factor kappa B (NFKB), was first used by Sen and Baltimore 
(1986) to describe the factor that bound an enhancer site in the immunoglobulin 
kappa B gene promoter of a B cell line. The nuclear factor responsible is now 
known to be a member of a larger NFKB family that controls the expression of a 
huge range of genes (Table 1.3; Baeuerle and Henkel, 1994). Some of the genes 
regulated by the NFKB family include those for other transcription factors (Toth et 
ai., 1995) meaning that NFKB activation frequently causes large-scale changes in 
gene expression. 
Table 1.3 Examples of the genes in which NFKB induces expression 
(after Karin and Delhase, 2000) 
Families Examples 
Cytokines IL-l, IL-2, IL-2R, IL-6, IL-8, TNF-a, 
TNF-~, IFN-~, GM-CSF, G-CSF, 
Lymphotoxin, 
Acute phase proteins iNOS, serum amyloid protein al 
angiotensinogen 
Cell adhesion molecules VCAM-l, ELAM-l, ICAM-l 
Antigen presentation molecules MHC I, MHC II 
The great majority of the genes regulated by the NFKB family are involved in 
inflammatory responses (Baeuerle and Henkel, 1994; Jobin and Sartor, 2000~ 
Karin and Delhase, 2000) and NFKB activity, therefore, appears to have a key role 
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in inflammatory diseases (Tak: and Firestein, 2001; Baldwin, 2001) such as 
Crohn's disease (Schreiber et at., 1998). 
1.5.2 The NFx:B family 
The NFKB transcription factors are dimeric proteins that can be found in 
homodimeric or heterodimeric form. Their subunits are drawn from the NFKB 
family members now known to include p50 (NFKB-1), p52 (NFKB-2), p65 
(ReIA), c-Rel, and RelB. These family members are largely defined by their 
possession of a reI homology domain (RHD) that is responsible for NFKB 
dimerisation, and by their ability to bind a lObp DNA consensus sequence (5'­
GGGRNNNTYCC-3') via interactions between the DNA and loops of the Nand 
C terminal domains of the NFKB subunits (Baeuede and Henkel, 1994). 
Importantly each of these family members possesses a subtly different DNA­
binding motif. Thus the DNA consensus sequence bound by the NFKB dimer is 
determined by the combination of the two subunits, and can be non-palindromic 
(Kunsch et ai., 1992 & Zabel et at., 1991). As such, each NFKB dimer is able to 
bind a different DNA consensus sequence, although there is a great deal of 
redundancy in this system. 
1.5.3 NFKB subunits 
The known NFlcB subunits include p65, pI 05/p50, PlOO/p52, c-Rel and RelB. Of 
these, the p65 and pSO subunits have most frequently been linked with 
inflammatory responses (Karin and Delhase. 2001). 
p105, p50 (NFKB-l) 
The gene product p105 must be proteolytically cleaved to yield the mature, DNA­
binding, pSO NFlcB subunit. Proteolytic post-translational modification of p 105 
involves the removal of the C-terminal domain of pI 05 that contains numerous 
ankyrin repeats, the hallmark of the lIcB family (Simeoidis et al., 1999), a group 
of proteins responsible for the inhibition of NFKB. Indeed, alternative splicing of 
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the pIOS gene product can lead to the production of the C-terminal domain alone, 
known as I1d38 (Dobrzanski et al., 1995). 
The DNA binding sequences of pSO are GGGACTTTC and GGGATTCCC 
(Fujita et al., 1992), similar in many respects to pS2. Whilst pSO does bind DNA, 
it lacks a transactivation domain and is therefore unable to stimulate transcription 
on its own. Mice homozygous negative (-/-) for the p50 gene have been 
demonstrated to be unable to develop both chronic and acute models of arthritis 
(Campbell et al., 2000), and to fail to develop tolerance to LPS CBohuslav et al., 
1998), indicating an essential role for p50 in the establishment of an inflammatory 
response. 
p65 CReIA) 
p65 contains a potent transactivation domain meaning that it is able to exert 
substantive effects on gene transcription. Importantly it is also capable of 
undergoing post-transcriptional modification in the form of phosphorylation, that 
may occur constitutively or inducibly (Naumann and Scheidwewir, 1994; Diehl et 
aI., 1995; Schmitz et al., 1995; Zhong et al., 1997; Schmitz et al., 2001). 
Phosphorylation of p65, induced by TNFa in HeLa cells, occurs on Ser 529 and 
results in an increase in NFKB-mediated transcription (Wang et al., 1998a & 
2000). This phosphorylation appears to be mediated by casein kinase II (CKII; 
Wang et al., 2000), a kinase that can also phosphorylate IKBa. (Pando and Verma, 
2000). LPS-induced PKA-dependent p65 phosphorylation has also been shown to 
be capable of increasing NFKB DNA-binding (Zhong et aI., 1997). Also, phorbol 
esters have been shown to induce phosphorylation of p65 that potentiate p65­
mediated transcription (Schmitz et al., 1995). 
1.5.4 The NFlCB dimers 
There are a large number of possible NFlCB dimer configurations although only a 
select few have been found to occur in cells. The most common of these is the 
p50/p65 heterodimer with the other known dimers including p65/p6S, p50/pSO, 
pSO/c-Rel (Harhaj et al., 1996), p6Slc-Rel (Parry and Mackman, 1994) pS2Ip6S, 
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p65/p52, and p52/p52 (Baldwin, 1996; Baeuerle and Henkel, 1994). Of these not 
all are thought to be transcriptionally active with p50 and p52 homodimers 
actually repressing transcription in certain circumstances (Baldwin, 1996). 
p65/p50 
The p65/p50 "classic" NFKB heterodimer has a 5bp DNA interaction for p50 (5'­
GGGRN-3') and 4bp for p65 that endows it with a stronger DNA interface than 
either homodimer. It binds to the decameric consensus sequence 5'­
GGGRNNYYCC-3' with an affinity of 1O-13_ 1O-10M (Grimm and Baeuerle, 1993). 
Binding of this heterodimer to the immunoglobulin KB element results in the 
formation of a 140 bend in the 11bp central section and the twisting out of plane of 
bases To and G 1 (Chen et al., 1998b), whilst a 17° bend is induced in the H2-KB 
element in the H2 gene promoter (Falvo et al., 1995). 
p50/p50 
The p50 homodimer is constitutively expressed in the nucleus of many cell types 
(Kilpinen et ai., 1996). It is not thought to significantly distort DNA shape (Fig 
1.7, Ghosh et ai., 1995) although there is some disagreement on this (MUller et al., 
1995). However, it does not possess the variable C-terminal region responsible for 
transactivation mechanism and it is therefore thought not to induce gene 
transcription by itself (Baldwin, 1996). 
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Figure 1.7 p50 homodimer / DNA interaction. 

The central helices represent the DNA with the pSG homodimer bound around it. 

The over-expression of pSG in macrophages is able to block LPS-induced 
transcription from a TNF-a-promoter reporter construct (Baer et at., 1998). 
Moreover, in pSG -/- mice, tolerance to LPS can not be induced suggesting that 
pSG homodimers are involved in the tolerance induced inhibition of LPS-induced 
TNFa production in macrophages (Bohslav et aI., 1998). Furthermore, once the 
plOO/pSO dimer has been processed to yield the uninhibited p50 homodimer it 
appears to be able to avoid IKBa binding and translocate uninhibited to the cell 
nucleus (Siebenlist et ai., 1994 & Baldwin, 1996). As such the p50 homodimer is 
thought by many to have a transcription repression function, although, the pSO 
homodimer is able to form a complex with Bcl-3, a transcriptional co-activator 
(Baldwin, 1996). 
Phasic Shift in NFKB Dimer Composition 
Induction of NFK:B dimers appears to alter with the duration of stimulation. 
Dimers containing p65 are involved at the beginning of a response whilst dimers 
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containing c-Rel appear to predominate over longer stimulation periods (Molitor 
et al., 1990; Arima et a!., 1991; Harhaj et al., 1996; Kanno et aI., 1994). This may 
be due to the increase in c-Rel expression caused by NFKB activation (Sun et ai., 
1994), although post-translational modification may also playa role (Naumann 
and Scheidereit, 1994; Diehl et al., 1995). 
1.5.5 Control of NF7<:B activation 
Not only does the NFKB family regulate the expression of a great many genes, but 
NFKB family members may also be activated by a large number of stimuli (Table 
1.4), some of which are themselves regulated through NFKB activation leading to 
the creation of positive feedback loops. As such, the control of NFKB activation is 
both vitally important and complex. 
Table 1.4 Factors that induce NFlCB activation 
(after Karin and Delhase, 2000) 
Factors 	 Examples 
Cytokines 	 IL-l, TNF-a 
Viruses 	 Hepatitis B human T cell leukemia virus 
(HTLV-l), human immunodeficiency 
virus-l (HIV-l), double stranded RNA 
Bacteria 	 E.coli, lipoploysaccharide (LPS) 
Phorbol Esters 	 Phorbol 12-myritate 13-acetate (PMA), 
Diacyl Glycerol (DAG) 
The alternate NF1Cl3 dimers can be activated by different stimuli and regulate 
different groups of genes, although there is heavy redundancy in the system 
(Baeuerle and Henkel, 1994). As a result, a given stimulus can have quite 
different effects in a cell depending on the NF1Cl3 dimers that are present. 
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Post-translational modification can be used as a means by which NFKB activity 
can be modulated. Both the NFKB dimer itself and the inhibiting IKE polypeptide 
can be altered by these means (Jobin and Sartor, 2000; Karin and Delhase, 2000). 
These modifications can alter the DNA sequences bound by NFKB, the factors 
that NFlCB may associate with during the initiation of transcription, and the 
dissociation of IKE from the NFKB complex. 
NFtcB activity is also likely to be controlled indirectly through changes to the 
intracellular signalling pathways that transmit the NFKB activation signals. This is 
known to be the case for the related MAPK pathways, which require adapter 
proteins such as MEK partner 1 (MPl) (Schaeffer et al., 1998) and JNK 
interacting-protein (JIPl) (Whitemarsh et al., 1998) to hold the signal cascade 
components together, organising them into a functional unit. However, whilst 
many means exist to control NFK13 activation, perhaps the most important is the 
inhibition of NFKB activation by IKB. 
1.5.6 hcB phosphorylation 
The ubiquitously expressed NFKB is retained in the cell cytoplasm in an inactive 
state through its interaction with an IKB family member. This heE family member 
is present as either a third peptide in a complex with the NFKB dimers or through 
the incomplete proteolytic processing of one of the dimer subunits (e.g. pl05 or 
p 100) which contain IKE ankyrin regions (Karin and Delhase, 1999). Once the 
IlCB has been separated from the NFKB dimer, a unique 17 amino acid nuclear 
localisation sequence (NLS) located in the c-terminus of the NRD (NF­
kappaB/Rel/dorsal) domain, is exposed, and induces the nuclear translocation of 
NFlCB. 
In the case of the incompletely processed dimer, exposure of the cell to a suitable 
stimulus causes the immature NFKB subunit (p105 or plOD) to be sequentially 
phosphorylated, ubquintylated by the Ubc5/E3RSIKB enzyme pair (Yaron et al., 
1998; Spencer et aI., 1999) and subsequently proteolytically modified by the 26S 
protease (Palombella et al., 1994; Traenckner and Bacuerle, 1995). This 
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proteolysis involves the removal of the carboxyl-terminal ankyrin like domain at 
the poly G-hinge region of the subunit. 
In the case of the trimeric complex, which contains a mature NFKE dimer and an 
IKE polypeptide, it is IKE that is phosphorylated. As with the immature dimer, 
IKB is then ubquitinylated and proteolytic ally degraded. 
The key event in the separation of IKE from NFKB is the phosphorylation step. 
The recently discovered complex, of approximately 800 kDa, and containing IKB 
kinase (IKK) (Chen et ai., 1996; Mercurio et ai., 1997; Regnier et ai, 1997; 
Woronicz et ai., 1997; DiDonato et al., 1997) is responsible for this. Collectively 
known as the hcB signal some (Zhang et aI., 2000a) this complex contains hcB­
kinase-a. (IKKa.) and IKK~ along with the regulatory/structural doublet IKKy / 
NEMO (Yamaoka et ai., 1998; Rothwarth et al 1998; lIP Consortium, 2000) 
andlor the IKK-complex-associated protein (IKAP) (Cohen et al., 1998). Of these 
components it is IKKa. and IKK~ that are responsible for the phosphorylation of 
IKBa and IKB~ on their N-terminal serines (Zandi et aI., 1998). Interestingly 
IKBa or IKB~ are much better substrates for the IKKs when they are bound to 
NFKB (Zandi et ai., 1998), a fact that may help explain how these IKBs can build 
up in cells even when the IKKs are active (Karin and Delhase, 2000). 
Of the two kinases, it appears that IKK~ is the more important in TNFa.-mediated 
NFKB activation (Li et at., 1997; Delhase et ai., 1999) with anti-inflammatory 
agents specifically inhibiting IKK~ activity (Yin et aI., 1998). IKKa on the other 
hand is likely to be involved in key early embryo development since, in IKKa -/­
mice, death occurs shortly after birth with the animals suffering developmental 
abnormalities (Takeda et al., 1999; Hu et al., 1999) of the skin (Van Hogerlind et 
al., 1999) and skeleton (May and Ghosh, 1999). 
Whilst IKKy does not appear to act directly on IKBu, it is nonetheless a vital part 
of the complex (Yamaoka et at., 1998). Its mutation in the human diseac;e 
incontinentia pigmenti leads to prenatal lethality in males and highly variable 
abnormalities of the skin, hair, nails, teeth and the central nervous system in 
heterozygous females (lIP consortium, 2000). In IKKy -/- mice, death occurs at 
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~.'.·.··.I ~I ..EI2.S-E13 and is caused by severe liver damage resulting from hepatocyte 
apoptosis (Rudolph et ai., 2000). Interestingly, the human heterozygous mutant 
phenotype resembles that of IKKa KO mice (Takeda et aI., 1999; Hu et al., 1999) Iwhist the IKKy -/- mouse phenotype resembles that of the IKK~ -/- mouse 
perhaps reflecting a regulatory or scaffold function of IKKy within the cell. 
Recently a fourth IKK, named IKKE, has been characterised (Peters et al., 2000). 
This appears to be part of a phorbol ester inducible complex that can 
phosphorylate lK:Ba and appears to be primarily involved in the activation of 
NFK:B in T cells when induced through the binding of the T cell receptor (TCR). 
The discovery of IKK£ also demonstrates that IKK isoforms can be expressed in a 
cell and function specific manner indicating that other IKK isoforms may be 
found in the future. 
The IKB signalsome can be activated in a number of different ways with 
phosphorylation the primary form of activation. Treatment of IKKs with the 
protein-phosphatase-2A (PP2A) abolishes their activity (DiDonato et ai., 1997) 
showing the necessity of phosphorylation. Also, a mitogen activated protein 
kinase kinase kinase (MAPKKK also known as MEKK) activation loop motif 
(SxxxS), a site readily phosphorylated by MEKK, has been described within 
IKKa and IKK~ that, when mutated in IKK-~ but not IKK-a, suppresses NFKB 
activation by TNFa or IL-l (Mercurio et al., 1997). Thus, a MEKK may be 
involved in the activation of IKK~. Indeed, the IKKs can also be directly activated 
by the recombinant MEKKl (Lee et ai., 1997) and during stimulation with TNF 
or IL-l, NFKB inducing kinase (NIK), another MEKK, also appears to activate the 
signalsome (Reginer et ai., 1997; Malinin et al., 1997; Woronicz et aI., 1997). In 
addition to MEKKI and NIK, another kinase named NF1Cl3 activating kinase 
(NAK) has been identified that is able to phosphorylate IKK~ thereby inducing 
!leBa degradation (Tojima et aZ., 2000). 
In contrast, whilst phosphorylation of the IKKs undoubtedly activates the hcB 
signalsome, it can also inhibit it. Auto-phosphorylation of IKK~ at its C-terminal 
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domain leads to a decrease in its activity and substitution of the serine residues 
involved leads to an increase in the basal activity of IKKP (Delhase et al., 1999). 
1.5.7Alternative mechanisms of NF1(B activation 
Whilst IKK. mediated IKB phosphorylation, followed by IKE ubiquitination and 
degradation is the classical form of NFKB activation, there are some exceptions. 
Protein kinase C (PKC), protein kinase A (PKA), and Raf-l are sufficient to cause 
dissociation of IKB and activation of NFKB in vitro (Tighe et ai., 1996), whilst in 
isolated colonic epithelial cells and HT -29 cells, a human colonic epithelial cell 
line, NFKB activation by IL-lp-stimulation does not involve the degradation of 
IKBa (Jobin et al., 1997). In the DLD-l human colonic epithelial cell line none of 
the IKB isotypes were found to degrade upon PMA-stimulation although increased 
NFKB activity was observed (Wilson et aI., 1999). Also in the rat monocytic cell 
line, RAW 264.7, Silca induced NFKB activation can not be blocked by MG-132, 
a relatively specific 26S protease inhibitor that prevents the degradation of b:B 
(Chen et ai., 1997). 
Also, whilst the IKB signal some is largely responsible for the phosphorylation of 
IKBa and IKBI3, the mechanism for plOO and p105 phosphorylation is less clear. 
In mice lacking the C-terrninal ankyrin domain of p105, a chronic inflammatory 
phenotype occurs that is probably caused by the associated constitutive NFKB 
activity (Ishikawa et aI., 1998). Also, in mice with a similar defect in pl00, 
constitutive NFKB activity is once again present (Ishikawa et al., 1999) indicating 
the importance of the ankyrin domain in the inhibition of dimers containing these 
subunits. Within this C-terminal region there is some evidence to suggest that 
phosphorylation must occur before proteolytic processing (Coux and Goldberg, 
1998; MacKichan et aI., 1996). However, the kinase responsible is unknown, 
although CKll has been suggested to be involved (MacKichan et al., 1996). 
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1.5.8 The IKB family 
The IKE family members, characterised by the presence of a 5-7 ankyrin like 
repeat (Simeonidis et al., 1999) within their carboxyl domains, include IKBa, 
IKB~, IKB,)" and Bcl-3. 
~ 
~I 
The importance of IKBa in the effective inhibition of NFKB is demonstrated in ! 

IKBa -/- mice, where death occurs through widespread inflammation caused by 

prolonged activation of NFKE (Klement et ai., 1996). 

IKBa, which functions through binding to NFKB and thereby masking the NLS on 
NFKB and itself, is able to inhibit NFKB dimers that contain p65 or c-Rel 
(Bohuslav et ai., 1998). IKBa, contains an N-terminal sequence that is recognised 
by G3BP2, a cytoplasmic protein that interacts with both IKBa and the NFKB I 
IKBa complex, helping to retain them in the cytoplasm (Prigent et aI., 2000). 
When IKBa is unbound it is able to translocate to the nucleus where it competes 
with DNA for NFKB-binding, and once bound to NFKB, it facilitates its return to 
the cytoplasm (Zabel and Baeuerle, 1990). 
As previously discussed (section 1.4.6), dissociation of the IKBa-NFKB complex 
is dependent upon IKBa phosphorylation. Several phosphorylation sites have been 
identified on IKBa including the following: IKK phosphorylation sites on Ser 32 
and Ser 36 (Brown et ai., 1995); CKII sites located in the carboxyl-terminal 
domain (Barroga et ai., 1995; Schwarz et aI., 1996); a PKC site located in the 
ankyrin repeat 6 (Shirakawa and Mizel 1989; Haskill et al., 1991); and a tyrosine 
phosphorylation site that can cause the dissociation but not the degradation of 
IKBa from NFKB in Jurkat T cells (Imbert et aI., 1996). Thus, the potential exists 
for multiple kinases to regulate the binding of IKBa to NFKB in vivo. 
IKB~, in common with IKBcx., is able to inhibit the activation of NFKB dimers that 

contain p65 and c-Rel (Bohuslav et ai., 1998), although there is some debate over 
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the ability of IKB~ to inhibit c-Rel (Talc and Firestein, 2001). Its degradation is 
stimulated by the phosphorylation of two serine residues Ser-19 and Ser-23 
(McKinsey et at., 1996) by the IKK signalsome (Zandi et aI., 1998). In common 
with IKBa, IKB~ can also be phosphorylated by CKII, a function required for the 
efficient turn over of lKB~ (McKinsey et al., 1997). 
However, in contrast to IKBa, the stimuli that lead to IKB~ degradation are 
different. Whilst 11d3a is degraded in response to a wide range of pro­
inflammatory stimuli, IKB~ is only degraded in response to stimuli that cause the 
long-term activation ofNFKB (Verma et ai., 1995; Thompson et ai., 1995; Bourke 
et al., 2000). For example, in B cells, in which IKB~ was cloned and 
characterised, IKB~ is degraded in response to IL-l or LPS, which causes a pro­
longed activation of NFKB. On the other hand, the transient activation of NFKB in 
B cells induced by TNFa or PMA-stimulation, does not induce IKB~ degradation 
(Thompson et ai., 1995). The greater duration of NFKB activation in response to 
h(B~ degradation, may be due in part to the lack of a KB element in the promoter 
region of the IKB~ gene. This means that NFKB activation does not induce IKB~ 
up-regulation (Baldwin, 1996 & Johnson et al., 1996). Also, whatever the 
mechanism of IKB~ up-regulation is, newly synthesised un-phosphorylated IKB~ 
can chaperone NFKB into the nucleus allowing it to avoid inhibition by IKBa 
(Suyang et al., 1996). 
Knockout studies demonstrate a distinct role for IKB~ in vivo with IKB~ -/- mice 
dying approximately seven days after birth due to constitutive NFKB activation in 
a number of cell types that leads to widespread inflammation (Klement et al., 
1996; Beg et aI., 1995b). A distinct role for IKB~ is further demonstrated in 
embryonic fibroblasts derived from IKBa -/- mice, which show minimal 
constitutive NFKB activity, as well as normal signal-dependent NFKB activation 
that is concomitant with Ild3~ degradation. However, IKBa is required for the 
post-activation repression of NFKB activity (Klement et al., 1996), indicating the 
unique roles that the IKB family members play in contrast to the redundancy 
which exists in the NFlCB subunits. 
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The degradation of I1CBf. is stimulated by phosphorylation of Ser-18 and Ser-22 
(Whiteside et ai., 1997). It is found almost exclusively in complexes containing 
the p6S (Rel-A)/cRel heterodimer or the respective homodimers to which it is able 
to bind and inhibit (Whiteside et at., 1997). It is also the dominant I1CB type in the 
human monocyte cell line THP-l (Whiteside et al., 1997). IKEE degradation and 
re-synthesis is slower than that of I1CBa., and its inhibitory effect is exerted in the 
cytoplasm only, unlike IKEa. which can also translocate to the nucleus (Whiteside 
et ai., 1997; Simeonidis et aI., 1997 & 1999). 
I1cBy 
This IKE family member can be either the alternatively spliced gene product of 
the pI OS gene, or the cleavage product of pI OS when it is acted upon by proteases 
releasing the mature pSO element of the protein (Bell et al., 1996). 
Bcl-3 
Bc1-3 is yet another member of the IKB family. It contains seven tandem ankyrin 
repeats, a proline-rich amino terminal, and a proline and serine rich carboxylic 
terminal. However, unlike the other lKEs, Bcl-3 is primarily found in the nucleus 
where it interacts with NFKE. Also, it isn't degraded in response to mitogenic 
stimuli, although degradation may occur in response to other stimuli such as pro­
inflammatory ones (Moine et al., 2000). 
The expression of Bc1-3 can be up-regulated in B and T cells in response to 
mitogenic stimuli (Ohno et ai., 1990 & Bhatia et ai., 1991), and by IL-9 in T cells 
and Mast cells (Richard et aI., 1999). This increased Bcl-3 expression is known to 
mediate increased nuclear levels of pSO homodimers (Richard et aI., 1999; 
Wanatabe et at., 1997) which may compete with p6S/pSO for DNA-binding and 
thereby lead to reduced gene transcription from certain genes (Richard et al., 
1999). 
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In the nucleus, Bc1-3 forms complexes with p50 or pS2 NFKB homodimers, 
although two conflicting functions have been proposed for this interaction. Firstly, 
Bcl-3 may inhibit the binding of p50 homodimers to DNA, allowing instead the 
access of the classic inflammatory NFKB dimer p65/p50 to the kappaB enhancer 
element (Franzoso et ai., 1997). Alternatively, the p50/pSO-Bcl-3 complex may 
interact with the nuclear factors Jab 1, Pirin, Tip60, and Bard 1 leading to the 
increased transcriptional activity of the complex, probably due to the histone 
acetylase activity of Tip60 (Dechend et al., 1999). 
1.5.9 Extraneous factors involved in NF1CB activity 
In controlling gene transcription, NFKB often works synergistically with a range 
of other factors. These factors can interact with NFKB, thereby strengthening the 
promoter complex, or they may influence the NFKB dimer type bound by a 
particular KB promoter, or help unravel the chromatin structure allowing easier 
access of the transcription machinery to the gene (Perkins, 1997). 
When present, stimulatory protein-1 (SP-l) skews the NFKB dimer type bound by 
the KB element in the human immunodeficiency virus CRIV) long terminal repeat 
(LTR) gene promoter, p50/p65 to p52/p65 (Schmid et ai., 1991; Ducket et ai., 
1993; Perkins et aI., 1994). 
The leucine zipper motif DNA-binding proteins, cyclic AMP response element­
binding protein (CREB)-binding protein (CBP) and p300, and the cyclin 
dependent kinases (CDKs) have all been shown to physically associate with the 
p65 subunit of NFKB in vivo causing an increase in transcription from KB 
elements. Not only does this demonstrate that the transcriptional activity of NFKB 
dimers can be altered through the binding of other factors, it also shows that the 
cell cycle can affect NFKB mediated gene transcription (Perkins et al., 1997). 
1.5.10 NFI(B and the Intestine 
Experiments in vivo have shown the importance of the p65 subunit in the 
maintenance of intestinal inflammation in both 2, 4, 6,-trinitrobenzene sulfonic 
acid (TNBS) and IL-lO -1- models of IBD in mice (Neurath et al., 1996). Also, in 
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intestinal tissue from ffiD patients it has been shown that NFKB activity is 
increased as compared to nonnal tissue, and that p6S is present in the activated ~. 
NFlCB (Schreiber et al., 1998; Ellis et al., 1998). However, when rat small 
intestine was challenged using PAP, the resulting NFKB activation was primarily 
of the pSO homodimer type (De Plaen et at., 1998). Moreover, the up-regulation of 
the p50 gene has been observed in the small intestine of mice upon P AF or TNFa 
stimulation (Tan et ai., 1994), and in rats through 19B-mediated anaphylaxis 
(Tavares et al., 1998). Thus, it seems unlikely that p65 is the only NFKB subunit 
that is important in the inflammation in the intestine. 
It is interesting to note that NFKB activity is present in the non-inflamed, as well 
as the inflamed, intestine, with the constitutive low-level activation of pSO 
homodimers having been demonstrated in the mouse small intestine (De Plaen et 
al., 1998). The function of this constitutive activity may involve the suppression 
of transcription from KB controlled genes because, as previously mentioned 
(section 1.4.4), the p50 homodimer lacks a transcription transactivation domain 
(Ghosh et al., 1995). 
One of the cell types in which NFKB activation has been shown to occur in the 
inflamed intestine, is intestinal epithelial cells (IECs; RogIer et al., 1998). In the 
IEe lines in which NFlCB activation has been studied so far, some differences in 
NFlCB activation as compared to most other cell types have been found. 
In the human colonic cell lines DLD-l and HT-29, abnormal IKBa degradation 
has been observed. HT-29 cells showed little IKBa degradation upon IL-l~ 
stimulation, and this degradation occurred after NFKB activation (Jobin et at., 
1997). In DLD-l cells, on the other hand, no IKB degradation occurred in 
response to PMA-stimulation (Wilson et aI., 1999). In common with HT-29 cells, 
IL-l ~-stimulation of DLD-l cells did induce I KBa degradation but this occurred 
after NFKB activation, indicating that the degradation of IKBa was not required 
for NFKB activation (Wilson et al., 1999). These findings of delayed or absent 
beBet degradation, are in contrast to the classical model of NFKB activation. 
where rapid IKBa degradation precedes NFKB activation (Karin and Delhase, 
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2000). This has led others to suggest that NF1d3 activation in IECs is abnormal 
(Jobin et al., 1997). 
Further evidence of abnormal NFKB activation in IECs stems from the 
observation that IKKa. is responsible for TNFa-stimulated IKBa phosphorylation 
in IEe, a process that can be inhibited by 5-aminosalicylic acid (5-ASA) (Yan and 
Polk, 1999). In contrast, pro-inflammatory stimuli in other cell types induce IKE 
phosphorylation via IKK~ (Li et al., 1999a; Delhase et aI., 1999) in a 5-ASA 
sensitive manner (Yin et al., 1998). 
In summary, NFKB activation occurs in, and is vital to, intestinal inflan1ITlation, 
with the subunits involved including p65 and p50. Also, NF1d3 activation in IECs 
does not generally follow the classical route of activation that occurs in other cell 
types, and, as such, represents an area that requires greater research. 
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1.6 An A Priori Rationale 
As previously discussed, NFKB activity has been shown to be essential to the 
establishment and maintenance of intestinal inflammation. Previous work in the 
laboratory where this study was based identified increased levels of the active 
form of p65, both within inflan1ed and non-inflamed CD tissue as compared to 
normal tissue from control subjects. The increase in non-inflamed tissue generally 
suggests the presence of an underlying abnormality in the intestine of CD patients. 
However, whilst a number of subunits are known to be present in the NFKB 
dimers activated in CD, in the previous study, the activation state of only one 
subunit of NFKB, namely p65, was examined. Also, due to the limitations of the 
technique used in the previous study, the intestinal epithelium had to be excluded, 
and subsequently, epithelial cells have been shown to be one of the predominant 
cell types in which active p65 can be found in CD (RogIer et ai., 1998). 
Thus, the first objective of this thesis, as described in chapter three, was to 
confirm and expand on the previous work from this laboratory. To this end the 
overall NFKB activity in inflamed or non-inflamed CD tissue was determined, and 
comparisons to non-inflamed control tissue made. Secondly, to ascertain whether 
the degradation of the IKB family members, IKBa. and Bcl-3, occurs in CD, the 
levels of these proteins were examined in both inflamed and non-inflamed CD 
tissue and compared to non-inflamed control tissue. 
Although intestinal epithelial cells (IEes) are one of the predominant cell types to 
contain active NFlCB in both the inflamed and non-inflamed intestine (RogIer et 
al., 1998), the stimuli of NFKB activation and the consequences of this activation 
on gene expression in IECs, remains to be fully characterised. Thus, as described 
in chapter four, the HeLa Ohio cell line was used to identify potential stimuli of 
NFKB activity in IEe. Subsequently, to determine whether these stimuli induce 
the expression of NFKB-mediated genes in an mc line, the effect of these same 
stimuli on TNFa, GM-CSF or NO production was examined in Caco-2 cells. 
Along with lECs, macrophages are another predominant cell type in which active 
NFlCB can be found in both the inflamed and non-inflamed intestine (RogIer et al., 
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1998), and they are known to play an important role in intestinal inflammation. In 
comparison to IECs, the stimuli that activate NFKB in macrophages, and the effect 
that this activation has on gene expression, are relatively wen established (Severn 
et aI., 1993). However, the intra-cellular signalling pathways that mediate NFKB 
activation in macrophages are only poorly understood. As such, a more detailed 
characterisation of these activation mechanisms will provide a more complete 
understanding of the processes involved in intestinal inflammation, and may lead 
to the identification of novel drug targets for the treatment of intestinal 
inflammation. Therefore, as described in chapter five, work was undertaken to 
better define the LPS-induced signalling pathways that lead to NFKB activation in 
macrophages. 
Finally, as described in chapter six, to allow NFKB activation during normal 
intestinal inflammation to be compared with that which occurs in CD (chapter 
three), NFKB activation was studied in the TNBS model of colitis. Overall NFKB 
activity was assessed in both inflamed and non-inflamed tissue from TNBS­
treated rats and compared to control tissue from Sham operated rats. Also, as 
results from chapter five suggest that PKC£ is involved in NFKB-mediated gene 
expression, to further investigate its role in intestinal inflammation, PKCE levels 
were determined in the TNBS model of colitis. In addition, to make further 
comparisons with, and to expand on, results from chapter three, the relative 
protein levels of the IKB family members, IKBa., lKB~ and Bcl-3, were examined. 
In summary, the work undertaken here has examined NFKB activation in the 
inflamed intestine in a way designed to make a novel contribution to our 
understanding of, the occurrence, mechanisms of, and genes mediated by, NFKB 
activity in the inflamed intestine. 
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2.1 Collection of Human Tissue 
Collection of human intestinal tissue was based on the technique of Ellis et ai., 
(1998). Human tissue was obtained during routine surgery at St. Thomas' 
hospital, or routine endoscopy procedures at St. Thomas' hospital and Middlesex 
hospital, by the resident gastroenterology clinicians. Ethical approval for the 
collection of human tissues was granted by the St Thomas and Middlesex hospital 
ethical committees respectively. In CD patients, tissue was taken from either 
macroscopically inflamed or non-inflamed regions of the large and small intestine. 
In control patients, biopsies were taken at least 4cm from macroscopic disease. 
Upon collection tissue was immediately snap frozen in liquid nitrogen and then 
stored until use either in liquid nitrogen or at -sooe. 
2.2 Collection of Animal Tissue 
The 2,4,6-trinitrobenzene sulfonic acid (TNBS) model of intestinal inflammation, 
based on that of Moris et al., (1989), was used. All handling of live animals was 
completed off site, at Celltech Chiroscience, Slough, by collaborators, with the 
appropriate licences and ethical permission having already been granted. 18 Male 
Sprague Dawley rats (Charles River, UK) with a median weight of 337.5g were 
fed with basic rat chow. These animals were divided into two groups each 
consisting of nine animals. The first group was treated 5 em intrarectally with 30 
mg of TNBS in 100 ml of 30% v/v ethanol, using a syringe and tube, on day zero. 
At the same time, and using the same technique, the second, Sham operated group 
(control), was treated with 30% v/v ethanol alone. The animals were sacrificed on 
day seven and tissue was resected from two separate areas of the large intestine ­
three centimetres proximal to the anus (distal colon) and two centimetres distal to 
the caecum (proximal colon). Within the TNBS treated group these two areas 
constituted the inflamed (distal) and non-inflamed (proximal) regions of the colon. 
All samples were snap frozen in liquid nitrogen immediately after excision. Tissue 
was subsequently maintained in a frozen state at -80°C until use. 
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2.3 Cell Culture 
All cell lines used for this work were acquired as live cultures from the European 
Collection of Cell Cultures (ECACC; UK). After receipt, all work carried out on 
them was completed in sterile conditions inside a class II hood using sterile, 
pyrogen free reagents, purchased from Sigma (Sigma-Aldrich Company Ltd., 
Poole, UK) unless otherwise stated, and using sterile, pyrogen free disposable 
plastic wear purchased from Helena Bioscience (Helena Bioscience, UK) unless 
otherwise stated. The cells were incubated in a cell culture cabinet (BOC, UK) at 
37°C in a 5% CO2 humidified atmosphere as recommended by ECACC. Cells 
were cultured in disposable 25 cm2 cell culture flasks, in six millilitres of culture 
medium, unless otherwise stated. 
The cell lines used were the HeLa Ohio cells, Caco-2 cells, and RAW 264.7 cells. 
HeLa Ohio cells are an adherent human Negroid cervical epithelial cell line that 
are a sub-clone of the HeLa cell line. Caco-2 cells are an adherent caucasian 
human intestinal epithelial cell line. RAW 264.7 cells are an adherent murine 
macrophage cell line. 
2.3.1 HeLa Ohio cell culture 
HeLa Ohio cells were grown in Dulbeccos Modified Eagles Medium (DMEM) 
containing 10% (v/v) Foetal Bovine Serum (FBS; Helena Bioscience, UK), and 
2mM L-glutamine until 90% confluence had been attained. Cells were then 
subcultured (passaged) as foHows: the culture medium was removed, the cells 
were washed twice with Hanks balance salt solution (HBSS) and incubated for 
four minutes at 37°C with a one times (Ix) 5 ~g/ml Trypsin- 2 ~glml ethylenedia­
minetetraacetic acid (EDT A) solution. With the cells detached they were 
resuspended in fresh culture medium to a volume of 30 ml. This diluted cell 
suspension was divided into fresh 25 cm2 flasks at 6 ml per flask yielding an 
approximate seeding of 6x 106 cellslflask, and incubated as described above. The 
cell medium was replaced once every two days during incubation. Cells would 
take approximately five days to reach confluency after a passage. 
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All HeLa Ohio cells used for experiments were maintained within 10 passages of 
one another. For stimulation, cells were grown to 90% confluency in 25 cm2 
flasks, the medium removed, and replaced with medium containing the 
appropriate stimulant and incubated for the appropriate time period. 
2.3.2 Caco-2 cell culture 
Caco-2 cells were grown in DMEM containing 10% v/v PBS (Helena Bioscience, 
UK), 2 mM L-glutamine, and 1% v/v non-essential amino acids until 90% 
confluence had been attained. Cells were then passaged as follows: the culture 
medium was removed, the cells were washed twice with HBSS and incubated for 
four minutes at 37°C with a Ix TrypsinlEDTA solution. The detached cells were 
resuspended in culture medium to a volume of 30 ml. This cell suspension was 
then divided into fresh 25 cm2 flasks at 6 ml per flask and incubated as described 
above. During culture the cell medium was replaced once every two days. Cells 
took approximately eight days to reach eonfluency after a passage. 
All Caco-2 cells used for experiments were maintained within 10 passages of one 
another. For stimulation, cells were grown in one of two ways. Either the cells 
were stimulated at 90% confluency, or the cells were grown to 100% confluency 
and maintained at this level for a further 14 days with the culture medium 
replaced every two days. Stimulation for Caco-2 cells was carried out in the same 
manner as for HeLa Ohio cells (section 2.1.1). 
2.3.3 RAW 264.7 cell culture 
RA W 264.7 cells were grown in phenol red free DMEM containing 10% v/v FBS 
(Helena Bioscience, UK) and 2 mM L-glutamine until 90% confluence had been 
attained. Cells were then passaged as follows below. 
The culture medium was removed and the cells detached from the flask surface by 
gently scraping them with a 25 em disposable cell scraper. The detached cells 
were resuspended in culture medium to a volume of 18 ml from which 6 ml 
aliquots were dispensed into fresh 25 cm2 flasks and incubated as described 
above. During incubation the cell medium waf) replaced once every two days. 
Cells would take approximately three days to reach confluency after a passage. 
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RAW 264.7 cells were grown onto glass slides (Henley, UK) for the purposes of 
immunocytochemistry (ICC). Glass slides were prepared by fIrstly washing them 
in a detergent (fairy liquid; Proctor and Gambol, UK) for 30 minutes followed by 
a 30 minute wash under running tap water. This was followed by a fIve minute 
soak in 70% v/v industrial methylated spirits (IMS; Merck, UK) after which the 
slides were allowed to dry within the sterile environment of a class II hood. 
Reusable silicon blocks containing eight wells (flexiPERM; Sigma) were prepared 
in the same manner as the slides. Once these had been allowed to air dry the 
silicon blocks could be mounted on the slides where they were held by 
hydrophobic interactions, creating eight individual wells on the slide. 
200 ~l of a lx105 cells/ml RAW 264.7 cell suspension was pipetted into the pre­
prepared eight-well glass slides. This cell suspension was created via a similar 
technique to that employed to passage the cells. After removal of culture medium 
from 90% confluent 25 cm2 flasks, the cells were gently scraped off, using a 25 
cm plastic disposable cell scraper, and then resuspended in the appropriate volume 
of cell culture medium. Once the eight well slides were loaded they were 
incubated for 24 hours until approximately 70% confiuent, after which they were 
ready for stimulation. 
RAW 264.7 cells were also grown into disposable 96-well tissue culture plates for 
the purposes of nitric oxide (NO) and cell viability assays. This was achieved by 
pipetting 200 f..ll of a lxl05 cells/rnl RAW 264.7 cell suspension, generated in an 
identical fashion to that used for loading glass slides, per well. Sterilised distilled 
water was also pi petted into the outer most wells of these plates to ensure that the 
plates remained fully hydrated throughout their use. The plates were subsequently 
incubated for 24 hours to achieve an approximate 90% confluency. At this stage 
the 96-well tissue culture plates could be used in stimulation experiments. 
All RAW 264.7 cells used for experiments were maintained within ten passages of 
one another. Stimulation for RAW 264.7 cells was carried out in the same manner 
as for HeLa Ohio cells (section 2.1.1) 
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2.4 MTT Cell viability assay 
The 3-[ 4,5-Dimethylthiazol-2yl]-2,5-dephenyletetazolium (MTT) viability assay, 
based on that of Denziot et al., (1986) and Carmichael et ai., (1987) was used for 
the purpose of assessing RAW cell viability in 96-well tissue culture plates, 
grown and stimulated as described previously (section 2.3.3). After stimulation 
the culture medium was removed and replaced with 25 ~l of MTT solution 
containing 5 mglml MTT (Sigma) in phenol red free Roswell Park Memorial 
Institute (RPMI)-1640 medium. After incubation of the plate for two hours the 
MTT solution was removed, leaving behind the insoluble MTT product. This was 
re-dissolved in a sodium dodecyl sulphate (SDS)-isopropanol mix, consisting of 
1 % wlv SDS (Sigma) and 5% v/v distilled water (dH20) in absolute propyl 
alcohol (Sigma), 100 ~l of which was added per well and mixed by repeated 
aspiration through a pipette. The absorbance of this solution was measured at 570 
nm with background subtraction at 620 nm using the ELISA plate 
spectrophotometer (Rosys Anthos HIlI, Anthos Labtech Instruments, Salzburg, 
Austria). 
2.5 Nitric Oxide (NO) assay 
The Greiss assay, based on that of Green et ai. (1982), allows the quantification of 
nitrite, the stable breakdown product of nitric oxide in aqueous media. In acid 
solution, nitrite is converted to nitrous acid (HN02) which diazotizes 
sulfanilamide. This sulfanilamide-diazonium salt is then reacted with N-(1­
Naphthyl)-ethylenediamine (NED) to produce a chromophore which is measured 
at 540 nm. 
Cell culture medium samples (Phenol Red free) were plated out at 90 ~1 per well 
in a 96-well plate alongside a sodium nitrite (Sigma) standard curve ranging from 
0- 100 ~M nitrite (see appendix; Fig 8.1). 90 ~l sulfanilamide (1% wlv in 3 M 
HeI; Sigma) was added to each well and incubated for five minutes at room 
temperature in darkness. This was followed by the addition of 90 III of a 1% wi" 
solution of NED (Sigma) and a further five minutes incubation in darkness during 
which a chromophore was produced in the presence of nitrite. The absorbance of 
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this chromophore was measured at 540 nm using an ELISA plate 
spectrophotometer (Anthos HII). Unknown nitrite concentrations were determined 
by plotting them off the sodium nitrite standard curve (See appendix Fig 8.1). 
2.6 BioRad™ Protein Assay 
The BioRad™ protein assay was used to determine the protein concentration of 
the sample homogenates. It is based on the Bradford protein assay (Bradford et 
at., 1976) in which the absorbance maximum for an acidic solution ofCoomassie 
Brilliant Blue 0-250 shifts from 465 nm to 595 nm when binding to protein 
occurs. However, it has the advantage over the Bradford assay that it is 
compatible with a wider range of detergents and is therefore compatible with the 
lysis buffers used herein. 
The protein assay reagent was prepared by diluting the BioRad™ dye 1:5 with 
deionised water (diH20), as per instructions. A standard curve of 0 (blank), 1, 2, 
4, 6, and 8 JlI of a 1 mg/ml BSA solution in dH20, was prepared in duplicate using 
a 96-well plate (see appendix; Fig 8.2). The different volumes of protein sample 
involved were found to be small enough relative to the protein assay dye that they 
had no discernible affect on the assay results (see appendix, Fig 8.2). Samples 
were added to separate wells and 200 JlI of diluted dye was added to all wells 
using a multi-channel pipette. Plates were incubated for five minutes in darkness 
at room temperature before being read at 595 nm using a 96-well plate 
spectrophotometer (Anthos HIll). The protein concentration of the samples was 
then read off the standard curve. 
2.7 EMSA (Electrophoretic-mobility shift assay) 
EMSA's are based on the change in molecular mass and charge caused by the 
binding of transcription factors to their target DNA sequence (Latchman, 1993). 
Samples are incubated with a radiolabelled oligonucleotide probe, the sequence of 
which matches the recognition site of the transcription factor of interest. If the 
relevant transcription factor is present it is able to bind the probe. Upon 
electrophoresis the progress of the bound probe through the gel is retarded due to 
its larger size and it forms a distinct band away from the free probe. Subsequent 
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exposure of the gel to auto-radiographic film reveals the position and quantity of 
the radiolabelled probe and, through the use of densitometry software, the amount 
of transcription factor present can be semiquantified. Inclusion of a negative 
control, in which an excess of non-labelled probe has been added, verifies the 
factor identified if it competes successfully with the labelled probe. 
The EMSA protocol used here, based on that of Keates et at., (1997), was used to 
assess the DNA-binding activity of the transcription factors NF'KB and Oct-I. 
Whilst NFKB is ubiquitously expressed, it is only able to bind DNA when it has 
been activated (Baeuerle and Henkel, 1994). Thus, in this study NFKB DNA 
binding indicates activation. 
Radio-labelled NFKB (5'-AGT TGA GGGGAC CGC CCG CGG CCCGT-3', 
Mouse Ig kappa light chain gene; Promega, UK) and Oct-l (5' -TOT CGA ATG 
CAA ATC ACT AGA A-3', Ig heavy chain gene; Promega) probes were created 
by ligation of 32p to these double stranded (ds) oligonucleotides. This was 
achieved as follows: a labelling reaction mixture was created, containing 2 ~l ds 
oligo, 1 JlI lOx kinase buffer (Promega), 1 ~1 T4 kinase (Promega), 2 J..Ll 32p_ATP 
(74 MBq/ml; Amersham), and 4 ~l of nuclease free water (Promega). The 
labelling mix was incubated at 37°C for 30 minutes to allow the ligation reaction 
to proceed. 
The oligonucleotide probe was then separated from the unbound radioisotope on a 
sephadex column. The column was created taking a 5 ml plastic syringe that had 
been plugged with glass wool partially filling it with a Sephadex G-50 gel 
(Sigma) in TE buffer solution (TrisIEDTA, 100 mM, pH eight; Sigma), and 
centrifuging it at 2000 g for five minutes to remove excess moisture. The reaction 
mix was then loaded on to the top of this column and centrifuged at 2000 g for 
five minutes, allowing the elution of the now labelled oligonucleotide probe 
whilst trapping the free isotope within the column. The probe was then diluted to 
a working concentration by the addition of 200 Jll of TE buffer pH 8. 
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2.7. 1 Sample Preparation 
Intestinal tissue was disrupted as follows (refer to sections 2.1 and 2.2 for 
methods of tissue collection). Tissue was shattered under liquid nitrogen using a 
pestle and mortar and put through three successive freeze thaw cycles in lysis 
buffer to ensure the lysis of the remaining cells. The lysis buffer consisted of 
reporter lysis buffer (Promega), protease inhibitor cocktail (Amersham), 0.5 mM 
Dithiothreitol (Dtt; Sigma), and 0.5 mM Phenylmethylsulfonyl Fluoride (PMSF; 
Sigma). After determining the protein content of the samples by BioRad Protein 
Assay (see section 2.6) appropriate aliquots to yield 20 ~g of protein were 
removed to separate 1.5 m1 microtubes and stored at -80oe until use. 
On the day of use, frozen samples were defrosted at room temperature. All 
subsequent steps were carried out on ice. A five times working concentration (5x) 
EMSA buffer was used at 5 III per sample. The 5x EMSA buffer contained 50 
mM Tris pH 7.5 (Sigma), 250 mM NaCI (Merck), 5 rnM MgCI (Merck), 2.5 mM 
Dtt, 2.5 mM, EDT A (Sigma), 20% v/v Glycerol (Sigma), and OAmg/ml sonicated 
salmon sperm DNA (Promega) in nuclease free water (Promega). A negative 
control was created by the addition of an excess (3 Ill) of unlabelled ds probe to a 
sample. The samples were made up to a final volume of 24 III with nuclease free 
water. To this solution 1 ~l of radiolabelled probe was added followed by a 40 
minute incubation on ice to allow the ligation reaction to occur. Subsequently 2 III 
of loading buffer was added and the samples loaded onto a polyacrylamide gel 
(see below for details). The loading buffer consisted of 25% v/v glycerol in 
deionised water (diH20) + 0.04% w/v Bromophenol Blue (Sigma). 
2.7.2 EMSA polyacrylamide gel preparation and running 
A glass plate assembly (BioRad) was assembled as per kit instructions. Briefly, 
three glass plates (-20 x 20 ern), one of which is notched, were first cleaned using 
70% v/v IMS (Merck). The plates were placed in a clamping device with 7.5 mm 
spacers between each plate and with the central plate having its notch orientated 
upwards. These clamped plates were then placed in a pouring rack creating a 
watertight seal at the base of the plates. A 6% v/v non-denaturing polyacrylamide 
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gel solution was then poured between the glass plates and a 20-tooth gel comb 
placed quickly in the top of each gel before it set. The gel solution consisted of 40 
ml diH20, 8.5 ml 40% w/v bis/acrylamide 19: 1 (Anachem, UK), 1.25 ml ten times 
working concentration (lOx) TBE buffer (Sigma), 700 1-11 of 10% w/v ammonia 
persulphate (APS; Sigma), and 60 1-11 N, N, N',N'-Tetra methyl-ethylenediamine 
(TEMED; Sigma). Once the gel was set, the gel combs were removed and the 
wells washed with running buffer (0.25% w/v TBE), using a pasteur pipette, to 
remove any non-polymerised gel. The samples were loaded into each well and the 
gels placed in an electrophoresis tank that was filled with running buffer (0.25% 
v/v TBE buffer). The gels were electrophoresed at 70 rnA using a BioRad power 
pack, for approximately 90 minutes. 
Once the gels had run they were removed from the glass plate assembly, placed 
onto blotting paper (Whatmann, UK), and dried under vacuum at 80DC for 90 
minutes until dry using a gel drier (Model 583, Gel Dryer, BioRad, UK). The dry 
gels were exposed to auto-radiographic film (X-200, X-ograph, UK) in a sealed 
auto-radiographic cassette (X-ograph) for 14 days at -70DC. They were then 
removed from the freezer and allowed to come to room temperature before the 
film was removed and developed using an automatic processor (Kodak). All 
manipulations of undeveloped film were carried out in a photographic dark room. 
The films were analysed using digital optical densitometry software (GelPro Ltd., 
UK) on a computer linked to a flatbed scanner configured to scan using 
transmitted light. 
2.8 Western Blotting 
Western blotting allows the semi-quantitative measurement of a specific protein 
within a given sample. Using a method based on that of Sambrook et al., (1989), 
the sample proteins are separated by gel electrophoresis and transferred to a 
stronger matrix, in this case a nitrocellulose membrane, which is incubated with 
an antibody raised against the antigen of interest. This first incubation is followed 
by a second using an antibody raised against the first antibody and which is 
conjugated to an enzyme (horseradish peroxidase; HRP). This enzyme is then 
allowed to react with a chemi-Iurninescent substrate that causes the evolution of 
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blue light wherever the first antibody has bound. The light is then captured on 
blue light sensitive film (X-200, X-ograph, UK). After development of the film, 
the presence of the target protein can be quantified by densitometry, carried out on 
the image of the bands captured on the film. 
2.8.1 Cell harvesting for Western blot 
Once the cells had been stimulated in 25 cm2 culture flasks (as described in 
section 2.3.1, 2.3.2 & 2.3.3) the cells were washed in ice cold phosphate buffer 
saline pH 7.4 (PBS; Sigma), and then scraped into 1 m1 of fresh ice-cold PBS (pH 
7.4) using a 25 cm disposable cell scraper. This cell suspension was pipetted into 
a 1.5 ml microtube (Labtech, UK) and the cells pelleted by centrifugation at 
12,000 g for five seconds in a rnicrofuge (Sanyo, MSE II), and the supernatant 
removed. At this point the cells were ready for nuclear!cytosolic fractionation. 
2.8.2 Western Blot sample preparation (NuclearlCytosolic fractionation) 
The nuclear/cytosolic fractionation method is based on that of others (Dignam et 
al., 1983; Osborn et al., 1989; Jonat et aI., 1990; Latchman, 1993). All reagents 
used are from the Sigma-Aldrich Company Ltd, unless otherwise stated. 
A cell pellet (see 2.8.1) was re-suspended in buffer A at 70 III per microtube. 
Buffer A consisted of 10 mM HEPES pH 7.9, 1.5 mM MgCb 10 mM KCl 
(Merck), 0.5 mM Dtt, and 0.25% v/v noident P-40. This solution was incubated 
for 20 minutes on ice, during which time lysis of the plasma membrane occurred. 
To retrieve the cytosolic fraction the samples were centrifuged for 15 sec at 12000 
g to pellet the nuclei, and the supernatant (cytosolic fraction) removed and stored 
subsequently at -20°C. 
The remaining nuclear pellet was resuspended in 15 III of Buffer B and incubated 
for 20 minutes on ice. Buffer B consisted of; 20 mM HEPES pH 7.9, 1.5 mM 
MgCh, 0.42 M NaCl, 0.5 mM Ott, 25% v/v Glycerol, and 0.5 mM PMSF in 
diH20. The cell suspension was then centrifuged at 12000 g for 30 seconds in a 
microfuge (Sanyo, MSE II) to pellet the cellular debris and the supernatant 
(nuclear fraction) was removed to a fresh 1.5 ml microtube. This was diluted in 75 
Jll of buffer C that consisted of 20 mM HEPES pH7.9, 50 mM KCl, 0.5 mM Dtt, 
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0.2 mM EDTA, and 0.5 mM PMSF. Just before the nuclear and cytosolic 
fractions were frozen, a BioRad™ protein assay (see 2.6) was performed to 
determine sample protein concentration. 
2.8.3 SDS-PAGE 
Sodium dodecyl sulphate (SDS) - polyacrylamide gel electrophoresis (PAGE) was 
used to separate the sample proteins. An SDS-P AGE gel is a vertical gel that 
contains two distinct layers of gel, a resolving gel at the bottom, and a stacking 
gel at the top. Two glass plates (10 x 10 cm2; Novex) and 1 mm thick spacers 
(Novex), similar to those used for EMSA, were first prepared by cleaning with 
70% IMS and assembled in a gel pouring box as per kit instructions (BioRad). 
The resolving gel consisted of 3.55 ml diH20. 2.5 ml Acrylamidel Bisacrylamide 
(40% 19:1; Anachem), 3.75 rnl of 1.5 M Tris buffer pH 8, 100 III SDS (10% w/v). 
100 J.Ll APS (10% w/v) and 10 III TEMED. This was poured into the bottom of the 
plate assembly. Water saturated isobutanol (isobutanol + 10% v/v diH20) was 
placed on top of the resolving gel whilst it set, creating an airtight seal (02 is 
inhibitory to gel polymerisation) whilst at the same time smoothing the surface of 
the gel. 
Once set, the isobutanol solution was washed off using diH20, and the stacking 
gel poured on top. The stacking gel consisted of 3.64 ml diH20, 0.63 ml 
AcrylamidelBis-acrylamide (40% 19: 1), 0.63 ml of 1 M Tris buffer pH 6.8, 50 J.LI 
SDS (10% w/v), 50 III APS (10% w/v), and 5 III TEMED. A ten-tooth gel comb 
was quickly placed into the top of each gel thereby creating the sample wells. 
Once the gel had set the gel combs were removed and the gel (still supported by 
its glass plates) placed into an electrophoresis tank (Novex) that was filled with 
running buffer containing 25 mM Tris.base (Sigma), 250 mM Glycine (Sigma), 
and 0.1 % w/v SDS in diH20. The tank was filled so that the running buffer 
covered the top of the gel(s). 
With the gels prepared, four times working concentration (4x) loading buffer was 
added to all the samples in the correct volume to yield the correct working 
concentration, and the samples heated for five minutes in freshly boiled water. 
53 

Chapter 2 
The 4x loading buffer consisted of 1 M Tris Hel (pH6.8), 8% w/v SDS, 40% v/v 
Glycerol, and 0.04% w/v Bromophenol Blue. Subsequently, the samples were 
loaded into each well, with one well being set aside for the addition of 5 /-ll of 
molecular weight markers (Rainbow Markers; Amersham). The gels were run at 
40 rnA (Power pack; Rigrunner, Anachem, UK) for approximately 90 minutes 
until the samples had migrated to the base of the gel. With this complete the 
proteins in the gel were transferred to a nitrocellulose membrane by 
electroblotting (see below). 
2.8.4 Electroblotting 
Electroblotting buffer was prepared by the combination of 700 ml diHzO, 100 ml 
of lOx-transfer buffer (200 mM Tris.base and 1.92 M Glycine in diH20), and 200 
ml methanol (AnalaR grade, Merck). Gel sized (approximately 10 cm2) blotting 
paper and nitro-cellulose ECL membrane (ECL Hybond; Amersham) were cut 
and soaked in transfer buffer for five minutes. The SDS-PAGE gel was removed 
from the supporting glass plates and EeL membrane placed on top of the gel. The 
gel and membrane were sandwiched between blotting paper and foam pads placed 
either side. This construction was placed inside the electroblotting module 
(Novex) orientated so that the gel was on the anode side and the membrane on the 
cathode. After filling the module with electroblotting buffer a 200 rnA current 
(power pack; Rigrunner, Anacem, UK) was passed through the module for 45 
minutes. 
2.8.5 Imm un oblotting 
With electroblotting complete the membrane was recovered and protein transfer 
verified by staining with Ponceau S solution (Sigma) for approximately five 
minutes. Ponceau S stains protein red allowing verification of equal protein 
loading and transfer. Membranes, on which equal protein loading had not been 
achieved. were discarded. Subsequently, the membrane was blocked in PBS 
containing 0.05%' v/v tween 20 (PBS-T) and 5 % w/v dried low-fat milk (Tesco, 
Luton, UK). for one hour (or in a PBS-T + 1(k) w/v dried low-fat milk overnight). 
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Once blocked, the membrane was washed twice for five minutes in PBS-T and 
then placed in the primary antibody solution. All antibody solutions contained 
PBS (pH 7.4) with 0.5% v/v Tween 20 and 1% w/v dried low-fat milk (Tesco). 
The primary antibodies (Santa Cruz), used were; polyclonal rabbit anti-p65 (A; 
#SC-109) 1:4000; polyc1onal rabbit anti-p50 (H-119; #SC-7178) 1:4000; 
polyclonal rabbit anti-IKBa (C-21; #SC-371) 1:2000; polyclonal rabbit anti-IKB~ 
(C-20; #SC-946); polyclonal rabbit anti-Bc1-3 (C-14; #SC-185) 1:500; and 
monoclonal mouse anti-PKCE (E-5; #SC-1681) 1:500. The primary antibody 
incubation was carried out at room temperature with agitation for 60 minutes. 
Subsequently the membranes underwent two five-minute washes in PBS-T 
followed by incubation with the secondary antibody at 1 :4000 dilution for 60 
minutes. The secondary antibody was goat polyclonal anti rabbit, horseradish 
peroxidase (HRP) conjugate (Dako, UK), for all the primary antibodies except the 
mouse anti-PKCE antibody. For the anti-PKCE antibody, a rabbit anti-mouse 
antibody was used, followed by a wash sequence and a further incubation with the 
goat anti-rabbit-HRP conjugate. 
With the final antibody incubation complete the membranes were subjected to 
three five minute washes in PBS-To The membranes were blotted dry using 
blotting paper, and covered with ECL substrate for one minute in darkness 
followed rapidly by the exposure of the membrane to a blue light sensitive film 
(X-200, X-ograph, UK). The film was developed by incubation in developer 
(GBX; Sigma) for five minutes followed by a 30 second wash in tap water, then 
an eight minute incubation in fixative (OBX; Sigma) with a final wash in tap 
water. All manipulations of the undeveloped film were carried out in a 
photographic dark room. The films were analysed using digital optical 
densitometry software (OelPro Ltd., UK) on a computer linked to a flatbed 
scanner configured to scan using transmitted light as described previously (see 
section 2.7.2). 
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2.9 ELISA for TNFa and GM-CSF 
To determine cell culture medium concentrations of GM-CSF and TNFa enzyme 
linked immuno-sorbent assay (ELISA) kits were used (Pharmingen). Kits were 
used according to manufacturer instructions. Briefly, all reagents were brought to 
room temperature before use. The ELISA standards were reconstituted in 1 ml of 
diH20, and allowed to equilibrate for 15 minutes. Aliquots of these standards 
were stored at -70°C. To prepare a standard curve, serial dilutions of the standards 
that ranged from 500 - 7.8 pg/ml for TNFa (see appendix; Fig 8.3) and 300 - 4.7 
pg/ml for GM-CSF (see appendix; Fig 8.4), were made in assay diluent. Assay 
diluent consisted of PBS (pH 7, Sigma) + 10% v/v FBS (Helena Bioscience). 
Assay diluent alone served as the control. 
The ELlS As were carried out in 96-well plates that were coated with the 
appropriate capture antibody. This capture antibody was diluted (according to kit 
specific ratios) in coating buffer consisting of 0.1 M carbonate buffer, pH 9.5. 100 
III of this solution was added per well to the 96-well plate, the plate sealed and 
incubated overnight at +4°C. After coating, the plates were washed three times 
with 300 III PBS-T per well per wash. Plates were blocked by the addition of 200 
III assay diluent per well and incubated at RT for one hour. After two washes (as 
above) 100 JlI of standard or sample was added to the appropriate wells and the 
plate sealed and incubated at RT for a further two hours. Subsequently the plates 
were washed five times and 100 III per well detector antibody was added, diluted 
as per individual kit instructions in assay diluent. The plate was sealed, incubated 
at RT for one hour and then washed seven times and 100 JlI per well of TMB 
substrate solution (Pharmingen) was added and the plates incubated for 30 
minutes at RT in darkness. The absorbance of each well was then read at 650 nm 
and the concentration of the samples determined by plotting the unknowns from 
the standard curve (see appendix; Fig 8.3 & Fig 8.4). 
2.10 Immunocytochemistry 
Immunocytochemisty CICC) uses antibodies to detect an antigen on a microscope 
slide, allowing its visualisation and revealing its location at a sub-cellular level. 
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Depending on the antibody used, a plethora of molecules can be detected. RAW 
cell monolayers were examined in this way. Omission of 10 antibody was used as 
a negative control. 
2. 10. 1 Stimulation of RAW cells on slides 
RAW cells were grown onto slides as previously described (see 2.1.4). These 
were then stimulated for one hour using the appropriate stimulant. To accomplish 
this the culture medium was removed from the slides and replaced with either 200 
~l of culture medium alone (control) or medium containing the stimulant. After 
stimulation the slides were washed in ice cold PBS (pH 7.4) followed by 
immediate fixation using the fixative detailed below. ICC was then carried out on 
slides immediately. 
2.10.2 FITC-Immunocytochemisty 
All reagents used were sourced from Sigma-Aldrich Company Ltd, unless 
otherwise stated. Fluorescein 5(6)-isothiocyanate (FITC)-ICC was carried out on 
RAW cells grown on 8 well slides (section 2.1.3). 
Slides were fixed by incubation for ten minutes at room temperature in a bath of 
formaldehyde 2% v/v in PBS (pH 7.4). This was followed by incubation in 
Noident PAO 0.5% v/v in PBS (pH 7.4) for ten minutes at RT, a five minutes 
incubation in 100 rnM glycine in PBS (pH 7.4) and a five minutes incubation in 
PBS + 0.05% v/v Triton-X (PBS-X) at RT. All of these fixation incubations were 
carried out in glass staining dishes (six slide, Sigma). All subsequent antibody 
incubations were carried out in PBS-X containing 1.5% v/v normal goat serum. 
Incubation with the appropriate primary antibody was carried out for one hour at 
RT at a 1:100 dilution using just enough volume to cover the sample area 
(approximately 70 ~l). Primary antibodies (Santa Cruz), raised against specific 
peptides, included; rabbit anti-p65 (A), rabbit anti-p50 (H-119), rabbit anti-I1d3a 
(C-2l), rabbit anti-Bcl-3 (C-14) or mouse anti-PKCc (E-5). The slides were 
washed twice for five minutes each in PBS-X, and the secondary antibody (goat, 
anti-rabbit, FITC conjugate) applied at a dilution of 1:400 and incubated for one 
hour at RT. This was followed by three sets of five-minute washes in PBS-X, after 
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which the slides were mounted in PBS (pH 7.4) containing 20% v/v glycerol. The 
slides were subsequently stored in darkness at +4°C until digital 
photomicrography could be carried out. 
To view the slides either a standard fluorescence microscope was used or a 
fluorescent microscope equipped with digital deconvolution technology. The 
deconvolution technique subtracts ambient light from the focal plane of interest 
thereby allowing the visualisation of a specific slice through the cell. Digital 
photomicrography was used to record these images. 
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3.1 introduction 
NFKB activity has a pivotal role in inflammatory responses (Baeuerle and Henkel, 
1994; Epstein, 1997) and as such is likely to play an important part in the chronic 
inflammation associated with CD. Indeed, the local administration of p65 
antisense phosphorothioate oligonucleotides is able to abrogate clinical and 
histological signs of intestinal inflammation in experimental TNBS-colitis 
(Neurath et al., 1996). Additionally, NFKB activation is likely to be important in 
the gut in general. In the human gastric epithelial cell line AGS, inhibition of 
NFKB activation by pyrrolidine dithiocarbamate (PDTC) reduced H.pylori­
induced IL-8 production by 90%, and active p65 was also found in the gastric 
epithelial cells of patients with H.pylori gastritis (Keates et aI., 1997) thereby 
associating NFKB activation with inflammation in the gut. 
Previous work within our laboratory, by Ellis et ai., (1998) demonstrated an 
increase in the number of cells that stain positive for the active form of p65 in 
inflamed CD tissue compared to non-inflamed controls using ICC. Interestingly, 
an increased number of cells also stained positive for the active form of p65 in the 
non-inflamed regions of intestine in CD patients compared to non-inflamed 
controls (Ellis et al., 1998) suggesting the presence of an underlying abnormality 
in the intestine of CD patient'. In addition, increased levels of pro inflammatory 
cytokines have been found in the non-inflamed mucosa of CD patients (Reimund 
et aI., 1996), a finding indicative of increased NFKB activity (Baeuerle and 
Henkel, 1994). 
However, whilst p65 activity has been previously studied in non-inflamed CD 
tissue (Ellis et al., 1998) no work has yet been carried out to compare the activity 
of the other NFKB subunits in non-inflamed CD tissue versus non-inflamed 
control tissue. This may be important because p65 is not the only subunit to have 
been found in the dimers activated in inflamed intestinal tissue. Indeed, both p50 
(Ardite et al., 1998) and c-Rel have been demonstrated in the NF1d3 dimer(s) 
activated in inflamed CD tissue (Schreiber et ai., 1998; RogIer et ai., 1998). 
60 

Chapter 3 
At the time of starting this study, there had been no other studies carried out to 
examine other members of the NFKB signalling pathway such as the IKB family 
members, even in inflamed CD tissue. Since IKEa. is the primary inhibitor of the 
NFKB subunits present in CD, p65 and c-Rel (RogIer et ai., 1998 & Schreiber et 
al., 1998), IKEa. expression is likely to have an important role in the regulation of 
NFKB activation in CD. It can therefore by hypothesised that IKBa. protein levels 
will drop in inflamed intestinal tissue, since, in the classical model of NFKB 
activation, it is the degradation of IKEa that permits the activation of the p65/p50 
heterodimer (Baeuerle and Henkel, 1994). 
Besides I1d3a., another IKE family member named Bcl-3 may have an important 
role in CD. Bcl-3 is responsible for modulating the activity of p50 homodimers 
(Pan and McEver, 1995; Watanabe et at., 1997) that have more recently been 
shown to be constitutively activated in the intestine (De Plaen et al., 1998), while 
the amount of active p50 homodimer increases in inflamed CD tissue (Ardite et 
al., 1998; Schreiber et ai., 1998). Currently, very little work has been carried out 
on Bcl-3 in vivo and the role of Bcl-3 in inflammatory responses remains to be 
determined. 
As such the initial aim of this chapter was to determine whether NFKB activity in 
CD was increased, either in inflamed or non-inflamed CD tissue when compared 
to non-inflamed control tissue. Secondly, the IKE family members IKBa. and Bcl­
3 were examined to determine whether their degradation was occurring in 
inflamed or non-inflamed CD tissue. 
NFKB DNA-binding activity was measured in inflamed, non-inflamed and non­
inflamed control intestinal tissue, by EMSA. This technique has two advantages 
over the previous ICC work carried out in our laboratory (Ellis et ai., 1998). 
Firstly, EMSA allows total NFKB activity to be measured and not just the activity 
of a single subunit. Secondly, in the previous study (Ellis et ai., 1998) the alkaline 
phosphatase (AP)-ICC technique used did not allow the inclusion of the intestinal 
epithelial layer in the study. This was due to the presence of endogenous AP 
activity in this tissue that can not be blocked by levamisole (Chan and Kellen, 
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1975). The EMSA approach utilised here does not have this limitation and 
therefore allows the incorporation of the epithelium in this study. 
Whilst the EMSA assay is able to measure NFKB activity, this information by 
itself does not prove the presence of increased NFKB activity. Firstly, a change in 
NFKB subunit expression must be ruled out. To this end, the level of p65 protein 
expression was determined by Western blotting. The p65 subunit was chosen for 
this purpose because of its previously demonstrated role in intestinal inflammation 
(see above). 
In addition, EMSAs previously carried out to assess NFKB activity in 
inflammatory diseases (e.g. Asthma; Adcock et al., 1994), in which a number of 
tissue types were examined, have been standardised by ensuring that equal 
amounts of protein are loaded in each well. Implicit in this method, is the problem 
that tissue protein levels may change in inflamed tissue compared to non-inflamed 
tissue. As such, samples loaded on the basis of equal protein content may not be 
reliably standardised for cellular content when comparisons are being made 
between inflamed and non-inflamed tissue. For this reason a potential alternative 
to equalising protein loading for EMS As, has been explored here. The activity of 
the ubiquitous transcription factor Oct-l has been measured with the intention of 
using it to correct NFlcB activity as assessed by EMSA. Oct-l was used since the 
activity of this transcription factor is thought to remain constant (Wang et al., 
1995) and has been used by others as a normalising control (Yoza et a!., 1996). 
Finally, to determine the protein levels of IKBa and Bc1-3 in the intestinal tissues, 
Western blotting was used. 
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3.2 Method 
3.2. 1 EMSA for NFKB activity in human intestinal tissue 
EMSA was carried out as previously described (see section 2.7) with the sample 
volumes loaded, matched for equal protein content. Unfortunately it was not 
always possible to obtain inflamed and non-inflamed tissue from within the same 
patient due to issues concerning patient care and tissue availability. 
For measurement of NFKB activity in resection tissue, the EMSA assay was 
repeated three times in an identical fashion, on the same tissue samples, and the 
results expressed as a mean of these three separate experiments. As only small 
variation between the results of each repeat was observed (CoV <1%) during 
analysis of the resection tissue, EMSA of biopsy tissue was carried out only once. 
Also, within the EMSA for NFKB activity in resection tissue, three patients had 
tissue collected from both inflamed and non-inflamed regions of the intestine. 
These paired tissue samples were analysed in a pair-linked manner. 
Patients. from whom resection tissue samples were obtained, had a mean age of 
44 years ± 17 (SD). Tissue was collected from between the distal colon and the 
terminal ileum. Patient gender was not recorded. 
Patients, from whom biopsy tissue samples were collected, had a mean age of 34 
years ± 9 (SD). Tissue was collected from between the distal colon and the 
terminal ileum. Biopsies from eight female patients and six male patients were 
used. 
3.2.2 EMSA for Oct-1 activity in human intestinal tissue 
To explore the possibJe use of Oct-l as an alternative to equal protein loading for 
intra-sample loading equalisation, Oct-l DNA-binding levels were measured 
using EMSA as described previously (see section 2.7). The samples used were 
derived from the same lysates used for the NFlCB EMSAs. NFlCB activation levels 
were then normalised for Oct-l activity on a sample by sample basis. 
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3.2.3 Measurement of p6S, I1cBa and Bcl-3 protein levels in biopsy tissue 
by Western blotting 
Western blotting was carried out as previously described (see section 2.8) with 
samples loaded into each well to yield a constant protein content. The samples 
used in these experiments were derived from the same lysates that were used for 
EMSA. The Western blot for p65 was repeated once using the same tissue 
samples and the results expressed as a mean of the two separate but identical 
Western blot gels. Due to the small intra-experimental variation observed «1 % 
CoV) the other Western blots were carried out only once. Due to lack of sufficient 
tissue, Western blotting was not carried out on resection tissue homogenates. 
3.2.4 Statistics 
A tissue sample from one patient represents a sample number of one (n= 1). If two 
patients were sampled this constitutes a sample number of two (n=2). The sample 
number used is stated in the figure and table legends. Results are expressed as 
mean ± standard error of the mean (SEM). To determine statistical significance 
results were analysed using the Mann-Whitney V-test (Wardlaw, 1985) with the 
critical threshold value of p<O.05 considered to be significant. 
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3.3 Results 
3.3.1 Oct-1 activity in biopsy tissue from inflamed and non-inflamed 
regions of CD patients and non inflamed controls 
Examination of Oct-l activity showed a statistically significant (p<O.05) increase 
in Oct-l activity in inflamed CD tissue compared to control, whilst the difference 
between inflamed and non-inflamed CD tissue was not statistically significant 
(Fig 3.1). This indicates that increased Oct-1 acti vity is associated with 
inflammation in the intestine. 
When NFKB activity was adjusted for Oct-l activity (see appendix; Fig 8.5) no 
significant difference was observed between any of the tissue types. Due to the 
fact that this finding is in contradiction to all other work published on NFkB 
activity in CD, and that there reason to believe that Oct-l activity may itself be 
affected in inflammation (see discussion; section 3.4.1), Oct-l correction was not 
utilised in the work presented here. 
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Figure 3.1 Oct-l activity in biopsied human intestinal tissue from CD and 
control patients 
Intestinal biopsy tissue was assessed for Oct-l activity by EMSA: a) EMSA film 
showing Oct-l bands, b) optical density (OD) plotted as mean (n= 7) ±SEM. *= 
p<O.05 vs control. The data show increased Oct-l activity in inflamed tissue as 
compared to control, with no significant difference between control and non­
inflamed tissue, or between inflamed and non-inflamed tissue. 
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3.3.2 NF"KB activity in intestinal biopsy tissue from inflamed and non­
inflamed regions of CD patients and from non-inflamed controls 
EMSA was used to determine overall NFKB activity in intestinal biopsy and 
resection tissues. In biopsy tissue, NFKB activity was found to be significantly 
(p<O.05) increased in inflamed CD tissue compared to both control tissue and 
non-inflamed tissue from CD patients (Fig 3.2). No significant difference was 
observed between control and non-inflamed CD tissue (Fig 3.2). Also, no 
significant difference was seen between the age, sex, or disease location for 
patients from which the biopsy tissue was collected (see appendix; Table 8.1). The 
results indicate that NFKB activity is increased in inflamed CD biopsy tissue but 
not in non-inflamed CD biopsy tissue or non-inflamed control biopsy tissue. 
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Figure 3.2 NFlCB activity in intestinal biopsy tissue from CD and control 
patients 
Intestinal biopsy tissue was assessed for NFKB activity by EMSA: a) image of 
EMSA film, negative control = inflamed tissue + excess unlabelled probe, b) OD 
plotted as mean (n=7) ±SEM. * =p<O.05 vs control and non-inflamed CD tissue. 
The data show significantly increased NFKB activity in inflamed tissue as 
compared. to control and non-inflamed CD tissue. 
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3.3.3 Protein levels of p65 in intestinal biopsy tissue from inflamed and 
non-inflamed regions of CD patients and from non-inflamed controls 
Western blotting was used to determine whether p65 protein levels differed 
between control, inflamed CD, and non-inflamed CD biopsy lysates. No 
significant difference was found between any of the three groups, control, 
inflamed CD, or non-inflamed CD (Table 3.1), indicating that p65 protein levels 
are unchanged in CD patients as compared to controls. Moreover, this also 
indicates that the increased NFKB DNA-binding detected in biopsy tissue (Fig 
3.2) is due to increased NFKB activity and not the increased expression of NFKB 
subunits. 
Table 3.1 Protein levels of p65 in intestinal biopsy tissues from CD and 
control patient's 
a) "0 ~ 
........ 
'd r:H 
0 
l:J ~ ~ ..... I ~ 
0 
u 
r:H 
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~ 
0 
z 
b) 
Control I CD inflamed .1 CD non-inflamed 
Mean 
(OD) 
116.1 113.1 137.3 
SEM 17.9 17.3 24.9 
Protein levels of p65 were assessed in intestinal biopsies by Western blotting. a) a 
representative image of a Western blot film, b) OD expressed as mean (n=7) and 
SEM. The data show no significant difference in the protein level of p65 between 
any of the three tissue types. 
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3.3.4 NFKB activity in intestinal resection tissue from inflamed and non­
inflamed regions of CD patients. 

In contrast to the findings in biopsy tissue (Fig 3.2), in resection tissue, no 

significant difference was observed between NFId3 activity in inflamed and non­

inflamed CD tissue (Fig 3.3). This indicates that NFKB activity is equal between 

inflamed and non-inflamed CD resection tissue. Unfortunately, control resection 

tissue was not available for study. 

When inflamed and non-inflamed tissue was taken from within the same patients, 
a trend of higher NFKB activity was observed in the non-inflamed tissue as 
compared to the inflamed tissue (Fig 3.4), although this trend was not statistically 
significant, probably due to sample numbers being too small. This result implies 
that NFKB activity is higher in non-inflamed CD resection tissue than the 
inflamed CD resection tissue. 
70 

Chapter 3 
a) ....... 
0 I-< 
~ 
::: 
0 
u 
~ 
'lj 
(Ij 
b/) 
<l.)
::: 
"0 
S 
(Ij 
<;:i 
;:::l
.... 
"0 
~ 

<;:i 
.S 
:::
I 
0 
;:::l 
b) 
800 
-
600 
0 
~ 
t: 
:::J 
~ 400 
:s-
<'IS 
"­
<'IS
-
"-
200C 
0 
o 
inflamed non-inflamed 
CD tissue type 
Figure 3.3 NFlCB activity in intestinal resection tissue from inflamed and non­
inflamed regions of CD patients 
Intestinal resection tissue assessed for NFKB activity by EMSA: a) image of 
EMSA film; negative control (inflamed tissue + excess unlabelled probe), b) 
Optical density (OD) expressed as mean (n=7) ± SEM. The data show that NFKB 
activity in the inflamed and non-inflamed tissues were not significantly different. 
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Figure 3.4 NFKB activity in intestinal resection tissue from pair-linked 
inflamed and non-inflamed regions from the same CD patients 
NFlCB activity in intestinal resection tissue from inflamed and non-inflamed 
tissue, taken from three patients. The data show that NFlCB activity is consistently 
higher in the non-inflamed tissue of CD patients, as compared to the inflamed. 
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3.3.5 "(Ba and Bcl-3 protein levels in intestinal biopsy tissue from control 
tissue, and inflamed and non-inflamed biopsy tissue from CD patients 
To determine whether IKBa is degraded in inflamed tissue or if its expression is 
abnormal in non-inflamed CD tissue, IKBa protein levels were assessed in 
intestinal biopsies by Western blotting. IKBa levels were found to be significantly 
(p= <0.05) increased in both inflamed and non-inflamed CD tissue as compared to 
non-inflamed control tissue (Fig 3.5). No significant difference was observed 
between IKBa levels in inflamed and non-inflamed CD tissue. 
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Figure 3.5 I KBa levels in biopsied human intestinal tissue from CD and 
control patients 
Intestinal biopsy tissue assessed for IKBa protein levels by Western blot: a) a 
representative Western blot film, b) OD plotted as mean (n=7) ± SEM. * = p<O.05 
compared to control. The data show that 11CBa protein levels are higher in both 
inflamed and non-inflamed CD tissue as compared to non-inflamed controls, 
whilst there is no significant difference between inflamed and non-inflamed CD 
tissue. 
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Bc1-3 protein levels were also assessed by Western blotting in the intestinal 
biopsy tissue, and in contrast to IKBa. (Fig 3.5), no significant difference was 
found in Bcl-3 protein levels between non-inflamed control, inflamed CD or non­
inflamed CD tissues (Table 3.2). 
Table 3.2 Protein levels of Bel·3 intestinal biopsies from CD and control 
patients 
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b) 
Control CD inflamed CD non-inflamed 
Mean 32.5 24.9 41.5 
(OD) 
SEM 6.3 9.8 5.2 
Intestinal biopsy tissue was assessed for Bc1-3 protein levels by Western blot: a) a 
representative image of Western blot film, b) OD expressed as mean (n=7) 
and SEM. The data show no significant difference between Bcl-3 protein levels 
between any of the three tissue types. 
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3.4 Discussion 
3.4. 1 The use of Oct-1 as an alternative sample standardisation method to 
equalisation of protein loading 
To be certain that a representative result is gained during EMSA, it is important to 
standardise sample loading between the inflamed and non-inflamed tissue used 
within this study. The most common method of standardisation, and the method 
used by other groups for EMSA based NF1d3 activity assessment (Schreiber et aI., 
1998; Theile et ai., 1999), is to load sample volumes in each well that have been 
equalised for protein content. However, this method has the inherent problem that 
the protein composition of a tissue can change during an inflammatory response, 
meaning that the amount of protein present changes compared to the number of 
cells present. Thus, the activity of Oct-I, a ubiquitous transcription factor, was 

examined as an alternative to standardisation by protein content. 

EMSA for Oct-l in biopsy tissue revealed significantly higher Oct-l DNA­
binding activity in inflamed tissue as compared to control when samples volumes 
loaded were matched for protein content (Fig 3.4). When these values were used 
to modify the NFKB activity results, no significant changes in NFKB activity were 
seen between either inflamed CD, non-inflamed CD or control tissue (see 
appendix; Fig 8.5). This finding is in contradiction with all other published data 
on NFKB activity in CD. 
In addition, Oct-l is known to repress IL-8 gene expression under control 
conditions, but upon IL-1 ~-stimulation this repression is lost leading to increased 
IL-8 (Wu et aI., 1997) providing evidence of the modulation of Oct-l activity 
during inflammation. Also, UV-induced DNA damage has been shown to be 
associated with increased Oct-I DNA-binding in a process that leads to the up­
regulation of the GADD4S gene (Jin et al., 2001), providing further evidence that 
Oct-l DNA-binding activity is modulated during inflammation. In addition, a 
recent paper has shown that Oct-l can directly interact with both p50 and p65 
subunits of NFlCB, and that together with NFKB, Oct-1 mediates increased TNFa 
production in both CD and UC, through polymorphisms in the TNF promoter 
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(Van Heel et aI., 2002). Thus, because Oct-l activity may not remain constant 
during an inflammatory response, or indeed during CD, Oct-l is unsuitable for 
equalising sample loading of inflamed and non-inflanled tissue samples. 
Significantly, this also implies that the increased Oct-l activity detected in the 
present study, may be partially responsible for the increased TNFa production 
seen in CD (Zarie et aI., 2001), an increase that is vital to the disease pathology 
(Schreiber, 2000). 
Furthermore, overall cell protein levels are less likely to change dramatically than 
the activity of a single transcription factor. Oct-l was, therefore, not used as a 
means of sample standardisation. Instead, sample loading was standardised by the 
equalisation of protein content. 
3.4.2 The NFKB signalling pathway in inflamed and non-inflamed CD 
tissue as compared to non-inflamed controls 
An initial aim of this chapter was to measure NFKB activation levels in the non­
inflamed intestinal tissue of CD patients and compare this to both inflamed 
regions from CD patients and intestinal tissue from control patients. This work 
was undertaken to further examine the previous findings from this laboratory 
(Ellis et al., 1998) which showed an increase in the number of cells staining 
positive for the active form of p65 in non-inflamed CD tissue compared to 
control. The EMSA procedure used here had the advantage over the previous 
work (Ellis et al., 1998) that overall NFKB activity could be measured, whilst the 
ICC technique used previously measured only the activity of the p65 subunit. 
Moreover, the EMSA method used here is able to assess NFKB activity in the 
entire tissue, whilst with the ICC method used previously (Ellis et at., 1998), the 
epithelium of the tissue had to be excluded from the study due to technical 
difficulties (see section 3.1). 
NFKB activity was assessed in both biopsy and resection tissue. Unfortunately, 
lack of availability meant that control resection tissue could not be included in the 
study. 
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Measurement of NF1d3 activity in biopsy tissue, revealed significantly increased 
NFKB DNA-binding activity in inflamed CD tissue compared to both non­
inflamed CD tissue and control tissue (Fig 3.2). No significant difference was 
found between non-inflamed CD biopsy tissue and control (Fig 3.2). To confirm 
that the increase in NFKB activity observed in the biopsy tissues was a result of 
increased NFKB activity and not simply an underlying increase in NFKB 
expression, Western blotting for p65 was carried out. This revealed no significant 
change in p65 protein expression in any of the three tissue groups (Table 3.1). 
As such, it seems likely that whilst the same amount of NFKB dimers are present 
in all three tissue types (Table 3.1), a greater proportion of these dimers are 
activated in inflamed CD biopsies as compared to non-inflamed CD biopsies or 
control tissue. ill confirmation of this hypothesis, others have recently shown that 
NFKB activity is increased in inflamed CD intestinal biopsy tissue compared to 
non-inflamed control tissue, with no change in p65 protein levels detected, 
although non-inflamed CD tissue was not examined in this work (Schreiber et ai., 
1998). Moreover, in previous work within this laboratory (Ellis et al., 1998), and 
more recently confirmed by others (RogIer et ai., 1998), the presence of an 
increase in the number of cells found to stain positive for active p65 subunit in the 
inflamed intestine of CD patients has been demonstrated. Thus, whilst the overall 
levels of active NFKB is increased in inflamed CD tissue (Fig 3.2), this increase is 
likely to be restricted to a subset of cell types. Indeed, in the work of RogIer et ai., 
(1998), co-staining revealed macrophages and epithelial cells to be the 
predominant cells in which p65 is activated. 
hnportantly, the need to examine overall NFKB activity rather than just that of the 
p65 subunit has been recently demonstrated by the finding that the p50 (Ardite et 
al., 1998), p65, and c-Rel (Theile et ai., 1999; RogIer et aI., 1998) subunits are 
present in the NFld3 complex activated in inflamed CD tissue. In fact, it has even 
been suggested that p50 homodimers predominate in the NF1d3 complex activated 
in CD (Ardite et al., 1998). If true, examining only the activation state of the p65 
subunit may not be representative of overall NFKB activity in intestinal tissue. 
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The increased NF1d3 activity in inflamed CD intestinal tissue demonstrated here 
may be induced by a number of factors (Tak and Firestein. 2001). For example. 
the proinflammatory cytokines TNFa and IL-I which are both key in mediating 
intestinal inflammation. can both activate NFKB (Zhang et al., 2000b; Jobin et al .• 
1999). Also, the pro-inflammatory bacterial component LPS, which is highly 
prevalent in the intestine, can penetrate the inflamed intestinal epithelium due to 
its increased permeability (Riki et a!., 2001), and is able to induce NFld3 
activation (MUller et ai .• 1993). Indeed, with NFKB activated by such a wide 
range of stimuli, it is unlikely that any single factor is responsible for its activation 
in inflamed tissue, and its activity need not have any direct bearing on aetiology of 
CD. 
Whilst the work described here on intestinal biopsies clearly demonstrated 
increased NFKB activity in inflamed CD tissue, evidence for increased NFld3 
activity in non-inflamed CD biopsy tissue is absent (Fig 3.2). This may reflect the 
fact that the full depth of the intestinal wall is not sampled in biopsy tissue. In the 
previous work from within this laboratory, resection tissue was used to show an 
increase in the number of cells that stain positive for active p65 in the non­
inflamed CD intestine (Ellis et al., 1998). Indeed, in that study, the submucosa 
was identified as the tissue containing the largest increase in p65 active staining 
cells in non-inflamed CD tissue. However, the submucosa is unlikely to be 
sampled during biopsy, especially considering the fact that the lamina propria is 
likely to swell when it is inflamed. 
Thus, in the present study, NF1d3 activity was also assessed in resection tissue 
from CD patients. In contrast to the results from biopsy tissue (Fig 3.2), no 
significant difference was found in NFKB activity between inflamed and non­
inflamed CD tissue (Fig 3.3). Indeed, in the pair-linked resection samples, where 
non-inflamed and inflamed tissue had been taken from the same patients, NFKB 
activity was consistently higher in the non-inflamed tissue than the inflamed (Fig 
3.4). Unfortunately due to the difficulties in obtaining resection tissue, no control 
tissue could be obtained. Indeed, the lack of other studies on resection tissue 
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probably relates to the difficulties involved in collecting it during surgery since 
the number of operations carried out is relatively low. 
Since increased NFKB activity is well-characterised in inflamed CD tissue (Ellis 
et aI., 1998; Schreiber et aI., 1998; Neurath et ai., 1996; RogIer et ai., 1998), it 
seems likely that the presence of equal NFlCB activity in the inflamed and non­
inflamed CD resection tissue is because NFKB activity in the non-inflamed CD 
tissue is elevated as compared to non-inflamed control tissue. This hypothesis is 
in agreement with previously discussed ICC based findings from within this 
laboratory (Ellis et al., 1998) and the more recent ICC based findings of others 
(RogIer et ai., 1998). 
Whilst the ICC studies would suggest that levels of NFlCB activity are higher in 
non-inflamed CD tissue than non-inflamed controls, the number of cells staining 
positive for active p65 were lower in non-inflamed CD tissue than inflamed CD 
tissue (Ellis et aI., 1998; RogIer et al., 1998). In contrast, in the present study, 
NFlCB activity shows a trend towards higher levels of NFKB activity in non­
inflamed CD tissue as compared to inflamed in resection tissue (Fig 3.3 & 3.4). 
This may reflect the fact that a greater proportion of the NF1<B complex activated 
in the non-inflamed CD tissue is of a dimer that does not contain p65. 
Alternatively, whilst a lower number of cells stain positive for the active form of 
p65 in the non-inflamed CD tissue as compared to the inflamed (Ellis et at., 1998; 
RogIer et ai., 1998), in the non-inflamed CD tissue, the activation of a greater 
proportion of the total cellular NF'KB may occur. 
Increased NFKB activity in non-inflamed CD tissue may have a number of 
possible causes. The presence of inflammation elsewhere in the intestine may 
induce NFKB activity in the non-inflamed intestine. Indeed the results of RogIer., 
(1998) suggest that this may be the case, since they found an increase in p65 
activity in non-inflamed tissue from patients with a non-ffiD inflammation. This 
increased NFKB activity in non-inflamed tissue could be caused by the diffusion 
of cytokines produced at the site of inflammation to non-inflamed intestinal 
regions where they might activate NFKB. Also, the re-circulation of activated 
leukocytes which has been shown to occur from site of mucosal inflammation to 
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other mucosal sites (Van Rees et al., 1997), could result m the spread of 
leukocytes in which NFKB has been activated. 
Alternatively, the presence of increased NFKB activity in non-inflamed CD tissue 
may reflect the fact that NFKB activation, which can take place within minutes of 
stimulation, is simply one of the first responses to occur during the establishment 
of an inflammatory response (Baeuerle and Henkel 1994). As such, NF"KB 
activation actually occurs before the macroscopic manifestation of inflammation. 
However, given the rapidity with which gene expression is brought about after 
NFKB activation, it seems unlikely that NFKB activation would be present for 
long before the tissue becomes macroscopically inflamed. Although, in the 
collagen-induced model of arthritis, increased NFKB activity has been observed 1­
2 weeks before the onset of clinical arthritis (Han et aI., 1998). 
The NFKB dimers thought to be involved in the inflammatory responses of CD 
(e.g. p50/p65, p50/pSO) are inhibited in vitro by IKBa (Henkel et ai., 1993 & 
Pando et al., 2000). It therefore seemed likely that IKBa degradation would play 
an important role in the regulation of NF"KB activity in CD. To explore this, IKBa 
levels were assessed in the intestinal biopsy samples, by Western blotting. 
Surprisingly, increased IKBa levels were observed in inflamed CD tissue (Fig 
3.5), the same tissue in which increased NFKB activity had been detected (Fig 
3.2). This finding contrasts with the recent work of others (Schreiber et aI., 1998) 
in which no significant difference was found in IKBa. protein levels in inflamed 
CD biopsy tissue, although their usage of a lower sample number may be 
responsible for their alternate finding. 
The increased IKBa protein levels observed here may result from an NFKB­
mediated up-regUlation of IKBa. expression. Indeed, three KB response elements 
exist in the IKBa promoter, which have been suggested to be involved in the 
generation of a negative feedback loop that limits NFKB activation. IKBa 
expression is hence induced shortly after NFKB activation (Ito et a!., 1994). The 
increasing levels of IKBa. then function in a negative feedback manner to inhibit 
further NFKB activity and as the IKBa levels increase, IKBa can enter the nucleus 
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and compete with DNA for the binding of NFKB (Zabel and Baeuerle, 1990). As 
such, NFKB activation stimulates its own inhibition. This system does not at first 
seem compatible with the results described here, where both NFKB activity and 
IKBa expression are raised in the same tissue. However, these apparently 
conflicting findings can be explained in two ways. 
Firstly, in the inflamed CD intestine, some cells may have only recently 
experienced NFKB activation, whilst in others, NFKB activation may be more 
established and have already led to an increase in IKBa expression and a 
subsequent return of NFKB activity to control levels. 
Secondly, NFKB activation in the inflamed intestine may have escaped the 
regulatory control of IKBa. This may occur through the postranslational 
modification of either p65 or IKBa which prevents IKBa from successfully 
inhibiting NFKB activity (Bourke et al., 2000). Also, NFkB activation may be 
occurring through the degradation of another IKB family member. Indeed, long­
term NFKB activation, such as that stimulated by n.,-1 or LPS in B cells, has been 
shown to involve IKB~ degradation (Verma et al., 1995; Thompson et al., 1995). 
The IKB~ promoter lacks a KB response element (Baldwin, 1996 & Johnson et al., 
1996) and therefore lKB~ degradation-induced NFKB activation, tends to be 
prolonged as there is no negative feedback loop in place to deactivate NFKB. It is 
also possible that other IKB family members are involved, e.g. IKBc: and IKBy. 
However, it is generally believed that IKBc: and IKBy playa relatively minor role 
in NFKB activation during inflammation (Tak and Firestein, 2001). 
Alternatively, NFKB activation may have escaped the inhibitory control of IKBa 
through the involvement of non-classical NFKB dimers, i.e. those that are not 
bound by IKBa. However, with only the pSO (Ardite et al., 1998), p65, and c-Rel 
(Theile et al., 1999; RogIer et al., 1998) subunits having been shown to be present 
in the NFKB dimer activated in CD, this does not seem likely, as IKBa can inhibit 
p65 and c-Rel containing dimers (Henkel et al., 1993 & Pando et al., 2000). The 
p50 homodimers, on the other hand, are thought to repress KB driven transcription 
82 
Ii" 
Chapter 4 
Chapter 4 

NFKB activation in human mucosal epithelial cell lines 

85 

Chapter 4 
-

4.1 Introduction 
In the previous chapter (chapter three), NPKB activation was shown to occur in 
both inflamed and non-inflamed CD tissue. Indeed, others have also shown NF1d3 
activation to occur in many inflammatory diseases of the bowel, including 
ulcerative colitis (UC) (Schreiber et ai., 1998), non-specific colitis and 
diverticulitis (RogIer et a!., 1998). Furthennore, NFKB activation has been 
demonstrated in animal models of intestinal inflammation, such as the 2,4,6­
trinitrobenzene sulfonic acid (TNBS; Neurath et al., 1996) and platelet-activating 
factor (PAP; De Plaen et aI., 1998) models of colitis. Through such animal 
models, NFKB activation has been shown to be essential in the establishment and 
maintenance of intestinal inflammation. Par example, the inhibition of NF1d3 
activity using p65 antisense leads to the abrogation of inflammation in the TNBS 
model of colitis (Neurath et aI., 1996). Also, the inhibition by Velcade™ 
(Millennium, Cambridge, US; formerly known as MG-341), of the 26S 
proteasome, which is involved in NFICB activation (Traenckner et al., 1994; 
Adams and Stein, 1996), leads to a reduction in the inflammation of the 
peptidoglycan/polysaccharide (PG-PS) model of colitis (Conner et aI., 1997). 
The nuclear localisation of the p50 subunit, which indicates the activation of p50 
containing NFKB dimers, has been demonstrated in the epithelium and lamina 
propria from rats in which intestinal inflammation was induced by PAF treatment 
(De Plaen et al., 1998). Also, the activated form of p65 has been shown to be 
present in epithelial cells in CD, UC and diverticulitis (RogIer et al., 1998). As 
such, whilst NF1d3 activity has been shown to be pivotal in intestinal 
inflammation, this activation has only been shown to occur in a select few cell 
types, including intestinal epithelial cells (IEes). 
Intestinal epithelial cells (IECs) reside at a crucial interface between the body and 
its environment, forming a physical barrier between the mucosal tissue and the 
immense antigenic load of the intestinal lumen, whilst at the same time enabling 
the efficient absorption of the luminal contents. The barrier function of IECs is 
regulated primarily through the modulation of the tight junctions, present between 
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the cells (Sung et al., 1992). Significantly, the function of these tight junctions 
may be modulated by NFKB, since NFKB has been shown to mediate intracellular 
adhesion molecule-l (ICAM-l) expression on intestinal epithelial cells (Jobin et 
ai., 1998a). 
As well as acting as a physical barrier, IECs also express classical MHC class I 
and class II and non-classical MHC class I molecules on their cell surface, thereby 
performing non-professional antigen presentation (Kagnoff and Eckmann, 1997; 
Christ and Blumberg, 1997). In addition, IECs are able to alert the immune system 
to invading pathogens through the generation of pro-inflammatory cytokines such 
as TNFa and GM-CSF, which they produce upon their invasion by pathogenic 
bacteria (lung et ai., 1995). As the expression of MHC molecules (Agresti et aI., 
1998), GM-CSF (MUller et al., 1993) and TNFa (Ito et aI., 1994; lung et ai., 
1995), are all mediated via NFKB activity in other cell types, it is likely that NFKB 
activity also has an important role in IEC function. 
However, the small number of studies carried out to date on NFKB activation in 
IEC, have shown subtle differences in NFKB activation in IECs. For example, as 
per the classical mechanism of NFKB activation (Baldwin, 1996), in 70713 pre-B 
cells, IL-l ~ stimulation leads to the rapid degradation of IKBa followed by NFlCB 
activation (Henkel et al., 1993). In contrast, in IEC lines and freshly isolated 
IECs, an absence of IKBa degradation has been observed during IL-l j3-induced 
NFlCB activation (Jobin et aI., 1997). 
In addition to non-classical NFKB activation in lECs, the stimuli that lead to 
NFKB activation in IEes are relatively poorly characterised. The majority of work 
has focused on the activation of NFKB by pathogenic bacteria. Various invasive 
bacterial strains (e.g. E.eoli; Witthoft et ai., 1998) have been demonstrated to 
induce the up-regUlation of NFKB controlled genes in the colonic epithelial 
tumour cell line Caco-2. The gene up-regulated include iNOS (Witthoft et aI., 
1998) IL-8 (Wu et al., 1997), GM-CSF (MUller et al., 1993) and TNFu (Ito et aI., 
1994; Jung et a!., 1995). Invasive, pathogenic bacteria have also been shown to 
induce NFlCB activation in the small intestinal cell line, T84 (Savkovic et al., 
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1997), as well as the AGS and Kato ill human gastric epithelial cells (Keates et 
ai.,1997). 
Given the importance of NFKB activation in the function of lEC, and the 
significance of IEC in intestinal inflammation, a better understanding of the 
stimuli that induce NFKB activation in lECs, and the mechanisms involved, will 
provide a better understanding of intestinal inflammation. 
Thus, the aim of this chapter was, to determine what stimuli might induce NFKB 
activation, and in turn, to reveal what changes in NFKB-mediated gene expression 
this activation may cause in an IEC line. For this purpose, NFKB activation in 
HeLa Ohio cells was initially investigated. HeLa Ohio cells are a human Negroid 
cervical epitheliaJ cell line, a sub clone of the HeLa cell line. This non-lEC line 
was used because it has the advantage of being highJy prolific and thus easy to 
grow. In addition, HeLa Ohio cells are a mucosal epithelial cell line and therefore 
share a number of characteristics in common with lECs. 
The stimuli used to examine NFKB activation in HeLa Ohio cells were LPS, IL­
l ~ and PMA. LPS was chosen as a stimulus as it is highJy relevant to intestinal 
inflammation due to the high levels of endotoxin found in the intestine (Fiocchi, 
1997; Kagnoff and Eckmann, 1997; RogIer and Andus, 1998). IL-l~ was 
examined due to the central role that it plays in mucosal inflammatory responses 
(Dinarello, 1996). Finally, PMA was used, due to its well-characterised role as a 
general cell activator (Nishizuka, 1984) and as a direct activator of NFKB 
(Bomsztyk et ai., 1991). NFKB activation was assessed by Western bloting, using 
cellular localisation of NFlCB subunits to indicate NFK:B activity and whole cell 
levels of IlCBa measured, to determine whether IKBa degradation occurred. 
Once the stimuli that are likely to activate NFKB in IECs had been determined in 
HeLa Ohio cells, to determine whether they would stimulate NFlCB-mediated gene 
transcription in an lEC line, these same stimuli were investigated in the human 
Caucasian colonic adenocarcinoma line Caco-2. The Caco-2 cell line wa<; chosen 
for this investigation since it is considered to closely resemble normal IEC 
(O'Flatherty et al., 1997). The central role that TNFa plays in the mucosal 
~--~-~----
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immune system has been demonstrated by the successful use of monoclonal 
antibodies raised against TNFa in the reduction in intestinal inflammation both in 
humans and in experimental models (Schreiber, 1998). Therefore, in addition to 
the IL-l~, LPS, and PMA stimuli used in the HeLa Ohio cell line, TNFa was also 
used to stimulate Caco-2 cells. 
Measurement of the expression of NFKB controlled genes was used as a reporter 
of NFKB activity. Indeed, it is important to note that nuclear translocation of 
NFKB need not necessarily imply an effect on gene expression. TNFa (Paul et al., 
1990; Ito et al., 1994), and GM-CSF (MUller et al., 1993) production were 
measured by ELISA, whilst NO production, and therefore iNOS expression (Kim 
et ai., 1997), was assessed using the modified Greiss assay. 
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4.2 Method 
Methods are as described previously (Chapter 2) except: 
4.2. 1 Post-con fluency culture of Caco-2 cells 

For the purpose of NO assessment, Caco-2 cells were grown 14 days past 

con fluency to induce their differentiation, rendering them more responsive to pro­

inflammatory stimuli, such as IFNy (Cavicchi and Whittle, 1999; Chavez et aI., 

1999). This differentiation is similar to that which occurs in vivo upon migration 
of cells from the crypt to the surface of the colon (Engle et aI., 1998). 
Caco-2 cells were grown to con fluency in 96 well plates as described previously 
(see section 2.3.2). They were subsequently cultured for a further 14 days. During 
this period the culture medium was replaced every two days, with old medium 
removed by vacuum using a multichannel pipette under sterile conditions. Care 
was taken not to disturb the cell sheet at the base of the culture wells. Fresh 
culture medium was quickly placed on the cells using a serological pipette. 
4.2.2 Modified Greiss assay 
Due to the low levels of NO produced by Caco-2 cells the standard Greiss assay 
(section 2.5) was not sensitive enough to detect changes in NO production. 
Instead a modified Greiss assay based on that of Marzinzig et al., (1997) was 
used. This modified assay was identical to the standard Greiss assay except that 
Sulfanilamide (1 % w/v in 3 M Hel; Sigma-Aldrich Company, Poole, UK; Sigma) 
was replaced with Dapsone (4,4' -diamino-diphenylsulfone, 14 roM in 3 M HCI; 
Sigma). This modification improves the assay sensitivity ten fold allowing the 
detection of 0.2 J1M nitrite (Marzinzig et at., 1997). 
4.2.3 Reagents used for cell stimulation 
All stimuli used were prepared under sterile conditions. Human recombinant IL­
1~ (R&D ltd, UK) was prepared to a concentration of 1 mglml in PBS (pH7.4) 
containing 1 mg/ml bovine serum albumin (BSA; Sigma). Lipopolysaccharide 
E.coli serotype 026: B6 (Sigma) was prepared in DMEM at a concentration of 10 
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mg/ml. PMA (Sigma) was prepared in Dimethylsulfoxide (DMSO; Sigma) at a 
concentration of 2 mg/mI. All control experiments in which PMA stimulation took 
place contained controls in which equal levels of vehicle (DMSO) were included. 
4.2.4 HeLa Ohio cell experiments 
Each experiment was carried out with one cell flask representing one sample 
number (n=l). All experiments had a minimum sample number of two, with the 
exact replicates carried out displayed within the figure and table legends. HeLa 
Ohio cells stimulated with IL-1P for 0,1,2 and 5 hours. IL-lP was used at a 
concentration of 10 nglml because this concentration has been previously 
demonstrated to induce NF1d3 activation in the bronchial epithelial cell line 293 
(Huang et al., 1997). The relative protein expression of p65 and p50 was 
measured by Western blotting, in the cytoplasmic and nuclear fractions of the 
HeLa Ohio cells, with the nuclear translocation of the NF1d3 subunits indicating 
an increase in NF1d3 activity, as described previously (section 2.8). 
To determine whether IKBa degradation accompanied NF1d3 activation in IL-lP­
stimulated HeLa Ohio cells, the relative protein levels of 11d3a were measured in 
whole ce111ysates HeLa Ohio cells, treated similarly to those above. Cells, were 
stimulated for 0,0.5, 1 and 2 hours, time points chosen because 11d3a degradation 
was anticipated to occur before IL-l p-stimulated NF1d3 activation and return to 
control levels before NF1d3 activation had finished. 
In LPS-stimulated HeLa Ohio cells, LPS was used at a concentration of 1 J..lglml 
since this has been previously shown to induce strong NF1CB activation in 
peritoneal macrophages (Velasco et aI., 1997). The protein levels of p65 and p50 
were assessed by Western blotting, as previously described (see section 2.8). 
IKBa levels were not assessed due to resource and time constraints. 
In PMA-stimulated HeLa Ohio cells, PMA was used at a concentration of 50 
ng/ml, previously shown to be a potent activator of NFKB in T cells (Kerr et al., 
1992). The protein levels of p65 and p50 were assessed by Western blotting, a<; 
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previously described (see section 2.8). IKBa levels were not assessed due to 
resource and time constraints. 
4.2.5 Caco-2 cell experiments 
NFKB-mediated gene expression and NFKB activity in response to pro­
inflammatory stimuli were investigated in Caco-2 cells. Initially, TNFa and GM­
CSF production were measured in Caco-2 cells by ELISA (as described in section 
2.9) in response to a range of IL-l~ concentrations over a 24 hour period. For all 
ELISA experiments, one sample represents one well of a 96 well plate, with a 
sample number of six (n=6) achieved for all ELISA assays. The concentration 
range of IL-l ~ chosen for these experiments was similar to the concentration used 
in the earlier experiments with HeLa Ohio. The cell viability of IL-l~-stimulated 
Caco-2 cells was assessed using the MTT assay (as described in section 2.4). For 
the MTT assay one sample (n=l) represents one well in a 96 well plate, with a 
total of six wells (n=6) having been measured in this assay. To directly determine 
the effect of IL-l ~ on NFJd3 activation in Caco-2 cells, the nuclear and 
cytoplasmic levels of the p65 subunit were measured in cells stimulated with 10 
ng/ml IL-l~ by Western blotting. For Western blotting, one sample (n=l) 
represents one flask of Caco-2 cells with a sample number of two (n=2) achieved 
for this assay. 
To assess the effect of LPS on NFKB-mediated gene expression in Caco-2 cells, 
TNFa. and GM-CSF production were measured by ELISA. In addition, the effect 
of LPS on Caco-2 cell viability was measured using the MTT assay. The LPS 
concentration range of 0-50 J..Lg/ml used was similar to the concentration used in 
the earlier experiments with BeLa Ohio cells. 
In PMA-stimulated Caco-2 cells, production of the NFlCB-mediated genes, TNFa 
and OM-CSF, was measured by ELISA, and the effect of LPS on Caco-2 cell 
viability was measured using the MTT assay. The PMA concentration range used 
had a maximal concentration of 50 ng/mI, the concentration used for the 
stimulation of HeLa Ohio cells, and one considered to be a potent activator of 
NFKB in other cell types e.g. T cells and monocytes (Steffan et ai., 1995). 
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To determine whether a combination of pro-inflammatory stimuli were capable of 
inducing NFlcB-mediated gene expression in Caco-2 cells, 5 ng/rnl IL-l~, 100 
ng/ml TNFa and 10 J!g/ml LPS were used in combination. The concentrations of 
IL-l ~ and TNFa chosen for these experiments replicated the concentrations used 
by others to stimulate NO production in Caco-2 cells (Cavicchi and Whittle, 
1999). In addition, the 10 j.lg/rnl LPS concentration used was identical to that used 
to stimulate Caco-2 cells in earlier experiments (see above). LPS was used 
because it has been shown to induce IFN expression in the mouse myeloid 
leukemic cell line (Onozaki et ai., 1988) and IFN increases the responsiveness of 
Caco-2 cells to stimulation with IL-l~ and TNFa (Cavichi and Whittle, 1999). 
The production of nitric oxide (NO) was measured as an indicator of NFKB 
activity, because expression of iNOS, the enzyme that generates NO in response 
to inflammatory stimuli, is dependent on NFKB activity (Xie et al., 1994). The 
Greiss assay was used to measure nitrite, the stable breakdown product of NO. 
For the purpose of this NO assay, one sample represents one well in a six well 
plate, and the experiment having been duplicated on a different day. 
4.2.6 Statistics 
To determine statistical significance, results were analysed using a Students t test 
(Fowler and Cohen, 1990) with the critical threshold value of p<0.05 considered 
to be significant. 
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4.3 Results 
4.3.1 Effect of IL-1f3 on NFreB activation and IreBa in HeLa Ohio cells 
Following stimulation of HeLa Ohio cells with IL-I p, the effect on NFKB activity 
was determined by measuring the cellular localisation of the p65 subunit by 
Western blotting, with an increase in nuclear localisation indicating an increase in 
NFKB activity. Nuclear levels of the p65 subunit subunit increased with time, 
peaking at approximately 200% time zero levels after two hours, with levels 
having returned to near time zero levels at five hours (Fig 4.1). Cytoplasmic p65 
levels remained unchanged over the five hour stimulation period (Table 4.1) 
indicating that only a relatively small proportion of p65 in the cytoplasm 
trans locates to the nucleus in response to IL-I p stimulation. Neither nuclear nor 
cytoplasmic levels of the p50 subunit changed over the five hour stimulation 
period (Table 4.2), indicating that the p50 subunit is not involved in IL-l B­
stimulated NFKB activation in HeLa Ohio cells. 
When the relative protein levels of IKBa were assessed in whole cell lysates of 
IL-I ~-stimulated HeLa Ohio cells, IKBa levels were shown have decreased by 
58% at 30 minutes stimulation, after which IKBa levels had risen to 
approximately 70% control levels at two hours (Fig 4.2). This suggests that IKBa 
degradation occurred before NFKB activation and indicates that an increase in 
IKBa levels precedes a decrease in the nuclear levels of p65 (Fig 4.1). 
• 
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Figure 4.1 Nuclear levels of p65 in IL.l~ stimulated BeLa Ohio cells 
HeLa Ohio cells were stimulated for 0, 1, 2 or 5 hours with IL-l~ (10 nglml). 
NFKB-p65 levels were assessed in the nuclear fraction of the cells, by Western 
blotting: a) image of a Western blot film, b) mean OD data (n=5) plotted as a 
percentage of the control (time zero) samples ± SEM. The results show an 
increase in the nuclear levels of p65 at one and two hours, with levels dropping 
back towards time zero levels at five hours (*=p<O.05 as compared to control). 
1 2 5 
time (hours) 
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Table 4.1 Cytoplasmic levels of p65 in IL-l~-stimulated HeLa Ohio cells 
a) o 1 2 5 time (hours) 
b) 
p65 levels as a % of control 
Mean Cytoplasmic 100 102 75 76 
SEM o 61 19 43 
He La Ohio cells were stimulated for 0, 1, 2 or 5 hours with IL-l~ (10 ng/ml) 
before harvesting and fractionating to yield the cytoplasmic portion of the cells. 
NFKB-p65 levels were assessed by Western blotting: a) image of a Western blot 
film, b) OD data are expressed as a percentage of control levels with mean (n=5) 
and SEM shown. The results show no change over the five hour stimulation 
period in cytoplasmic p65 levels. 
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Table 4.2 Nuclear and Cytoplasmic levels of p50 in IL.l~·stimulated HeLa 
Ohio cells 
a) o 1 2 5 time (hours) 

b) 
c) 
p50 levels as a % of control 
Mean Nuclear 100 99 115 83 

SEM o 48 65 49 

Mean Cytoplasmic 100 98 73 84 

SEM o 73 8 50 

HeLa Ohio cells were stimulated for 0, 1, 2 or 5 hours with IL-l~ (10 nglml) 
before harvesting and fractionating to yield the nuclear and cytoplasmic portions 
of the cells. p50 levels were assessed by Western blotting: a) image of the nuclear 
Western blot film, b) image of the cytoplasmic Western blot film, lanes as above. 
c) OD data are expressed as a percentage of control levels with mean (n=5) and 
SEM shown. The results show no change over the five hour stimulation period in 
the cellular localisation of p50. 
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Figure 4.2 IKBa levels in IL-lp-stimulated HeLa Ohio cells 
HeLa Ohio cells were stimulated for 0, 0.5, 1 or 2 hours with IL-IP (10 ng/ml). 
IKBa levels were then assessed by Western blotting a) image of Western blot 
film, b) OD data (n= 1) plotted as a percentage of the control (time zero) samples. 
Data are representative of two experiments. The results show a decrease in the 
levels of IlCBa at 0.5 hours with a partial return to control levels at 1 and 2 hours. 
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4.3.2 Effect of LPS on NFKB activation in HeLa Ohio cells. 
The effect of LPS on NFlCB activation in HeLa Ohio cells was determined from 
the cellular localisation of the p65 and p50 NFlCB subunits as measured by 
Western blotting. LPS (1 /lg/ml) stimulation of HeLa Ohio cells induced a time­
dependent increase in nuclear localisation peaking at two hours and maintained 
for at least five hours (Fig. 4.3), indicating that LPS-stimulation induces NFKB 
activation in HeLa Ohio cells. Also, the increased nuclear levels of p65 were 
associated with a decrease in the cytosolic levels of p65 in the LPS-stimulated 
cells (Fig 4.4). This may be because a greater proportion of the cytoplasmic p65 
content translocates to the nucleus in response to LPS-stimulation than occurs 
during IL-l ~-stimulation, in which no change in cytoplasmic p65 levels was 
observed (Table 4.1). However, the low sample number for LPS-stimulated HeLa 
Ohio cells (n=2) makes it difficult to draw a firm conclusion. 
Analysis of p50 levels indicated that LPS-stimulation did not induce a change in 
either nuclear or cytoplasmic levels (Table 4.3), suggesting that the p50 subunit is 
not present in the NFlCB dimer activated by LPS in HeLa Ohio cells. 
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Figure 4.3 Nuclear levels of p65 in LPS-stimulated BeLa Ohio cells 
HeLa Ohio cells were stimulated for 0, 1, 2 or 5 hours LPS (1 J.lglml) before 
harvesting and fractionating to yield the nuclear portion of the cells. Nuclear p65 
levels were assessed by Western blotting: a) image of Western blot film, b) OD 
data (n= 1) plotted as a percentage of the control (time zero) sample. The results 
are representative of two experiments. The results show an increase in the nuclear 
levels of p65 in LPS-stimulated HeLa Ohio cells at 2 hours. 
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Figure 4.4 Cytoplasmic levels of p65 in LPS-stimulated HeLa Ohio cells 
BeLa Ohio cells were stimulated for 0, 1, 2 or 5 hours LPS (1 ~g/ml) before 
harvesting and fractionating to yield the cytoplasmic portion of the cells. 
Cytoplasmic p65 levels were assessed by Western blotting: a) image of Western 
blot film, b) OD data (n= 1) plotted as a percentage of the control (time zero) 
sample. The data are representative of two experiments. The results show a 
gradual decrease in cytoplasmic p651evels with time, in LPS-stimulated cells. 
o 1 2 5 
time (hours) 
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Table 4.3 Cellular location of pSO in LPS-stimulated HeLa Ohio cells 
a) o 1 2 5 time (hours) 

b) 
c) 
p50 levels as a % of control 
Mean Nuclear 100 91 110 90 

SD o 46 53 50 

Mean Cytoplasmic 100 83 84 81 

SD o 22 60 49 

HeLa Ohio cells were stimulated for 0, 1, 2 or 5 hours LPS (1 Ilglrnl) before 
harvesting and fractionating to yield the cytoplasmic and nuclear portions of the 
cells. p50 levels were assessed by Western blotting with 10 Ilg protein loaded per 
well. a) image of nuclear Western blot film, b) image of cytoplasmic Western blot 
c) OD data are expressed as a percentage of control levels with mean (n=2) and 
SEM shown. The data show now significant change in either the nuclear or 
cytoplasmic levels of p50 in LPS-stimulated HeLa Ohio cells. 
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4.3.3 Effect of PMA-stimulation on HeLa Ohio cell NF1(B activation. 
Following PMA-stimulation of HeLa Ohio cells, NFKB activation was determined 
by measuring the cellular localisation of the p65 and p50 NFKB subunits by 
Western blotting. PMA (50 nglml) stimulation induced nuclear translocation of 
p65 with nuclear levels peaking at approximately 300 percent of control at two 
hours stimulation (Fig 4.5), indicating that PMA activates NFKB in HeLa Ohio 
cells. Nuclear p65 had returned to control levels at five hours (Fig 4.5). 
Cytoplasmic levels of p65 appeared unaffected by PMA-stimulation (Table 4.4), 
indicating that the proportion of cytoplasmic p6S that translocates to the nucleus 
upon PMA-stimulation is relatively small. 
Levels of p50, measured by Western blotting, showed a similar trend, with 
nuclear levels peaking at two hours with an approximate 800 percent increase 
compared to control (Fig 4.6), whilst cytoplasmic pSO levels were unchanged over 
the five hour stimulation period (Table 4.5). This indicates that p50 is also present 
in the NFKB dimer activated by PMA and that the amount that translocates to the 
nucleus from the cytoplasm is once again relatively small as compared to total 
cytoplasmic levels of p50. Nuclear levels of pSO were still above control levels at 
five hours indicating that NFKB dimers containing pSO may be activated over a 
longer period of time than those containing p65 without p50. However, it must be 
noted that the low sample number (n=2) and consequent increase in experimental 
error make it difficult to draw definite conclusions concerning PMA-stimulated 
p50 activation. 
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Figure 4.5 Nuclear levels of p65 in PMA-stimulated HeLa Ohio cells 
HeLa Ohio cells were stimulated for 0, 0.5, 1, 2 or 5 hours PMA (50 ng/mJ) 
before harvesting and fractionating to yield the nuclear portion of the cells. p65 
levels were assessed by Western blotting a) Image of Western blot film, b) mean 
OD data (n= 4) plotted as a percentage of the control (time zero) samples ± SEM 
(*=p<O.05 as compared to control). The results show an increase in the nuclear 
levels of p65 with time, which peaks at 2 hours and drops to near control levels by 
5 hours PMA-stimulation. 
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Table 4.4 Cytoplasmic levels of p65 in PMA-stimulated HeLa Ohio cells 
a) o 0.5 1 2 5 time (hours) 
b) 
p65 levels as a % of control 
Mean Cytoplasmic 100 123 94 108 118 
SEM o 47 24 35 41 
HeLa Ohio cells were stimulated for 0,0.5, 1,2 or 5 hours with PMA (50 nglml) 
before harvesting and fractionating to yield the cytoplasmic portion of the cells. 
p65 levels were assessed by Western blotting: a) image of Western blot film, b) 
OD data are expressed as a percentage of control levels with mean (n=4) and SEM 
shown. The data show no significant difference in cytoplasmic p65 levels over 
time, in PMA-stimulated HeLa Ohio cells. 
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Figure 4.6 Nuclear levels of pSO in PMA-stimulated HeLa Ohio cells 
HeLa Ohio cells were stimulated for 0,0.5, 1,2 or 5 hours PMA (50ng/ml) before 
harvesting and fractionating to yield the nuclear portion of the cells. p50 levels 
were assessed by Western blotting: a) image of a Western blot film, b) OD data 
(n= 1) plotted as a percentage of the control (time zero) sample. Data are 
representative of two experiments. The data show a peak in the nuclear levels of 
p50 at 2 hours, indicating the activation of p50 by PMA-stimulation. 
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Table 4.5 Cytosolic levels of p50 in PMA-stimulated HeLa Ohio cells 
a) o 0.5 1 2 5 time (hours) 
b) 
p50 levels as a % of control 
time (ho~r's) ••. 
Mean Cytoplasmic 100 181 140 96 102 
SEM 0 161 132 85 104 
HeLa Ohio cells were stimulated for 0, 0.5, 1, 2 or 5 hours PMA (50 nglml) 
before harvesting and fractionating to yield the cytosolic portion of the cells. p50 
levels were assessed by Western blotting with 10 Ilg protein loaded per well. a) 
image of Western blot film, b) OD data are expressed as a percentage of control 
levels with mean (n=2) and SEM shown. The data show no significant change in 
cytoplasmic p50 levels in PMA-stimulated HeLa Ohio cells over the five hour 
period studied. 
107 

Chapter 4 
4.3.5 Effect of IL-1f3 on Caco-2 cell NF1CB-mediated gene expression and 
NF1CB activity 
Following IL-l ~-stirnulation of Caco-2, NFKB-mediated gene expression was 
determined by measuring the production of TNFa and GM-CSF by ELISA. Also, 
to determine whether any failure to produce TNF-a or GM-CSF was due simply 
to cell death, cell viability was measured by the MTT assay. 
Caco-2 cells stimulated with a range of ll..-lP concentrations showed no 
significant difference in GM-CSF (Table 4.6) or TNF-a (Table 4.6) production. 
Also, no change was observed in cell viability after the 24 hour stimulation period 
except with the highest concentration of 100 ng/ml IL-l ~ which significantly 
(p<O.05) increased Caco-2 cell viability compared to control levels (Fig 4.7). The 
lack of TNF-a or GM-CSF production therefore indicates that IL-I ~ does not 
stimulate NFKB-mediated gene expression in Caco-2 cells. 
NFKB activity was measured directly in Caco-2 cells, in response to IL-l~­
stimulation, through the cellular localisation of the p65 NFKB subunit by Western 
blotting. At 10 ng/mI, IL-l Pdid not stimulate a significant nuclear translocation 
of p65 over the five hour period studied (Table 4.7), indicating that NFKB is not 
activated by ll..-l ~-stimulation in Caco-2 cells. 
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Table 4.6 Effect of IL-l(3 stimulation on Caco-2 cell GM-CSF and 
TNFa. production 
IL-l{3 (ng/ml) a 
MeanGM-CSF 
0.07 0.09 0.10 iO.08 0.09(pg/ml) 
SEM 0.01 0.02 0.01 0.01 0.01 
Mean TNFa 
2.4(pg/ml) 
SEM 2.1 20.3 4.2 0.1 25.7 
Caco-2 cells were grown to confluency before stimulation with a-l~ at 0, 0.1, 1, 
10 and 100 nglml for 24 hours. Cell culture medium was harvested and GM-CSF 
levels (pglml) and TN Fa levels (pglml) assayed by ELISA. Data (n =6) expressed 
as mean and SEM. The data indicate that no significant GM-CSF or TNFa 
production occurred in response to a-I ~-stimulation. 
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Figure 4.7 MTT assay of IL-l~ dose response curve in Caco-2 cells 
Caco-2 cells were stimulated with IL-l~ at various doses for 24 hrs. Cell viability 
was then assessed using the MTT assay. Data (n= 6) are plotted as mean ± SEM. 
The data show a significant increase in the number of viable Caco-2 cells at 100 
ng/ml IL-I ~ (* =p<0.05 as compared to control). 
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Table 4.7 Effect of IL-IJ3 stimulation on nuclear and cytoplasmic levels of p65 
in Caco-2 cells 
a) o 1 3 5 time (hours) 
b) 
."".,.: \·.:{ .. '{iii" ·.·.~\.*Kn.!!.t'" 
, 
c) 
p65 levels as a % of control 
Mean Nuclear 100 69 94 75 
SEM 0 8 20 36 
Mean Cytoplasmic 100 113 206 232 
SEM 0 106 124 90 
Caco-2 cells were grown to confluency before stimulation with JL-l~ at 10 nglml 
for 0, 1, 3, and 5 hours respectively. Cells were then harvested and fractionated 
for analysis of nuclear and cytoplasmic p65 protein levels by Western blot. a) 
image of nuclear Western blot film, b) image of cytoplasmic Western blot c) OD 
data (n=3) are expressed as a percentage of control levels with mean and SEM 
shown. The data show no significant change in p65 levels in either nuclear or 
cytoplasmic fractions in response to IL-l~-stimulation, with time. 
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4.3.6 Effect of LPS on Caco-2 NFICB-mediated gene expression 
The effect of LPS in Caco-2 cells, on NFKB-mediated gene expression, was 
determined by measuring TNFa and GM-CSF levels by ELISA. LPS (0.1 j..Lglml) 
induced a small, compared to that produced in other cell types, but statistically 
significant (p <0.05), increase in TNFa production in Caco-2 cells (Fig 4.8), 
although this effect was not seen with higher concentrations of LPS, nor did LPS 
have any effect on GM-CSF levels (Table 4.9). This indicates that LPS does 
activate NFKB in Caco-2 cells. 
Like the response to IL-l~, LPS caused no significant change in Caco-2 cell 
viability after 24 hours, except at the highest concentration of 50 j..Lglml where a 
significant decrease in cell viability was observed (Fig 4.9). A decrease in Caco-2 
cell viability is not likely to be responsible for the loss of significant TNFa 
production at 1 j..Lg/ml LPS (Fig 4.8) as, at this concentration of LPS, Caco-2 cell 
viability is unchanged as compared to control levels (Fig 4.9). 
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Figure 4.8 Effect of LPS stimulation on TNFa. production in Caco-2 cells 
Confluent Caco-2 cells were stimulated with LPS (E.coli 026:B6) at 0, 0.1, 1, 10, 
and 50 ~g/ml for 24 hIs. Cell culture medium was harvested and TNFa levels 
(pglml) assayed by ELISA. Data (n= 6) plotted as mean ± SEM (*= p<0.05 as 
compared to control). The data show that LPS (0.1 ~glml) induces a significant 
increase in Caco-2 cell no production. 
Table 4.8 Effect of LPS stimulation on GM-CSF production in Caco-2 cells 
GM-CSF (pg/ml) 
Mean 0.056 0.059 0.060 0.066 0.064 
SEM 0.003 0.005 0.06 0.004 0.003 
Caco-2 cells were stimulated with LPS (E.coli 026:B6) at 0, 0.1, 1, 10, and 50 
~glml for 24 hIs. Cell culture medium was harvested and GM-CSF levels (pglml) 
assayed by ELISA. Data (n =6) expressed as mean and SEM. The data shows that 
LPS-stimulation has no significant effect on Caco-2 cell GM-CSF production. 
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Figure 4.9 Cell viability of Caco-2 ceUs after LPS-stimulation 
Caco-2 cells were grown to confluency before stimulation with LPS (E.coli 
026:B6) at various doses for 24 hrs. Cell viability was then assessed by MTT 
assay. Data (n= 6) plotted as mean ± SEM (*=p<O.05 as compared to control). 
Data indicate that 50 f..Lglml LPS-stimulation induces a decrease in Caco-2 cell 
viability. 
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4.3.7 Effect of PMA on Caco-2 cell NFKB-mediate gene expression 
The effects of PMA-stimulation on NFlCB-mediated gene expression in Caco-2 
cells, was detennined by measuring TNFa. and GM-CSF production using 
ELISA. PMA-stimulation had no effect on GM-CSF (Table 4.9) or TNFa 
production (Table 4.9), indicating that PMA-stimulation, and therefore PKC 
activation, is not sufficient to induce NFlCB-mediated gene expression. 
In contrast to the effects of IL-l ~ (Fig 4.7) and LPS (Fig 4.8), a the concentration 
range of PMA used had no effect on Caco-2 cell viability after 24 hours of 
stimulation even at the highest concentration of 50 nglml (Table 4.10). This 
indicates that the failure of PMA to induce GM-CSF or TNFa production in 
Caco-2 cells can not be attributed to a decrease in cell viability induced by PMA. 
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Table 4.9 Effect of PMA-stimulation on GM-CSF and TNFa production in 
Caco-2 cells 
Chapter 4 
PMA (ng/ml) 0 I 0.1 I 1 I 10 I 50 
MeanGM'-CSF 
(pg/mJ) 0.063 0.061 0.066 0.059 0.063 
SEM 0.006 0.011 0.014 0.008 0.004 
MeanTNFa 
(pg/ml) 13.98 27.38 17.59 0.06 0.28 
SEM 3.81 14.67 11.93 0.06 0.24 
Caco-2 cells were stimulated with PMA at 0,0.1, 1, 10 and 50 ng/ml for 24 hours. 
Cell culture medium was harvested and GM-CSP levels (pg/ml) and TNPa levels 
(pglml) assayed by ELISA. Data (n =6) expressed as mean and SEM. The data 
show that PMA does not induce the expression of either GM-CSF or TNFa over 
the concentration range studied. 
Table 4.10 Effect of PMA-stimulation on Caco-2 cell viability 
Viability as Absorbance (570 nm) 
Mean 0.55 0.52 0.46 0.49 0.45 
SEM 0.04 0.06 0.06 0.07 0.09 
Caco-2 cells were stimulated with PMA at 0, 0.1, 1, 10 and 50 ng/ml for 24 hours. 
Cell viability was then assessed by the MTT assay. Data (n= 6) plotted as mean 
absorbance (Abs; 570 nm) and SEM. The data show that PMA-stimulation has no 
significant effect on Caco-2 cell viability over the concentration range studied. 
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4.3.8 Caco-2 cell NO production 
Following stimulation of Caco-2 cells with a combination of IL-ll3, LPS and 
TNFa, the effect on NFKB-mediated gene transcription was determined by 
measuring NO production using the modified Griess assay. A small, but 
statistically significant (p<0.05) increase in NO production of 30 percent was seen 
in response to IL-ll3, LPS and TNFa combined (Fig 4.10). IL-ll3 and LPS used 
together and without TNFa were not sufficient to induce a significant increase in 
NO levels. This indicates that IL-ll3, LPS and TNFa combined are capable of 
inducing NFKB-mediated gene transcription in Caco-2 cells. 
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Figure 4.10 The effect of IL-ll3, LPS and TNFa on NO production in 
differentiated Caco-2 cells 
Caco-2 cells were grown 14 days past confluency before stimulation with either 
lL-ll3 (5 nglml) and LPS (10 Jlg/ml) or IL-ll3 + LPS + TNFa (200 nglml) for 24 
hrs. NO levels were assessed by a modified Greiss assay. Data (n= 3) plotted as 
mean ±SEM (* = p<0.05 as compared to control). The data show that only IL-ll3, 
LPS and TNFa combined were able to induce significant NO production. 
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4.4 Discussion 
The work described here set out to determine what stimuli might induce NFKB 
activation in lECs, and in tum, to reveal what changes in NFKE-mediated gene 
expression this activation may cause. For this purpose, NFICB activation in HeLa 
Ohio cells was initially investigated. 
In HeLa Ohio cells, IL-l~ (10 nglml) stimulation induced increased nuclear levels 
of the p65 (Fig 4.1) subunit whilst nuclear and cytosolic levels of p50 did not 
significantly change (Table 4.2). Associated with the increase in nuclear p65 was 
the degradation of IKEa, which occurred at 30 minutes of IL-I ~-stimulation (Fig 
4.2). lKEa degradation was then followed by a gradual increase in IKBa levels, 
although, at two hours, these levels had not fully recovered to time zero levels 
(Fig 4.2). This suggests that the degradation of lKEa occurs before p65 nuclear 
translocation and also that increased levels of IKBa precede the drop in nuclear 
levels of p65, which occurred at five hours (Fig 4.1). 
This hypothesis is in accordance with the generally accepted model of NF1d3 
activation whereby lKEa is first degraded allowing the nuclear translocation of 
NFlCB followed by up-regulated lleBa expression and consequently the inhibition 
of NFleB activity (Balwin, 1996). Furthermore, IKEa has recently been shown to 
regulate the activation of NFKB dimers containing the p65 subunit (Bohuslav et 
ai., 1998 & Algarte et aI., 1999). Thus, in the present study it has been shown 
that, in HeLa Ohio cells, IL-I ~ induces IleBa degradation and hence NFICB 
activation that involves dimers that contains p65 but not p50. 
The fact that no change in nuclear or cytoplasmic levels of p50 was observed in 
IL-l~-stimulated HeLa Ohio cells indicates, either that the pSO activated by IL-l~ 
could not be detected using Western blotting, or that pSO was not present in the 
NFKB dimer activated. The absence of p50 from the NFKB dimer activated by IL­
1~ would likely have functional consequences since different dimers bind subtly 
different DNA consensus sequences and therefore activate different sets of genes 
(Baldwin, 1996). For exanlple, the p65lc-Rel dimer as opposed to the p6S/p50 
dimer, has been shown to selectively bind the KB sequence in the GM-CSF 
118 

Chapter 4 
promoter (Parry and Mackman, 1994). As such, the alternate dimer composition 
suggested by the results presented here may represent one of the mechanisms by 
which NFKB activation in different cell types can have different results. 
The hypothesis that NFKB is activated by IL-l~ in HeLa cells has recently been 
confirmed by others using EMSA to measure NFKB DNA-binding activity (Yang 
et al., 2001), although the subunits involved were not examined. Moreover, IL­
l ~-induced, NFlCB-mediated gene expression (Kunsch and Rosen, 1993; Hiscott 
et al., 1993) has been previously demonstrated in Caco-2 cells, another epithelial 
cell line, through the induction of the IL-8 and IL-l gene expression (Jung et al., 
1995 & Jobin et aI., 1997). In addition, in the present study, the finding that ll..-l ~ 
induces IKBa. degradation in HeLa Ohio cells (Fig 4.2) has been recently 
confirmed by others who showed a 40 percent decrease in IKBa. at 30 min and 60 
min stimulation in HeLa cells (Yang et al., 2001). 
Like IL-l~, LPS was also found to stimulate nuclear translocation of p65 in HeLa 
Ohio cells (Fig 4.3), without having an effect on p50 levels (Table 4.3). The levels 
of nuclear p65 peal(ed at approximately 180 percent above time zero levels at two 
hours. This was very similar to the peak of 200% at two hours for nuclear p65 
levels in IL-I ~-stimulated HeLa Ohio cells (Fig 4.1). In contrast to IL-l~­
stimulation, in LPS-stimulated HeLa Ohio cells, a decrease in cytoplasmic p65 
levels also occurred (Fig 4.4), indicating that a relatively larger proportion of p65 
translocates to the nucleus upon LPS-stimulation. However, the nuclear and 
cytoplasmic p65 levels may be slightly inaccurate in LPS-stimulated cells due to 
the relatively low sample numbers and the consequent increase in experimental 
error involved. 
The fact that LPS, like IL-1~, induces nuclear translocation of p65 but not p50 
suggests that the signalling pathway activated by LPS may share some common 
components with the pathway which is activated by IL-1~. Indeed the toll like 
receptor (TLR) and the IL-l receptor (IL-IR) share a cytosolic TolllIL-lR (TIR) 
motif. As such, TLRs are thought to belong to the IL-1R superfamily (O'Neill and 
Greene, 1998) and have recently been proposed to activate similar intracellular 
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signalling pathways that eventually lead to NFKB activation (Fig 4.11; Baldwin, 
2001). 
6 8 
__1...11.-______1...11.-__ cell surface plasma 
membrane 
Fig 4.11 Intracellular signalling pathway of LPS and IL-lf}-stimulated NFKB 
activation 
Adapted from Malinin et at., 1997 and Baldwin, 2001. 
However, whilst the HeLa Ohio cells were responsive to LPS, the majority of 
I 
I 
i 
epithelial cells are not (Pugin et at., 1994). This is because detection of resident 
bacterial flora, commonly found at epithelial surfaces, would result in epithelial 
surfaces being in a continuous state of inflanunation. Thus, the fact that LPS 
activates NFKB in HeLa Ohio cells may indicate that this cell line may be more 
responsive to LPS than the majority of epithelial cells. This may reflect the fact 
that HeLa Ohio cells are derived from cervical epithelium. a more sterile 
environment than the intestine. Recently however, others have demonstrated that 
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LPS (10 Ilglml) stimulation of HeLa cells does not induce IL-8 gene expression 
(De Grado et aI., 2001). This would suggest that NFKB-regulated genes may not 
be induced by LPS since IL-8 expression is largely NFKB controlled (Harant et 
aI., 1996). Therefore, NFKB activation in HeLa Ohio cells may not necessarily 
trigger gene expression, possibly because the level of NFKB activation achieved is 
below the threshold required to induce gene transcription. 
While increased nuclear pSO was not detected in response to either IL-l ~ or LPS­
stimulation, this was not the case in PMA-stimulated HeLa Ohio cells. In fact, 
PMA (50 ng/rol) induced marked nuclear translocation of both the p65 (Fig 4.5) 
and p50 (Fig 4.6) subunits. A particularly high level of p50 translocation was 
observed with nuclear levels peaking approximately 700 percent above control 
levels whilst for p6S only a 300 percent increase was observed. The higher 
prevalence of pSO in the nucleus suggests a greater involvement for pSO in the 
NFKB dimers activated by PMA, such as pSO homodimers. Thus, the results from 
this study suggest a different NFKB activation mechanism for PMA-stimulation as 
compared with IL-l ~ or LPS-stimulation, as these stimuli appear to be able to 
activate different NFICB dimer subsets within the same cell type. 
The relative effectiveness of PMA as a stimulant when compared to IL-l~ or LPS 
may be related to the fact that epithelial cells generally possess lower numbers of 
cell surface cytokine receptors, such as IL-l~R, as compared to monocytes (Panja 
et ai., 1998). As such, PMA may be more potent because there is no cell surface 
receptor for PMA and it instead penetrates the cell membrane to directly activate 
proteins containing a Cl domain (Kazanietz, 2002) and thereby activating the 
NFKB pathway (Peters et al., 2000; Wilson et ai., 1999). 
Not only are pSO homodimers activated in response to PMA-stimulation as 
demonstrated here, but also, examples of pSO homodimer activation in response to 
pro-inflammatory stimuli are present in the literature. Activation of pSO 
homodimers has also recently been reported in the intestine of CD patients (Ardite 
et ai., 1998) as well as in the intestine of platelet activation factor (PAF) 
stimulated rats (De Plaen et ai., 1998). Thus, the present study forms part of 
growing evidence to suggest a role for pSO homodimers in inflammatory 
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responses. However, whether this role is as a transcriptional activator or a 
repressor is unclear since p50 homodimers have been proposed to function both as 
a transcriptional activator (Baldwin, 1996) and repressor (Bohslav et at., 1998). 
In addition, the intracellular signalling pathway activated by IL-l ~ and LPS (Fig 
4.11) is likely to differ from that which is activated by PMA as demonstrated by 
the different dimer subsets activated by these stimuli. As previously stated this 
situation probably reflects the ability of PMA to penetrate the cell membrane and 
activate NFKB through PKC activation (Shirakawa and Mizel, 1989) without the 
requirement for cell surface receptor aggregation. 
With activators of NFKB having been established in the mucosal epithelial cell 
line, HeLa Ohio, these same stimuli were used with Caco-2 cells to determine 
whether they are capable of inducing NFKB-mediated gene expression in this IEe 
line. To this end the NFlCB regulated genes, TNFa and GM-CSF, were studied 
and used as reporters of NFKB activation. In addition, to ensure that any changes 
in the production of these reporter molecules did not simply reflect a change in 
cell viability, the MTT assay was used to measure cell viability. 
Neither IL-1 ~ (0-100 nglml; Table 4.6) nor PMA (0-50 ng/ml; Table 4.9) had any 
significant effect on TNFa or GM-CSF cytokine production. However, while LPS 
did not induce significant GM-CSF production (Table 4.8), 0.1 ~glml LPS did 
induce a statistically significant (p<0.05) increase in TNFa production (11 pg/rnJ; 
Fig 4.8). The 11 pg/ml TNFa produced is similar to the 3 pg/ml TNFa recently 
demonstrated to be induced by hypoxia in the small intestinal epithelial cell line, 
T84 (Taylor et at., 1999). However, other cell types are capable of producing far 
higher levels of TNFa e.g. 1000 pg/ml TNFa induced in T cells by PMAlPHA­
stimulation (Gedag et at., 2000). This may indicate that mucosal epithelial cells 
do not stimulate immune responses through the production of TNFa but instead 
focus on leukocyte recruitment by the production of chemo-attractants such as IL­
8 (Jung et at., 1995). 
MTT assay revealed that only high concentrations of IL-l~ (100 ng/ml; Fig 4.7) 
and LPS (50 ~g/ml; Fig 4.9) were associated with a change in cell viability, while 
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PMA had no effect at all (Table 4.10). This demonstrates that any lack of NFKB­
mediated gene expression in Caco-2 cells can not be attributed to a loss of cell 
viability. Thus, of the stimuli examined, only LPS induces NFKB-mediated gene 
expression in Caco-2 cells. However, this expression is selective as, while the 
production of TNFa is up-regulated, the production of GM-CSF is not. 
Furthermore this up-regUlation occurs at a relatively low level as compared to 
other non-IEC lines. 
While in vitro, IEC lines seem to produce low levels of TNFa as compared to 
other cell lines, it must be noted that in vivo, where a number of pro-inflammatory 
stimuli are likely to be present, much higher levels of TNFa may be produced. 
The purpose of TNFa production by IEC may be, in part, the recruitment of 
neutrophils (Ming et at., 1987), one of the first cells to arrive at a site of 
inflammation. Neutrophils can then in turn produce there own range of 
chemotactic agents, thereby propagating the inflammatory response. 
To confirm that the absence of IL-l3-stimulated NFKB-mediated gene expression 
in Caco-2 cells was due to a failure to activate NFKB, NFKB activation was 
measured directly using Western blotting. Results indicated that no nuclear 
translocation of p65 occurred in response to IL-I ~-stimulation (Table 4.7), 
indicating that NFKB activation did not occur. 
In contrast to the lack of effect of IL-I ~ on NFKB activity or NFKB-mediated 
gene expression in Caco-2 cells described here, others have shown IL-1 ~ (10 
nglml) to activate NFKB activity in DLD-1 cells, another human IEC line (Wilson 
et al., 1999). Moreover, IL-l ~ receptors are known to be present on Caco-2 cells, 
albeit a low number (Panja et at., 1998). Thus, the ineffectiveness of IL-1~­
stimulation in Caco-2 cells is likely to reflect either a cell-specific inability of IL­
1~ to induce NFld3 activation, or a requirement for very high levels of IL-l~ to 
stimulate NFKB activation, relative to DLD-1 cells. 
Like IL-1~, PMA also failed to induce the expression of NFKB-mediated genes in 
Caco-2 cells. However, recently, others have shown PMA-stimulated NFKB 
activation in DLD-l cells (Wilson et al., 1999). Thus, it seems likely that the 
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inability of PMA to induce NFtcB regulated gene expression in Caco-2 cells is 
likely to reflect a cell specific deficiency in PMA-induced NFKB activation in the 
Caco-2 cell line, or a requirement for multiple activation signals before gene 
expression can occur in the Caco-2 cell line. 
The fact that, in Caco-2 cells, LPS-stimulation induced an increase in the 
production of TNFa but not GM-CSF, may reflect the presence of different 1CB 
consensus sequences in the promoters of these two genes (Collart et al., 1990; 
Schreck and Baeuerle, 1990). Alternatively, this finding may represent a 
requirement for the activation of other signal transduction pathways before GM­
CSF transcription can commence, indicating that NFKB activation alone is not 
sufficient to induce that activation of both GM-CSF and TNFa, as originally 
hypothesised. Furthermore, LPS has recently been shown to stimulate GM-CSF 
production in monocytes in a NF1d3 independent manner (Meja et aI., 2000) 
indicating that other factors may be more important in GM-CSF gene expression 
than simple NFKB activation. 
Whilst no CD14 mRNA expression has been detected in IECs, rnRNA is present 
for TLR2, TLR3 and TLR4, which co-operate in LPS recognition (Cario et aI., 
2000). Toll receptors, in tum, are known to be involved in signal transduction 
pathways that culminate in NFKB activation (Zhang and Ghosh, 2001). Thus the 
potential for endotoxin-mediated NFKB activation does appear to exist in Caco-2 
cells. However, others have shown LPS to have no effect in Caco-2 cells on IL-8 
production (Schuerer-Maly et ai., 1994 & Jung et aI., 1995), another gene 
regulated by NFKB (Kunsch and Rosen, 1993). Indeed LPS is generally a poor 
activator of mucosal epithelial cell lines (Eckmann et aI., 1993a & 1993b), 
perhaps indicating that a specific lack of certain NFKB signalling pathway 
components in IECs might limit LPS-induced NFKB activation. 
The idea that IECs are relatively unresponsive to pro-inflammatory compounds is 
further supported by the fact that lL-1 ~ and PMA did not induce an NFKB 
dependent response. This lack of responsiveness may reflect the environment of 
lEC in vivo i.e. rich in pro-inflammatory stimuli. Indeed, others have shown that 
stimulation of lECs with pro-inflammatory compounds is not as effective a means 
124 
l 
Chapter 4 
of inducing an inflammatory response as bacterial invasion (Jung et al., 1995 & 
Witthoft et al., 1998). 
Indeed, the growing evidence for delayed or abnormal NFKB activation in lECs as 
compared to other cells, may help explain their unresponsive nature. IEC cell lines 
have delayed and incomplete 11d3a degradation following cytokine activation 
(Jobin et ai., 1997), and it has recently been shown that IECs have lower than 
normal IKK activity (Jobin et al., 1999). Furthermore, they have been 
demonstrated to possess high levels of IKB~ (Thompson et al 1995; Wu et al., 
1999), an IKB family member that is degraded only in response to stimuli that 
induce long-term NFKB activation (Bourke et al., 2000 & Bourcier et al., 1997). It 
is therefore possible that, epithelial cells, which generally possess low numbers of 
cell surface cytokine receptors (Panja et ai., 1998), may require a combination of 
stimuli to accomplish NFKB activation. 
To determine whether a combination of stimuli could induce NFlCB activation in 
Caco-2 cells, LPS, TNFa and IL-l~ were used in combination to stimulate 
significant NO production (Fig 4.10), an indirect indicator of NFKB activity (Xie 
et aI., 1994). When the three stimuli were used together, a small increase in NO 
production by the Caco-2 cells was detected, indicating activation of NFKB by 
these stimuli. LPS (Collart et ai., 1990), TNFa (Israel et aI., 1989) and IL­
l ~ (Shirakawa et al., 1989) have all been shown, on an individual basis, to induce 
NFKB activation in leukocytes. Thus, whilst there is no direct evidence to show 
the ability of these stimuli to activate NFKB in Caco-2 cells, it does seem likely 
that they would. Moreover, the ability of a combination of stimuli to induce NO 
production in Caco-2 cells has been confirmed recently by others, where IL-l~, 
TNFa and IFNy were administered together to achieve a significant increase in 
NO production (Cavicchi and Whittle, 1999). 
While little direct evidence exists for NFlCB activation in IEes, inhibition of 
NFKB is known to be an effective means of down-regulating epithelial 
inflammatory responses. For example, a transfected IKBa super-repressor reduced 
IL-l, TNFa or PMA stimulated iNOS expression in IEes (Jobin et ai., 1998a & 
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1998b). Thus, although NFlCB is not easily activated in IECs, it is still central to 
the generation of these pro-inflammatory responses. 
Chapter 4 
4.4.1 Summary 
In summary, LPS, IL-l~ and PMA all activate NFK.B in BeLa Ohio cells, whilst 
in Caco-2 cells, only LPS is capable of inducing the expression of NFKB­
mediated gene expression and therefore NFlCB activity. While NFKB-mediated 
gene expression was not measured in HeLa Ohio cells, it seems likely that up­
regulation of gene expression will have occurred unless there is a threshold of 
NFKB activation that must be reached before NFKB-mediated gene expression can 
occur. Thus, when taken together, the evidence suggests that NFKB is not easily 
activated in the Caco-2 cells with only LPS able to induce the low-level 
expression of an NFlCB-mediated gene. This situation may reflect the high level of 
pro-inflammatory stimuli that IECs are normally exposed to in vivo. To avoid 
continual activation in this environment IECs may have developed a requirement 
for multiple stimuli to induce an inflammatory response. Thus, only when used 
together were IL-l ~, TNFa, and LPS able to stimulate Caco-2 cell NO 
production. The unresponsive nature of the Caco-2 cells may be the result of a 
low level of cytokine receptor expression, and abnormal NFKB activation. 
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NFlCB activation in a macrophage cell line 
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5.1 Introduction 
Macrophages are a prominent cell type present in the inflammatory infiltrate in 
both CD and DC (Allison et al., 1988; Murch et al., 1993). Moreover, the 
macrophage derived cytokines TNFa (Murch et ai., 1993) and IL-l (Cappello et 
aI., 1992) playa pivotal role in intestinal inflammation. For example, the blockade 
of IL-1 in rabbit immune colitis (Cominelli et ai., 1992) and the blockade of 
TNFa in CD (Targan et aI., 1997) both lead to the resolution of intestinal 
inflammation. Thus, macrophage derived cytokines, and therefore macrophages 
themselves, play an important role in intestinal inflammation. 
The expression of both TNFa (Collart et aI., 1990; Shakhov et aI., 1990) and IL-l 
(Lebedeva and Singh, 1997) genes are regulated at the transcriptional level in 
murine macrophages by NFKB. In CD, macrophages produce both TNFa (Beil et 
al., 1995) and IL-l (McAlindon et al., 1997) and are a primary source of activated 
NFKB in the lamina propria and submucosa (RogIer et al., 1998; Ellis et aI., 
1998). Furthermore, when p65 anti-sense oligonucleotides were administered 
locally to suppress inflammation in the rat DSS model of colitis, the majority of 
these oligonucleotides were found in macrophages (Neurath et ai., 1996). As such, 
NFKB activity seems likely to be of great importance in the inflammatory 
response of macrophages and therefore, highly relevant to intestinal inflammation. 
One of the primary stimuli of NFKB activity in macrophages is LPS, which is able 
to induce the production of pro-inflammatory genes such as iNOS (Kim et ai., 
1997) and TNFa (Collart et aI., 1990; Shakhov et aI., 1990). LPS is prevalent in 
the intestine (Kagnoff and Eckmann, 1997) and has been postulated to playa role 
in the aetiology of CD (Grimm et al., 1995), and DC (Keshavarzian et al., 1992). 
However, the intracellular signalling pathways involved in LPS-stimulated NFKB 
activation in macrophages remains to be fully characterised. 
Currently, the signal transducing receptor for LPS remains to be determined. 
However, a large number of intra-cellular signalling components have been 
identified in LPS-stimulated NFKB activation in both macrophages and other cell 
types. For example, NFKB can be activated in the cytoplasmic fraction of 70'ZJ3, a 
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murine pre-B cell line, by incubation with the catalytic subunit of PKC 
(Shirakawa and Mizel, 1989). Also, in a cell free system derived from the human 
monocytic cell line THP-1, inhibition of PKC prevents LPS-stimulated NFKB 
activation (Ishikawa et al., 1995). However, with at least 11 isoforms of PKC 
existing in RAW cells, all of which differ in sensitivity, stimuli, cellular location, 
and tissue expression (Hug and Sarre, 1993), the PKC isoform involved in LPS­
stimulated NFKB activation remains to be defined. 
In addition to PKC, in peripheral blood monocytes, the inhibition of protein 
tyrosine kinases with herbimycin A and genistein (PTKs) has been shown to 
reduce the LPS-stimulated production of the cytokines TNFa, IL-6 and IL-1 
(Geng et ai., 1993), the expression of which is regulated by NFKB (Baeuerle and 
Henkel, 1994). Furthermore, ERK and p38 have also been suggested to playa role 
in LPS-stimulated NFKB activation in the RAW 264.7 macrophage cell line 
(Hwang et aI., 1997) and histone acetylation, mediated by histone acetyl­
transferases (HATs) may also playa role in the regulation of NFlCB-induced 
transcriptional activity (Perkins et ai., 1997). 
Thus, the aim of this chapter has been, to better define the LPS-induced signalling 
pathways that bring about NFKB activation in macrophages, and thereby, to gain a 
better understand of the signalling pathways involved in NFKB activation in the 
inflamed intestine. To this end, LPS-stimulated NFKB activation has been studied 
in RAW 264.7 cells, a murine macrophage cell line, and the role of PKC, protein 
tyrosine kinases, ERK, p38 MAP kinase, and histone acetylation studied (Fig 5.1). 
Chapter 5 
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Figure 5.1 Diagram of pathways suggested to be involved in NFKB activation. 
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5.2 Method 
Cell culture, stimulation, Western blot, ICC, and Greiss assay methods are as 
described previously (Chapter 2). 
5.2. 1 Approach 
To examine the role of PKC in LPS-stimulated NFld3 activation, Phorbol 12­
myristate 13-acetate (PMA) , a direct activator of DAG-sensitive PKC isoforms 
(Pontremoli et al., 1986) has been used. If DAG sensitive PKC isoforms are 
responsible for NF1d3 activation, then low concentrations of PMA should be able 
to trigger NF1d3 activity. In addition, high concentrations of PMA e.g. 50 ng/mI, 
are known to induce the degradation of certain DAG sensitive PKC isoforms 
(Favaron et at., 1990). Thus, high PMA concentrations may inhibit LPS­
stimulated NF1d3 activity. 
In addition to the PMA approach, the specific inhibitors of PKC kinase activity, 
Bisindolylmaleimide I (Bis) and Go 6983 (Go), were also used. Bis shows high 
selectivity for PKC a, ~J, ~Ij, 'Y, S and e isoforrns whilst Go inhibits PKC a, ~, 'Y, S 
and ~ isoforms. The use of PKC inhibitors provides another means of testing 
whether the PKC family is involved in LPS-stimulated NF1d3 activation. 
As a more isoform specific means of PKC inhibition, MALY TAT-linked 
peptides were used to inhibit translocation of specific PKC isoforms. PKC 
translocation can be important in PKC function (see section 1.3.7). The MAL Y 
peptides mimic the PKC variable regions 1 and 2 eVl-2) that are necessary for 
binding of PKC to the receptors for activated C kinase (RACK) proteins and 
thereby prevent translocation of specific PKC isoforrns. Thus the eVI-2 peptide 
can specifically inhibit PKC£ translocation (Mayne and Murray, 1998). The 
addition of a TAT sequence (GGGGYGRKKRRQRRR-GGGG) to the MALY 
peptides ensures that they are transported into the nucleus, an important facet 
because some PKC enzymes are found there (Martelli et al., 1991). 
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To investigate the role of tyrosine kinases in LPS-stimulated NFKB activation the 
Src kinases have been targeted using the inhibitor PP2. If Src kinases are 
involved, their inhibition should cause a decrease in LPS-stimulated NF1d3 
activity. 
To investigate the role of the ERK pathway, the inhibitor PD98059 (PD) has been 
used and for the p38 MAP kinase pathway, the inhibitor SB203580 (SB) has been 
used. Once again, if ERK or p38 MAP kinase family members are involved in 
LPS-stimulated NF1d3 activity, their inhibition should cause a decrease in LPS­
stimulated NF1d3 activity. 
NFKB activity has been measured directly by Western blotting, using the nuclear 
translocation of NFKB subunits to indicate NFKB activity. ICC was used as an 
alternative and confirmatory method for the detection of the nuclear translocation 
of NFKB subunits. In addition, the IKB family members IKBa and Bcl-3 are likely 
to have an important role in NFKB activity in the intestine (see chapter three), and 
as such, their protein levels were assessed both by Western blotting and ICC. 
In addition to the direct measurement of NFlCB activity, the levels of NFkB 
mediated gene expression was also assessed. This was done through the detection 
of the free radical nitric oxide (NO), the production of which is easily measured 
by the Greiss assay. NO is produced through conversion of arginine and ATP by 
the nitric oxide synthase (NOS) family of enzymes (MacMicking et aI., 1997). Of 
the two types of NOS that exist in macrophages only inducible NOS (iNOS) is up­
regulated by pro-inflammatory stimulation and is capable of producing high 
concentrations of NO that can have a direct anti-microbial activity as well as cell 
signalling functions (MacMicking et ai., 1997). 
The gene promoter of iNOS contains 22 putative transcription factor binding 
elements (Xie et ai., 1993) but only the K.B element is essential in large-scale 
iNOS up-regulation (Kim et aI., 1997 & Xie et al., 1994). Thus, NO production 
has been used here as a marker for NFKB activation. 
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5.2.2 Reagents used for cell stimulation and inhibition 
Lipopolysaccharide E.coli serotype 026: B6 (Sigma) was prepared in DMEM at a 
concentration of 10 mg/ml for the stock solution. Appropriate dilutions were then 
made to achieve the working concentration of 1 Jlglml that was established 
through preliminary investigations (described in sections 5.2.2 and 5.3.1). 
The DAG molecular mimic, PMA (Sigma), was prepared in DMSO at a 
concentration of 2 mg/ml. PMA was used in a concentration range previously 
shown to induce NFKB activation (chapter 4) and to cause the degradation of 
some PKC isoforrns (Favaron et al., 1990). 
In all experiments in which the stimulant used had been dissolved in a vehicle 
(Dimethylsulfoxide; DMSO; Sigma), the experimental controls contained 
matching levels of the vehicle. 
For the purpose of the specific inhibition of PKC translocation the following 
MALY-TAT linked peptides were used: MALY 01 (Classic PKC inhibitor, cVl­
2) =TAT- RFARKGALRQKNHEVK, MALY 10 (PKCE inhibitor, EVl-2) = 
TAT- EAVSLKPT, MALY II (scrambled PKCE inhibitor) =TAT- LSETKPAV. 
These were kindly provided by Dr Ian Adcock (Imperial College, London) and 
used at concentrations previously established to be efficacious for the inhibition of 
specific PKC isoform translocation (Yedovitzky et al., 1997). 
The PKC inhibitor Bisindolylmaleimide (Bis; Calbiochem, Beeston, Nottingham, 
UK) was prepared in DMSO at a concentration of 20 mM. It was used at a final 
concentration of 20 J.LM, previously shown to effectively inhibit the PKC a, ~I' Brr, 
y, 5 and E isoforms (Ku et al., 1997) 
The PKC inhibitor {2-[1-(3-Dimethylaminopropyl)-5-methoxyindol-3-yl]-3-( 1H­
indol-3-yl) malernide} (Go 6983; Calbiochem) was prepared in DMSO at a 
concentration of 10 mM. It was used at a final concentration of 10 J.LM, previously 
shown to effectively inhibit the PKC a, B, y, 5 and Sisoforms (Gschwendt et al., 
1996). 
The Src inhibitor {4-arnino-5-( 4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4­
d]pyrimidine} CPP2; Calbiochem) was prepared in DMSO at a concentration of 50 
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mM. The concentration range used has been previously shown to inhibit the Src 
kinase family (Hanke et al., 1996). 
The JAK2 inhibitor [a-cyano-3,4-dihydroxy)-N-benzylcinnarnide] (AG-490; 
Calbiochem) was prepared in DMSO at a concentration of 10 mM. It was used 
over a concentration range previously shown to 0 be specific for JAK2 inhibition 
(Levitzki, 1990). 
The ERK inhibitor 2' -Amino-3' -methoxyflavone (PD980589; Calbiochem) was 
prepared in DMSO to a concentration of 10 mM. The concentration range used 
has been previously shown to inhibit the ERK protein family (Dudley et aI., 
1995). 
The p38 MAP kinase inhibitor [4-( 4-Flurophenyl)-2-( 4-methylsulfinylphenyl)-5­
(4-pyridyl)1H-imidazole] (SB203580; Calbiochem) was prepared in DMSO to a 
concentration of 10 mM. The concentration range used has been previously shown 
to inhibit the p38 MAP kinase protein family (Lee et al., 1994). 
The histone deacetylase (HDAC) inhibitor trichostatin A (TSA) was prepared to a 
concentration 1 Ilg/ml in DMSO. TSA was used over the concentration range of 
0-10 ng/ml that has previously been shown to effectively inhibit HDAC activity 
(Gray and Ekstrom, 1998). 
5.2.3 RAW cell experiments 
The RAW 264.7 murine macrophage cell line was selected for use in this work 
because of its ability to grow prodigiously, and its ability to secrete high levels 
(50 !lM) of NO in response to LPS (Wang et aI., 1994). 
For the purposes of NO assay, RAW cells were grown in 96 well plates (see 
section 2.1), and stimulated for 24 hours, with a minimum of six wells used for 
each individual treatment. A 24 hour stimulation period was chosen after an 
analysis of NO produced over time demonstrated that the majority of NO (greater 
than 95 percent) was produced during the initial 24 hour stimulation period. This 
same 24 hour stimulation period has been used by others for the assay of LPS­
stimulated NO production in RAW cells (Paul et aI., 1997). Immediately after 
stimulation, cell viability was assessed using the MTT assay (see section 2.4). 
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Over the 24 hour stimulation period 1 ~g/ml LPS was found to induce significant 
NO production (Fig 5.1) without causing a decrease in cell viability (Fig 5.2). For 
this reason 1 Jlg/ml LPS was used for all subsequent experiments. 
To confirm that the NO detected was generated by NOS activity, the NOS 
inhibitor NG-Nitro-L-arginine Methyl Ester (L-NAME; Kubes et al., 1991) was 
used. The concentration-effect curve (0-100 ~) utilised was chosen since 100 
~M has previously been shown to inhibit NOS activity (Kubes et al., 1991). 
For the purposes of Western blotting experiments, RAW cells were grown in 25 
cm2 flasks (see section 2.1) and stimulated for up to five hours with the 
appropriate stimuli. This experiments were carried out over five hours to allow 
comparisons with results from Chapter Four. A minimum sample replicate of two 
was achieved for all Western blots. 
For the purposes of Immunocytochemistry (ICC) experiments, RAW cells were 
grown onto slides (see section 2.1) and stimulated for one hour. This time period 
was chosen because results from experiments analysed by Western blotting 
demonstrated nuclear translocation of p65 within this period, and this is a time 
commonly used to study NFKB activation (Ellis et at., 1998). The images cell ICC 
stained cells presented are representative of the entire slide. 
5.2.4 Statistics 
For the purposes of Western blotting, one sample number equals one flask of 
cells, with exact sample numbers of each result expressed in the figure and table 
legends. For the purposes of Greiss assay, one sample number represents one well 
of a 96 well plate, with exact sample numbers expressed in the figure and table 
legends. For the purposes of the MIT assay, one sample number represents one 
well of a 96 well plate, with exact sample numbers expressed in the figure and 
table legends. In situations where a second experiment was carried out, this 
second experiment was carried out on a different day from the first, and duplicates 
the first, although the results are not shown. To detennine statistical significance, 
results were analysed using a Students t test (Fowler and Cohen, 1990) with the 
critical threshold value of p<O.05 considered to be significant. 
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5.3 Results 
5.3.1 Effect of LPS on RAW cell NO production 
To determine the appropriate concentration of LPS to use for subsequent 
experiments, RAW cells were stimulated for 24 hours with a concentration range 
of 0-50 Jlg/ml LPS, and the accumulated NO breakdown production, nitrite, was 
assessed by Greiss assay. 
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Figure 5.2 Effect of LPS-stimulation on RAW cell NO production 
RAW cells were treated with various concentrations of LPS (E.coli 026:B6) for 24 
hrs before removal of cell culture medium for nitrite measurement by Greiss 
assay. Data from one experiment (n= 9) are plotted as mean ±SEM (*** = 
p<O.OOl as compared to control), and are representative of two separate 
experiments. Data show a significant production of nitrite, and therefore NO, at 1 
J.lg/ml LPS and above. 
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Unstimulated RAW cells were found to produce little or no detectable NO. 
However, NO production was induced in a concentration dependent manner by 
LPS-stimulation (Fig 5.2). LPS at 1llg/rnl significantly increased (p= <0.001) NO 
production whilst a maximum NO production of 40 ~ was reached with 10 
J..lg/ml LPS, with no further increase at the higher concentration of 50 J..lglrnl LPS. 
Assessment of cell viability by MTT assay showed that 0.1 J..lglrnl LPS 
significantly (p<O.Ol) increased absorbance compared to the control, whilst 10 
and 50 Ilglml LPS significantly decreased absorbance (Fig 5.3). The increase in 
absorbance at the 0.1 Ilg/ml LPS concentration is probably a result of increased 
cell number induced by the activation of cells in response to LPS-stimulation. The 
decrease in absorbance detected at the higher LPS concentrations is likely to 
represent a decrease in cell viability. This finding was confirmed by the 
observation of shrivelled cells upon microscopic inspection of the cells (results 
not shown). 
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Figure 5.3 MTT assay of LPS-stimulated RA W cells 
The same cells used in Figure 5.2 were assayed for cell viability by MTT assay 
after removal of cell culture medium for Greiss assay. Data from one experiment 
(n= 9) are plotted as mean ± SEM (** = p<O.Ol, *** = p<O.OOl as compared to 
control), and are representative of two separate experiments. The data show an 
increase in viable cells at 0.1 mg/ml LPS and a decrease in cell viability at 10 and 
50 ~g/ml LPS. 
These experiments indicate that 1 jlglml LPS induces significant NO production 
in RA W cells without any effect on RAW cell viability. Therefore 1 jlg/ml LPS 
was the concentration used for all subsequent experiments. 
i 
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To determine the time period over which the LPS-stimulated NO production 
occurred, a time course of LPS-stimulated NO production was performed over 96 
hours. Analysis of 1 Ilglml LPS-stimulated NO production over different time 
points revealed that the majority of NO, approximately 42 IlM, was produced 
during the first 24 hours of stimulation (Fig 5.4). After 24 hours stimulation the 
medium was replaced with fresh medium, again containing LPS, and only a 
further 7 IlM nitrite was produced. Between 48 and 96 hours, only a further 4 IlM 
nitrite was produced. This indicates that the majority of LPS-stimulated NO 
production occurs during the intial 24 hour period. 
50 
* 
40 
-:E 30 
.a. 
CI) 

.'!::

... 20 
Z­
10 
 *** 
*** 
0 
0-24 24-48 0-48 48-96 
time (hours) 
Figure 5.4 LPS-stimulated RAW cell NO production over differing time 
points 
RAW cells were treated with LPS (l Ilg/ml) for varying time points with the 
medium and LPS replaced with fresh after either 24 or 48 hours. Data from one 
experiment (n= 6) are plotted as mean ± SEM (* = p<O.05, *** = p<O.OOl 
compared to 0-24 hrs), and are representative of two separate experiments. The 
data shows that the majority of NO production in response to LPS-stimulation 
occurs in the first 24 hours, with significantly less NO produced during the 
following 48 hours. 
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To confirm that the NO detected (Fig 5.2) was indeed a result of NOS activity and 
not due to miscellaneous nitrite production, the NOS inhibitor L-NAME was used 
(Fig 5.5). As expected, L-NAME alone did not induce NO production (Fig 5.5). 
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Figure 5.5 Effect of L-NAME on NO production in RA W cells. 
RAW cells were treated with the NOS inhibitor L-NAME at 1, 10 and 100 ~ for 
24 hours. Data (n= 6) are plotted as mean ± SEM. L-NAME stimulation did not 
induce significant NO production. 
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Figure 5.6 Effect of L-NAME on RAW cell viability. 
The RAW cells used in Figure 5.5 were incubated with MTT for a further 2 hrs 
after removal of cell culture medium. Data Cn= 6) are plotted as mean ± SEM (* = 
p<O.05, *** = p<O.OOl as compared to 0 ~M L-NAME). The data show that L­
NAME alone, increases the number of viable cells at 10 llM, whilst at 100 ~ it 
significantly decreases them. 
MTT viability assay showed that when used alone 10 ~M L-NAME caused a 
small but significant increase in RAW cell viability whilst 100 ~ L-N AME 
caused almost complete cell death (Fig 5.6). These results indicate that treatment 
with 10 llM L-NAME leads to increased mitochondrial respiration (the cell 
function measured by the MTT assay) whilst 100 ~ L-NAME causes a 
significant decrease in the number of viable cells that are present. 
0 
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When used in conjunction with LPS, L-NAME inhibited LPS-stimulated NO 
production in a concentration dependent manner leading to the almost complete 
aborogation of LPS-stimulated NO production at 100 ~ L-NAME (Fig 5.7). 
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Figure 5.7 Effect of L·NAME on LPS-stimulated NO production in RAW 
cells. 
RAW cells were treated with the LPS at 1 /lg/ml and the NOS inhibitor L-NAME 
at 1, 10 and 100 j.lM for 24 hours. Data from one experiment (n= 6) are plotted as I 
mean ± SEM (*** =p<O.OOl as compared to LPS alone), and are representative 
.'of two separate experiments. The data show that 1 !lM L-NAME significantly 
(p<O.OOl) inhibits LPS-stimulated NO production, and that this effect increases in 
a concentration dependant manner. 
When L-NAME was used in conjunction with LPS (1 Ilglml), L-NAME increased 
cell viability in a concentration dependent manner (p<O.OOl) when compared to 
LPS alone (Fig 5.8). However, 100 IlM L-NAME, when used in conjunction with 
LPS, was associated with the near total absence of viable cells (Fig 5.8), in an 
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identical manner to when 100 J!M L-NAME was administered alone (Fig 5.6). 
These findings indicate that the inhibition of NOS NO production rescues the 
RAW cells from LPS associated cell death and therefore suggests that it is the NO 
production that causes this RAW cell death. These results also suggest that the 
highest concentration of L-NAME is toxic and induces cell death before the 
initiation of LPS-stimulated NO production. 
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Figure 5.8 Effect of L·NAME and LPS on RAW cell viability 
The RAW cells used in Figure 5.7 were incubated with MTT for a further 2 hrs 
after removal of cell culture medium. Data from one experiment (n= 6) are plotted 
as mean ± SEM (*** = p<O.OOl as compared to control), and are representative of 
two separate experiments. The data show that LPS induces a decrease in cell 
viability, but that L-NAME can reverse this effect with LPS + 10 J!M L-NAME 
stimulation resulting in a higher number of viable cells than in the control group. 
However, the highest concentration of L-NAME causes an almost complete loss 
of cell viability. 
Interestingly, in LPS treated cells, 10 J!M L-NAME induces a significant increase 
in mitochondrial respiration levels over those of the control suggesting that when 
the negative effects of NO production are removed (Fig 5.8), LPS actually 
stimulates cell growth and/or metabolic activity. 
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5.3.2 The effect of LPS on NFfCB activation in RAW cells 
To study the effect of LPS (1 ~g/ml) on NF1d3 activity directly, the cellular 
localisation of p65 was assessed by Western blotting (Fig 5.9). Nuclear levels of 
p65 peaked at approximately 400% above control levels at two hours of LPS­
stimulation and thereafter remained unchanged upto five hours of stimulation (Fig 
5.9). Cytoplasmic levels of p65 were not found to significantly change at the time 
points studied (Table 5.1). The absence of any change in cytoplasmic p65 whilst 
nuclear p65 levels increase, may signify that only a small proportion of the total 
cellular p65 is activated by LPS. Thus, while p65 is moving from the cytoplasm to 
the nucleus, the change in cytoplasmic levels is too small to detect. 
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Figure 5.9 Nuclear levels of p65 in LPS-stimulated RAW cells 
RAW cells were stimulated with 1 llg/ml LPS for 0, 1, 3 and 5 hours. The cells 
were then harvested and lysed to yield the nuclear fraction in which p65 levels 
were assessed by Western blotting. The data show increasing nuclear p65 levels, 
peaking at 3 hours and remaining unchanged at 5 hours: a) a representative image 
of a Western blot film, b) data Cn= 6) plotted as mean % of control, ± SEM 
(*=p<0.05 as compared to control). 
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Table 5.1 Cytoplasmic levels of p65 in LPS-stimulated RAW ells 
a) o 1 3 5 time (hours) 
b) 
Mean Cytoplasmic 100 87.9 119.3 81.1 
SEM o 10.5 36.7 13.3 
RAW cells were stimulated with 1 ~g/ml LPS for 0, 1, 3 and 5 hours. The cells 
were then harvested and lysed to yield the cytoplasmic fraction in which p65 
levels were assessed by Western blotting. The data show no change in 
cytoplasmic p65 levels over the 5 hour stimulation period: a) a representative 
image of a Western blot film, b) data (n= 6) plotted as mean % of control, ± SEM. 
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ICC was used as a confirmatory method for the detection of NFKB activation in 
LPS-stimulated cells. Stimulation of RAW cells with LPS (1 J.lglml) for one hour 
induced nuclear translocation without any visible decrease in cytoplasmic levels 
(Fig 5.10). These findings correlate with those from the Western blotting (Fig 5.9 
& Table 5.1). Interestingly, the p65 nuclear localisation observed was punctuated 
in appearance. This may represent the physical proximity of an increased number 
of gene promoters targeted by the LPS activated NFKB. 
a b 
Figure 5.10 ICC for p65 in RAW cells 
RAW cells were stimulated with (a) medium alone or (b) LPS (1 J.lglml) for 1 
hour before the cells were formaldehyde fixed and stained for p65 localisation by 
ICC. Images were captured using a digital deconvolution technique (x 600), and 
are representative of two experiments. The images show increased nuclear 
staining in the LPS-stimulated cells with no visible change in cytoplasmic p65 
levels. The red arrows indicate areas of intense staining that may represent the 
physical proximity of numerous KB promoters. 
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5.3.3 Effect of LPS-stimulation on RAW cell "(Ba expression and 
localisation 
To assess the effect of LPS-stimulation on 11d3a protein levels in RAW cells, 
Western blotting was used. Stimulation with LPS (1 /lg/ml) was found to have no 
effect on either nuclear or cytoplasmic (Table 5.2) levels of IKBa at up to five 
hours of stimulation. 
Table 5.2 Nuclear and Cytoplasmic llCBalevels in LPS-stimulated RAW cells 
a) o 1 3 5 time (hours) 
b) 
c) 
Mean Nuclear 100 104.5 103.2 108.3 
SEM o 6.9 3.4 2.4 
Mean Cytoplasmic 100 90.4 109.2 96.0 
SEM o 6.9 2.9 2.8 
RAW cells were stimulated with one J,Lg/ml LPS for 0, 1, 3 or 5 hours. The cells 
were then harvested and lysed to yield the nuclear and cytoplasmic fractions in 
which IKBa levels were assessed by Western blotting. The data show no 
significant change in nuclear or cytoplasmic IKBa protein levels over the 5 hour 
stimulation period: a) a representative image of a nuclear fraction Western blot 
film, b) a representative image of a cytosolic fraction Western blot film, c) data 
Cn= 5) are expressed as the mean of the percentage of control and SEM. 
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ICC was used to confirm the Western blot result. IKBa staining was found in both 
the cytoplasm and the nucleus, but no visible difference was apparent in the IKBa 
staining between the stimulated and unstimulated cells (Fig 5.11) thereby 
confirming the Western blotting findings which also showed no change in nuclear 
of cytoplasmic IKBa protein levels with LPS-stimulation (Table 5.2). The data 
does not preclude an earlier «60 min) effect on IKBa levels, but does not show 
the subsequent enhancement of basal IKBa levels usually observed subsequently. 
a b 
Figure 5.11 ICC for IlCBa in RAW cells 
RAW cells were stimulated with medium alone (a) or 1 J..Lglml LPS (b) for 1 hour 
before the cells were formaldehyde fixed and stained for IKBa. localisation by 
ICC. Images were captured digitally (x 400). No visible difference is apparent 
between the staining of the control and LPS-stimulated cells. 
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5.3.4 Effect of LPS-stimu/ation on BcI-3 in RAW 264.7 cells 
To determine the effect of LPS on the protein expression and cellular localisation 
the IKE family member Bcl-3, Western blotting was used. Stimulation with 1 
!J.g1ml LPS led to an approximate drop in nuclear levels of Bc1-3 of 75% at three 
hours compared to time zero levels (Fig 5.12). These levels had recovered to 80% 
of control levels at five hours (Fig 5.11). No change was observed in the 
cytoplasmic levels of Bcl-3 over the five hour time period studied (Table 5.3). 
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Figure 5.12 Nuclear levels of BcI-3 in LPS-stimulated RA W cells 
RAW cells were stimulated with 1 J.Lglml LPS for 0, 3 and 5 hours. The cells were 
then harvested and lysed to yield the nuclear fraction in which p65 levels were 
assessed by Western blotting. The data show a decrease in the nuclear levels of 
Bcl-3 at three hours that increases to near control levels at five hours: a) a 
representative image of a nuclear Western blot film, b) OD data (n= 1) plotted as a 
% of control, and is representative of two experiments. 
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Table 5.3 Cytoplasmic levels of Bd-3 in LPS-stimulated RAW cells 
a) o 3 5 time (hours) 
b) 
time 
Mean Cytoplasmic 100.0 111.0 124.8 
SD 0.0 5.6 37.7 
RAW cells were stimulated with 1 Ilg/ml LPS between 0, 3 and 5 hours. The cells 
were then harvested and lysed to yield the cytoplasmic fraction in which NFKB­
p65 levels were assessed by Western blotting. The data show that cytoplasmic 
levels of Bcl-3 do not change over the five hour stimulation period: a) a 
representative cytoplasmic Western blot fIlm, b) data (n= 2) expressed as the 
mean of the percentage of control and SD 
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ICC was used to confirm the Western blot findings and revealed a decrease in 
nuclear levels of Bcl-3 after one hour of LPS (1 Ilglml) stimulation (Fig 5. 13b), 
with little if any change detectable in the cytoplasm compared to control (Fig 
5.l3a). 
These findings indicate that either the nuclear Bcl-3 is degraded in response to 
LPS-stimulation or, if it translocated to the cytoplasm, that the cytoplasmic levels 
are much higher than those in the nucleus. 
a b 
Figure 5.13 ICC of Bcl-3 in RAW cells 
RAW cells were stimulated with medium alone (a) or with 1 Jlglml LPS (b) for 1 
hour before the cells were formaldehyde fixed and then stained for Bcl-3 
localisation by ICC. Images were captured using a fluorescence microscopy (x 
400) and are representative of two experiments. The images show a decrease in 
nuclear staining for Bcl-3 in the LPS-stimulated cells compared to the 
unstimulated cells since in the LPS-stimulated cells the differential between the 
cytoplasm and nucleus is greater. 
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5.3.5 Effect of PMA on RA W cell NO production 
To detennine the role of the PKC enzyme family in LPS-stimulated RAW cell 
NO production, PMA, an activator of DAG sensitive PKC isoforms, was used. 
PMA alone was found to have no significant effect on either NO production 
(Table 5.4) or cell viability (Table 5.5) in RAW 264.7 cells over the concentration 
range of 0-50 ng/ml, at 24 hrs stimulation. This indicates that PKC activation is 
not by itself sufficient to induce NO production. 
Table 5.4 Effect of PMA on NO production in RAW cells 
,• 
~ Nitrite (~M) 
Mean 0.66 0.36 0.60 0.80 0.49 
SEM 0.10 0.09 0.11 0.14 0.11 
Raw cells were stimulated with various doses of PMA for 24 hrs before 
measurement of NO in the cell culture medium by Greiss assay. Data from one 
experiment (n= 12) are expressed as mean and SEM and are representative of two 
experiments. The data show that PMA does not induce significant NO production 
in RAW cells. 
Table 5.S Effect of PMA on RAW cell viability 
Viability as Absorbance (570 nm) 
Mean 0.495 0.469 0.480 0.485 0.535 
SEM 0.013 0.022 0.013 0.009 0.010 
RAW 264.7 cells were stimulated for 24 hrs with various doses of PMA and then 
assayed for cell viability using the MTT assay. Data from one experiment (n= 12) 
are expressed as mean and SEM and are representative of two experiments. The 
data show that PMA has no significant effect on RAW cell viability. 
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5.3.6 Effect of PMA on LPS-stimulated RAW cell NO production 
To determine whether PKC activation by PMA might function synergistically 
with LPS in stimulating RAW cell NO production, PMA and LPS were used in 
combination. Whilst PMA (50 ngJml) alone had no effect on either RAW cell NO 
production (Table 5.4) or viability (Table 5.5), when used in conjunction with 
LPS it significantly decreased LPS-stimulated NO production (Fig 5.14) and 
removed the negative effect ofLPS on cell viability (Fig 5.15). 
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Figure 5.14 The effect of PMA on LPS-stimulated RAW cell NO production. 
RAW cells were stimulated for 24 hrs with either vehicle alone (control), 1 Ilglml 
LPS, 50 ng/ml PMA or 1 Ilg/ml LPS + 50 ng/ml PMA. NO levels were assayed 
by Greiss assay. Data from one experiment (n= 6) are plotted as mean ± SEM 
(***= p<O.OOl vs LPS, +++ =p<O.OOl vs PMA), and are representative of two 
separate experiments. The data show that PMA significantly inhibits LPS­
stimulated NO production. 
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Figure 5.15 The effect of PMA on LPS·induced RA W cell toxicity 
Upon removal of cell culture medium from the cell samples in figure 5.14 the 
same cells were incubated with MTT to assay cell viability. The data from one 
experiment (n= 6) are plotted as mean ± SEM (*** = p<O.OOl vs control), and are 
representative of two separate experiments. The data show that LPS-stimulation 
induces a significant decrease in RAW cell viability 
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To further investigate the ability of PMA to inhibit LPS-stimulated NO 
production and improve cell viability in LPS treated cells, a time course 
experiment was carried out. For cells treated with LPS alone, NO production was 
significantly (p<O.OOI) increased after eight hours of stimulation, with NO levels 
peaking at approximately 36 )..lM at 24 hours (Fig 5.16). In contrast, for cells 
treated with LPS + PMA, significant (p<O.Ol) NO production occurred at ten 
hours, two hours later than with LPS alone, and NO levels peaked at 
approximately 50% the level achieved with LPS alone (Fig 5.16). 
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Figure 5.16 Time coure of LPS and PMA + LPS on RA W cell NO production. 
RAW cells were stimulated for 0-24 hrs with either 1 p,glml LPS or 1 j..Lg/ml LPS 
+ 50 ng/ml PMA. NO levels were assayed by Greiss assay. Data from one 
experiment (n= 6) are plotted as mean ± SEM (*** = p<O.OOl vs LPS time zero, 
++ = p<O.Ol, +++ = p<O.OOl vs LPS + PMA time zero), and are representative of 
two separate experiments. The data show that NO production in cells stimulated 
with LPS + PMA is lower than that in cell stimulated with LPS only. 
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When cell viability was measured by MTT assay, LPS was found to induce a 
significant (p<O.OOI) increase at eight hours of stimulation (Fig 5.17). After this 
time, cell viability began to drop and ended approximately 40% below (p<O.OOI) 
control levels at 24 hours of stimulation. This loss of viability was associated with 
an increase in NO levels (Fig 5.16), indicating that NO concentrations in excess of 
15 ~ may be associated with decreased cell viability. In RAW cells stimulated 
with LPS (1 Jlg/ml) in conjunction with PMA (50 nglml), cell viability, like that 
for LPS alone, was increased at eight hours (p<O.OI) compared to time zero (Fig 
5.17). However, this increase in cell viability persisted in the LPS + PMA­
stimulated cells until 18 hours (Fig 5.17) after which, NO levels rose past 15 ~M 
(Fig 5.16) and RAW cell viability levels fell, dropping to time zero levels at 24 
hours (Fig 5.17). Thus, the presence of PMA leads to the inhibition of LPS­
stimulated NO produced, associated with an improvement in cell viability. 
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Figure 5.17 Time course of LPS and LPS + PMA on RAW cell viability 
Upon removal of cell culture medium from the cell samples in figure 5.16 the 
same cells were incubated with MTT to assay cell viability. Data from one 
experiment (n= 6) are plotted as mean ± SEM (*** = p<O.001 vs LPS time zero, + 
= p<O.05, +++ =p<O.OOl vs LPS + PMA time zero), and are representative of two 
separate experiments. The data show an increase in the number of viable cells 
with both treatments at 8 hours, followed by a decrease in LPS-stimulated cells 
and a delayed decrease in cells stimulated with LPS + PMA. 
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5.3.7 Effect of PKC inhibition on LPS-stimu/ated RAW cell NO production 
Since cell stimulation with chronic levels of PMA (50 nglml) is known to induce 
PKC degradation (Favaron et al., 1990), it was speculated that the loss of certain 
PKC isoforms might mediate PMA's inhibition of LPS-induced RAW cell NO 
production and associated cell death. To investigate this hypothesis, the PKC 
inhibitors Go 6983 (Go) and Bisindolymalemide I (Bis) were used. If PKC 
isoform degradation was the cause of the inhibitory effects of PMA, then the 
inhibition of PKC activity should be able to mimic the results gained with PMA. 
When used at the concentrations previously shown to effectively inhibit specific 
subsets of PKC (Calbiochem, UK), Go (10 J.1M) and Bis (20 J.1M) alone were 
shown to have no effect on RAW cell NO production after 24 hours stimulation 
(Fig 5.18). However, when combined with LPS, Bis significantly reduced LPS­
stimulated RAW cell NO production, whilst Go had no effect (Fig 5.18). This 
indicates that one of the PKC isoforms inhibited by Bis is responsible for LPS­
stimulated NFKB activation whilst those that are inhibited by Go are not. This 
leaves only one isoforrn, that of PKCc:. 
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Figure 5.18 Effect of PKC inhibitors on LPS-induced NO production in 
RA W 264.7 cells. 
Cells were treated with vehicle (control), Bisindolylernaleimide (Bis) 20 ~, G5 
6978 (Go) 10 /lM, LPS 1 Ilglrnl, LPS 1 /lg/rnl + Go 10 pM, or LPS 1 Ilglrnl + Bis 
20 ~ for 24 hours. Data (n= 9) are plotted as mean ± SEM (*** = p<O.OO1 vs 
LPS alone), and are representative of two separate experiments. The data show 
that only Bis is able to inhibit LPS-stimulated RAW cell NO production. 
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When these same cells were assessed for viability by MIT assay both Go and Bis 
by themselves were able to significantly (p<O.OOI) increase RAW cell viability at 
24 hours compared to control (Fig 5.19). When used in combination with LPS, 
they had the same effect (Fig 5.19). Of the two inhibitors, Bis was able to induce a 
significantly (p<O.OOI) larger increase in cell viability than Go. The fact that Bis 
had a greater effect than Go on RAW cell viability during LPS-stimulation may 
reflect its ability to inhibit RAW cell NO production. However, the fact that both 
Go and Bis improved RAW cell viability when used alone indicates that the PKC 
enzyme family may be involved in controlling cell survival and that PKCE in 
particular, may be important in this regard. 
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Figure 5.19 Effect of PKe inhibitors and LPS on RAW 264.7 cell viability 
Cells were treated with vehicle (control), LPS 1 ~glm1, LPS 1 ~glrnl + Go 6978 
(Go) 10 ~, LPS 1 J..lglrnl + Bisindolylemaleimide (Bis) 20 ~, ~o .l? 11M, or 
Bis 20 J..lM for 24 hours. The cells were then subjected to MTT ViabIlIty assay. 
Data (n= 9) are plotted as mean ± SEM (*** =p<O.OOl vs LPS alone), and ru:e 
. t Th data show that Go and BIS
representative of two separate expenmen s. e . . h th 
stimulation is associated with an increase in the number of viable cells, WIt e 
effect of Bis the most pronounced. 
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5.3.8 Effect of PMA on LPS-stimulated NFKB activation 
To directly determine the effect that PMA has on NF1d3 activity in LPS­
stimulated RAW cells, Western blotting was used to assess the cellular 
localisation of p65. Stimulation with LPS (1 Ilg/ml) in conjunction with PMA 
induced an 800% increase in nuclear levels of p65 at 30 and 60 minutes (Fig 
5.20). At 120 minutes, nuclear p65 levels had returned to control levels. This 
compares to LPS-stimulation alone where nuclear levels of NFKB peaked at 400% 
at two hours and were still raised at five hours stimulation (Fig 5.7). 
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Figure 5.20 Nuclear levels of p65 in LPS +PMA-stimulated RA W cells 
RAW cells were stimulated with 1 J.1g/ml LPS + 50 nglml PMA for between 0 and 
120 minutes. The cells were then harvested and lysed to yield the nuclear fraction 
in which NF1d3-p65 levels were assessed by Western blotting. The data show an 
increase in nuclear p65 protein levels, indicating NFKB activation, followed by a 
return to control levels at 120 minutes: a) a representative Western blot film, b) 
OD data (n: 1) plotted as a percentage of control, and is representative of two 
experiments. 
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In the Cytoplasm, LPS + PMA-stimulation induced a 60% drop in NFKB levels at 
60 minutes (Fig 5.21). Cytoplasmic NFKB levels had returned to control levels by 
120 min. This compared to LPS-stimulation alone where no change in 
cytoplasmic NFKB levels were observed over the five hour period studied (Fig 
5.8). This indicates that a greater proportion of p65 is activated in cells stimulated 
with LPS + PMA and shows that the duration of NFKB activation is shorter than 
in cells stimulated with LPS alone. 
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Figure 5.21 Cytoplasmic levels of p65 in LPS +PMA-stimulated RAW cells 
RAW cells were stimulated with either 1 ~g1ml LPS or 1 ~g1ml LPS with 50 
ng/ml PMA for between 0 and 120 minutes. The cells were then harvested and 
lysed to yield the cytoplasmic fraction in which p65 levels were assessed by 
Western blotting. The data show a drop in cytoplasmic p65 protein levels at 60 
minutes stimulation, which recovers to control levels at 120 minutes stimulation: 
a) a representative image of a Western blot film. b) data (n= 1) plotted as a 
percentage of control, and is representative of two experiments. 
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To determine whether pSO nuclear translocation also occurred, ICC was carried 
out for pSO. Here pSO was found to translocate to the nucleus in response to LPS, 
PMA and LPS + PMA whilst in control cells pSO was predominantly cytoplasmic 
(Fig 5.22). However, the greatest number of cells displaying nuclear pSO 
localisation was seen in LPS + PMA-stimulated cells as determined by a manual 
count of the number of cells within the field of view (results not shown). Also, the 
intensity of nuclear staining was visibly higher in LPS + PMA-stimulated cells 
(Fig 5.22). This demonstrates that both the pSO and p65 subunits are involved in 
LPS and PMA-stimulated NFlcB activation, probably in the classic pSO/p65 
heterodimer. 
control 
PMA 
LPS 
LPS + 
PMA 
Figure 5.22 ICC for p50 in RAW cells 
RAW cells were stimulated with medium alone (control; top-left), 1 Ilgirnl LPS 
(top-right), 50 ngiml PMA (bottom-left) or 50 nglml PMA + 1 Ilg/ml LPS 
(bottom-right) for 1 hour before the cells were formaldeyde fixed and stained for 
pSO localisation by ICC. bnages were captured using fluorescence microscopy 
coupled with a digital image capture system (x 400) and are representative of two 
experiments. Results show little nuclear staining in control cells, with increases in 
LPS or PMA-stimulated cells, and the majority of cells displaying strong nuclear 
p50 localisation in cells stimulated with LPS + PMA. 
, 
! 
i 
I 
/
I 
I 
I164 	 I 
I, 
Chapter 5 
5.3.9 Effect of PKC inhibition on LPS-stimulated NF"KB activation 
Bis has already been shown to inhibit LPS-stimulated RAW cell NO production 
(Fig 5.17), indirectly indicating that one of the PKC isoforms inhibited by Bis is 
responsible for LPS-stimulated NFKB activation in RAW cells. To assess the 
effect of Bis on LPS-stimulated NFKB activation directly Western blotting for the 
p65 NFKB subunit was carried out. 
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Figure 5.23 Nuclear p65 levels in LPS-stimulated PKC inhibited RAW cells. 
Protein levels of p65 in the nuclear fraction of RAW cells stimulated for three 

hours with either control, LPS (1 Ilglrnl) or LPS (1 Ilg/rnl) + Bis (20 IlM). The 

PKC inhibitor Bis, has no effect on LPS-stimulated p65 nuclear translocation: a) a 

representative Western blot film, b) data (n= 3) plotted as the mean of the 

percentage of control ± SEM (*=p<O.05 as compared to control). 

LPS + Bis 
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RAW cells were stimulated for three hours, a time point at which maximal LPS­
stimulated NFKB activation has been previously observed (Fig. 5.7). At this time 
LPS-stimulated a 400% increase in nuclear p65 levels (Fig 5.23) confinuing 
previous results (Fig 5.7). However, Bis had no significant effect p65 levels (Fig 
5.22) indicating that the PKC isoforms inhibited by Bis are not involved in the 
LPS-stimulated nuclear translocation of p65. 
In the cytoplasmic fraction neither LPS nor LPS + Bis had a significant effect on 
p65 levels (Table 5.6), indicating that too small a proportion of the cytoplasmic 
pool of p65 is activated by LPS alone for it to generate a significant decrease in 
cytoplasmic levels. This correlates with the earlier Western blot results in which 
LPS did not induce a change in cytoplasmic p65leve1s (Table 5.1). 
Table 5.6 Cytoplasmic p65 levels in LPS-stimulated PKC inhibited RAW 
cells 
a) control LPS LPS + Bis Stimulant 
b) 
Mean Cytoplasmic 100 70 122.2 
SEM o 14.9 22.7 
Protein levels of p65 in the cytoplasmic fraction of RAW cells stimulated for 3 
hours with either control, LPS (1 j..lglml) or LPS (1 j..lglml) + Bis (20 j..lM). The 
data show no change in cyotplasmic levels of p65 with either LPS or LPS + Bis: 
a) a representative Western blot film, b) data (n= 3) expressed as the mean of the 
percentage of control and SEM. 
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5.3.10 Role of PKCe in LPS-induced NO production in RAW 264.7 cells 
The contrasting effects of the PKC inhibitors Go and Bis on LPS-stimulated RAW 
cell NO production indicate that PKC£ may play an important role in LPS­
stimulated NO production. To investigate this hypothesis further the cellular 
localisation of PKC£ was determined in both control and LPS-stimulated RAW 
cells. This would show whether LPS was able to elicit a change in PKC£ 
localisation, a hallmark of activation for other PKC isoforms (Newton, 1997). 
ICC for PKC£ in RAW cells demonstrated a predominant! y nuclear localisation in 
unstimulated cells (Fig 5.24a). One hour LPS-stimulation induced some 
cytoplasmic translocation (Fig 5 .24b). 
167 

is 
Chapter 5 
a b 
Figure 5.24 ICC for PKCE in PMA-stimulated RAW cells 
RAW cells were stimulated with (a) medium alone or (b) with LPS (1 ~g/ml) for 
one hour before the cells were formaldehyde ftxed and then stained for PKCE 
localisation by ICC. Images were captured using a digital deconvolution technique 
and are representative of two experiments. Images show predominantly nuclear 
localisation with slightly increased cytoplasmic staining in LPS-stimulated cells. 
Next, to determine whether PKCE translocation was playing a role in LPS­
stimulated RAW cell NO production, PKC translocation inhibitors were used. 
When used alone, PKC translocation inhibitors for both classical PKC (cPKC) 
isoforms and PKCE had no significant effect on RAW cell NO production (Table 
5.7) or viability (Table 5.8). Similarly, in RAW cells stimulated with LPS, these 
inhibitors once again had no significant effect on either RAW cell NO production 
(Table 5.6) or cell viability (Table 5.7). Thus, PKCE translocation does not seem 
to be important in LPS-stimulated RAW cell NO production and, therefore, its 
translocation is unlikely to be involved in LPS-stimulated NFKB activation. 
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Table 5.7 Effect of PKC translocation inhibition and or LPS on RAW cell NO 
production 
Nitrite (11M) 
±SEM 
MALYOI 47.1 
±0.2 ± 1.6 ±0.3 ±2.7 ±4.2 ±5.l ±2.0 
MALYIO 0.7 
±0.2 
0.9 
±OA 
0.9 
±0.3 
44.6 
±3.3 
47.3 
±0.8 
40.3 
± 1.9 
46A 
±0.9 
MALYII 0.7 
±0.2 
0.6 
±0.3 
0.7 
±0.3 
44.6 
±2.8 
46.2 
±0.9 
43A 
±2.9 
45.9 
±0.5 
RAW cells were stimulated with medium alone (control), LPS (1 Ilglml) , or 
various concentrations of the MALY TAT-linked PKC inhibitor peptides (01 = 
cPKC inhibitor, 10 =PKCg specific, n = scrambled PKC£ inhibitor peptide), 
with or without LPS for 24 hours. The data show that the MAL Y peptides have no 
effect on LPS-stimulated RAW cell NO production. Data are expressed as mean 
and SEM (n= 3). Results are representative of two experiments. 
Table 5.8 Effect of PKC translocation inhibition and or LPS on RAW cell 
viability 
Viability as Absorbance (570 nm) ± SEM 
MALYO] 0.74 0.71 0.77 0.41 0.39 0.30 
±0.03 ±0.05 ±0.05 ±0.04 ±0.1 ±0.03 
MALY]O 0.74 
±0.03 
0.69 
±0.04 
0.71 
±0.04 
OAl 
±O.04 
0.40 
±0.08 
0.30 
±0.06 
0.50 
±O.04 
MALYII 0.74 0.78 0.79 OA1 OA4 0.35 0.43 
±0.O3 ±0.11 ±0.06 ±0.04 ±O.l ±O.ll ±0.O3 
RAW cells were stimulated with medium alone (control), LPS (1 J..Lglml), or 
various concentrations of the MALY TAT-linked PKC inhibitor peptides (01 = 
cPKC inhibitor, 10 = PKCg specific, II = scrambled PKCc inhibitor peptide), 
with or without LPS for 24 hours. Cell viability was then assessed by MTT assay. 
The data show that the MALY peptides had no effect on RAW cell viability. Data 
are expressed as mean and SEM (n= 3). Results are representative of two 
experiments. 
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5.3.11 Effect of MEK inhibition on LPS·stimulated RAW cell NO production 
To determine the role of the ERK signalling pathway in LPS-stimulated NFKB 
activation in RAW cells, the MEK inhibitor PD98059 was used. RAW cells were 
stimulated with LPS (l ~g/rnl) either with or without the PD98059 (PD) at a 
concentration of 10 ~M. PD alone had no effect on RAW cell NO production (Fig 
5.25). However, when combined with LPS, PD induced a small, but significant, 
13% increase in RAW cell NO production compared to LPS alone. Thus, the ERK 
signal pathway may be involved in the inhibition of LPS-stimulated RAW cell 
NO production. 
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Figure 5.25 Effect of :MEK inhibition on LPS-stimulated RAW cell NO 
production 
RAW cells were stimulated for 24 hrs with medium + vehicle (control), PD 
0980589 (PD, 10 ~), LPS (1 Jlglml), or LPS + PD. Data (n= 6) plotted as mean 
± SEM (** =p<O.Ol, ** =p<O.OOl as compared to LPS alone). The data show 
that the MEK inhibitor, PD, is able to induce a small increase in LPS-stimulated 
NO production. 
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The MTT assay showed that PD alone had no effect on RAW cell viability. LPS 
(1 jlglrnl) alone significantly (p<O.OOI) decreased RAW cell viability by 68%. 
However, PD (10 jlM) used in conjunction with LPS slightly reduced (p<O.OI) the 
negative effect of LPS on RAW cell viability (Fig 5.26) indicating that the ERK 
signalling pathway may also be involved in the mediation of the LPS-induced 
decrease in cell viablity. 
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Figire 5.26 Effect of MEK inhibition on RAW cell viability 
RAW cells were stimulated for 24 hours with medium + vehicle (control), PD 
0980589 (PD, 10 jlM), LPS (l jlg/rnl), or LPS + PD. Cell viability was assessed 
by MTT assay. Data (n= 6) plotted as mean ± SEM (** = p<O.Ol compared to 
LPS alone). The data show that the MEK inhibitor, PD, is able to rescue the RAW 
cells from the LPS-induced decrease in cell viability. 
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5.3.12 Effect of p38 MAPK inhibition on LPS-induced NO production in 
RAWce/ls 
To determine whether the p38 MAP kinase pathway has a role in LPS-stimulated 
NFKB activation in RAW cells, the effects of the p38 MAP kinase inhibitor 
SB203580 (SB) were assessed on LPS-stimulated RAW cell NO production. The 
results showed that at a 1 l-LM concentration SB had no significant effect on LPS­
stimulated NO production (Fig 5.27). However, 10 11M SB significantly reduced 
LPS-stimulated NO production by approximately 25%. 
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Figure 5.27 The effect of p38 MAPK inhibition and LPS-stimulation on RAW 
cell NO production 
RAW cells were stimulated for 24 hours with medium + vehicle (control), LPS (1 
J...tglrnl), and 1 or 10 l-LM SB 203580 alone or in conjunction with LPS. Data (n= 6) 
plotted as mean ± SEM (*=p<O.05 as compared to LPS alone). Results are 
representative of two experiments. The data show that inhibition of p38 MAPK 
with 10 l-LM SB, significantly inhibits LPS-stirnulated NO production. 
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MTT assay revealed that LPS alone significantly (p<O.OOl) decreased cell 
viability whilst addition of SB significantly reduced the negative effect of LPS­
stimulation at both 1 j..lM and 10 ~M SB concentrations (Fig 5.28). When used 
alone, 10 j..lM SB significantly (p<0.05) increased RAW cell viability compared to 
control. These results indicate that the p38 MAP kinase pathway is involved in 
mediating cell death and further confirms the negative relationship between NO 
production and cell viability. 
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Figure 5.28 The effect of p38 MAPK inhibition and LPS-stimulation on RAW 
cell viability 
RAW cells were stimulated for 24 hrs with either medium + vehicle (control), 1 Or 
10 j..lM of SB 203580 alone, 1 J.lg/ml LPS, or 1 j..lg/ml LPS with 1 or 10 ~M of SB 
203580. Data (n= 6) plotted as mean ±SEM (*=p<O.05 compared to control. ++ = 
p<O.Ol, +++ = p<O.OOl as compared to LPS alone). Results are representative of 
two experiments. The data show that SB rescues RAW cells in a concentration 
dependent manner, from the LPS-induced decrease in cell viability. 
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5.3.13 Effect of MEK and p38 MAPK inhibition combined on LPS-induced 
RA IN cell NO production 
To examine possible interaction between the ERK and p38 MAP kinase pathways 
the effect of combined PD (10 IlM) and SB (10 ~) on LPS-stimulated NO 
production was examined. As demonstrated previously (Fig 5.27) SB significantly 
(p<O.OOl) inhibited LPS-stimulated RAW cell NO production. However, when 
PD was combined with SB, no further effect was seen (Fig 5.29) indicating the 
absence of any interaction between the two pathways in LPS-stimulated NO 

production. 
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Figure 5.29 Effect of MEK and p38 MAPK inhibition on LPS-stimulated 
RAW cell NO production 
RAW cells were stimulated for 24 hrs with medium + vehicle (control), LPS (1 
Ilglml), LPS + SB203580 (SB, 10 liM), or LPS + SB + PD98059 (10 IlM). Data 
(n= 6) plotted as mean ± SEM (*** = p<O.OOl compared to LPS ~one). ~he data 
show that 10 roM SB inhibits LPS-stimulated NO productlOn, whilst the 
combination of the MEK inhibitor, PD, with SB, has no further effect. 
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Assay of cell viability by MTT assay showed that SB was able to significantly 
(p<O.OOl) reduce LPS-induced toxicity (Fig 5.30), confirming my previous results 
(Fig 5.28). The combination of PD with SB had no different effect to SB alone 
(Fig 5.30) indicating that the p38 MAP kinase and ERK pathways do not interact 
in the mechanisms involved in the LPS-induced decrease in cell viability. 
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Figure 5.30 Effect of MEK and p38 MAPK inhibition combined with LPS­
stimulation on RA W cell viability 
RAW cells were stimulated for 24 hrs with medium + vehicle (control), LPS (1 
~glml), LPS + SB 203580 (SB, 10 ~M), or LPS + SB + PD 980589 (10 J1M). 
Viability was assessed by MTT assay. Data (n:::: 6) plotted as mean ± SEM (*** :::: 
p<O.OOl compared to LPS alone). The data show that SB is able to rescue RAW 
cells from an LPS-induced decrease in cell viability, but the combination of PD 
with SB has no further effect. 
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5.3.14 Effect of Src kinase inhibition on LPS-stimulated RAW cel! NO 
production 
To determine the role of Src kinases in LPS-stimulated RAW cell NO production 
the Src kinase inhibitor PP2 was used. PP2 alone had no effect on NO production 
(Fig 5.31). When used in combination with LPS, PP2 significantly (p<O.001) 
reduced LPS-stimulated NO production with the greatest reduction of 
approximately 85% being seen at the highest PP2 concentration used, i.e. 50 flM 
(Fig 5.31). 
25 
20 
-
== 15:::t.
-Q) 
.:t:= 
'"'.:t:= 10
z 
5 
0 
0 5 50 o 5 50 
I 
+ 1 Ilg/ml LPS PP2 (flM) 
Figure 5.31 The effect of Src kinase inhibition on LPS-induced NO 
production in RA W cells 
RAW cells were stimulated for 24 hrs with medium + vehicle (control), 5 or 50 
J.iM PP2, 1 flglml LPS, or 1 J,Lg/ml LPS with PP2. NO levels were assayed by 
Greiss assay. Data (n= 9) plotted as mean ± SEM (*** = p<O.OOl compared to 
LPS alone). The data show that the Src kinase inhibitor, PP2, reduces LPS­
stimulated RAW cell NO production in a concentration dependent manner. 
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Whilst PP2 decreased LPS-stimulated RAW cell NO production (Fig 5.31), MTT 
assay revealed that PP2 also decreased RAW cell viability (Fig 5.32). At 5 11M, 
PP2 caused a 46% decrease in cell viability, and at 50 11M a 76% decrease was 
observed (Fig 5.32). PP2 had a near identical effect on the viability of cells when 
used in combination with LPS (Fig 5.32). Thus, the 46% drop in RAW cell 
viability caused by 5 !lM PP2 may account for the approximate 25% reduction in 
LPS-stimulated NO production, meaning that at 5 11M PP2 does not inhibit LPS­
stimulated NO production. However, 50 11M PP2 caused an 85% reduction in 
LPS-stimulated NO production whilst cell viability was only reduced by 76%, 
suggesting that, at 50 11M, PP2 does inhibit LPS-stimulated NO production. 
At a 50 !lM concentration PP2 is known to inhibit JAK2 (Salazar and Rozengurt, 
1999) and, as such, these results may indicate that JAK2 is involved in LPS­
stimulated RAW cell NO production, whilst the Src kinase family are not. At the 
same time, it is possible that the Src kinase family is involved in cell survival 
since inhibition by 5 /lM PP2 (although this would need to be confirmed with 
lower concentrations) caused a 46% reduction in cell viability (Fig 5.32). 
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Figure 5.32 Effect of Src kinase inhibition on RA W cell viability 
RAW cells were stimulated for 24 hrs with either medium alone (control), 1 Ilglml 
LPS, 1 Ilglml LPS with 5 or 50 IlM of PP2, or PP2 alone. Data (n= 9) plotted as 
mean ± SEM (***=p<O.OOl compared to control. +++ =p<O.OOl compared to LPS 
alone). The data show that the Src kinase inhibitor, PP2, decreases RAW cell 
viability in a concentration dependent manner. 
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5.3.15 Effect of JAK2 inhibition on LPS-stimulated NO production in RA W 
cells. 
Through the use ofPP2 in section 5.3.14, JAK2 was implicated in LPS-stimulated 
NO production in RAW cells. To determine whether JAK2 does indeed have a 
role, the JAK2 inhibitor AG-490 was used. 
As expected, AG-490 alone had no effect on RAW cell NO production. When 
used in combination with LPS, only 10 ~ AG-490 led to a significant (p<O.Ol) 
35% reduction in LPS-stimulated NO levels (Fig 5.33). 
o 	 0.1 1 10 o 0.1 1 10 
I 
+ LPS 1 jlg/rnl 
AG-490 (J!M) 
Figure 5.33 Effect of JAK2 inhibition on LPS-induced RAW cell NO 
production 
RAW cells were stimulated for 24 hours with medium alone (control), 1 ~glml 
LPS, or LPS with 0.1, 1 or 10 ~ of AG-490, or AG-490 alone. Data (n= 9) 
plotted as mean ± SEM (**=p<O.Ol compared to LPS alone). Results are 
representative of two experiments. The data show that the JAK2 inhibitor, AG­
490, significantly inhibits LPS-stimulated NO production when used at 10 J.LM. 
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Cell viability, measured by MTT assay, demonstrated that AG-490 had no 
significant effect on RAW cell viability when used alone or in conjunction with 
LPS (Table 5.9). The fact that AG-490 can significantly reduce LPS-stimulated 
NO production without affecting RAW cell viability indicates that JAK2 is 
involved in LPS-stimulated NO production. This also indicates that JAK2 is not 
involved in the previously described PP2-mediated decrease in cell viability. 
However, given the relatively small reduction in LPS-stimulated NO production 
achieved, it seems likely that the role of JAK2 is relatively minor compared to that 
ofPKC. 
Table 5.9 Effect of JAK2 inhibition on RAW cell viability 
Viability as Absorbance (570 nm) 
Mean 0.635 0.647 0.618 0.755 0.655 0.555 0.642 0.691 
SEM 0.042 0.040 0.028 0.084 0.041 0.018 0.034 0.065 
RAW cells were stimulated for 24 hours with either medium alone (control), 1 
~g/ml LPS with 0.1, 1 or 10 ~ of AG-490, or the same concentration of AG-490 
but in combination with LPS. Cell culture medium was then removed and cell 
viability assessed by MTT assay. Data (n= 9) plotted as mean ±SEM. Results are 
representative of two experiments. The data show no significant difference 
between AG-490 treated cells and the control. 
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5.3.16 Effect of JAK2 and p38 MAPK inhibition on LPS-induced RAW cell 
NO production and cell viability 
To determine whether any interaction occurs between the p38 MAP kinase and 
JAK2 signal pathways, SB and AG-490 were used in combination to inhibit LPS­
stimulated NO production. When used at a concentration of 1 ~M AG-490 alone 
had no significant effect on LPS-induced NO production (Fig 5.33). Also, at a 
concentration of 1 ~M SB alone had no effect on LPS-induced RAW cell NO 
production (Fig 5.27). 
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Figure 5.34 Effect of p38 MAPK and JAK2 inhibition on LPS-stimulated 
RAW cell NO production 
RAW cells were stimulated for 24 hrs with either medium + vehicle (control), 1 
J.lg/ml LPS, LPS + 1 J.LM SB 203580 or LPS + 1 !JM SB 203580 and 1 ~M AG­
490. Data (n= 6) plotted as mean ± SEM (*** =p<O.OOl as compared to LPS 
alone). The data show that when SB and AG-490 are combined they significantly 
inhibit LPS-stimulated NO production whilst 1 J.LM SB alone does not. 
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However, when the two inhibitors were combined a synergistic effect was 
observed with NO production being significantly reduced by 80% (Fig 5.34). This 
level of inhibition exceeds that achieved using either SB (Fig 5.27) or AG-490 
(Fig 5.33) alone. It also correlates with a significant (p<0.05) increase in cell 
viability with the RAW cells being rescued from the LPS-induced cell death (Fig 
5.35). This indicates that the p38 MAP kinase and JAK2 signal pathways do 
indeed interact in LPS-stimulated RAW cell NO production. 
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Figure 5.35 Effect of p38 MAPK and JAK2 on LPS-stimulated RAW cell NO 
production 
RAW cells were stimulated for 24 hrs with either medium + vehicle (control), 1 
Ilglml LPS, LPS + 1 11M SB 203580 or LPS + 1 J.LM SB 203580 and 1 J.LM AG­
490. Data (n= 6) plotted as mean ±SEM (*=p<0.05, ***=p<0.001 as compared to 
control. The data show that SB alone was able to rescue RAW cells from an LPS­
induced decrease in cell viability, whilst when SB was combined with AG-490 in 
LPS-stimulated cells, the number of viable cells increase to above the level of the 
control. 
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5.3.17 Effect of TSA on LPS-stimulated RAW cell NO production and 
viability 
To determine the whether histone acetylation plays a role in LPS-stimulated RAW 
cell NO production, and hence NFKB activation, the histone de acetylase (HDAC) 
inhibitor Trichostatin A (TSA) was used. TSA had no effect on RAW cell NO 
production when used alone (Fig 5.36). However, when used in combination with 
LPS it significantly (p<O.05) decreased NO production in a concentration 
dependent manner (Fig 5.36). 
25 
* 20 
-::E 15
::L
-CD 

'L: 
-
.1:: 10 
Z 
5 
0 
control 1 10 0 1 10 
I 
+ 1 !J,9/ml LPS 
TSA(nglml) 
Figure 5.36 Effect of HDAC inhibition on LPS-stimulated RAW cell NO 
production 
RAW cells were stimulated for 24 hrs with either medium + vehicle (control), 
TSA (lor 10 nglml), LPS (l J..Lg/ml) or LPS + TSA (lor 10 nglmJ). Data en:: 6) 
plotted as mean ± SEM (*=p<O.05, **=p<O.OI as compared to LPS alone). The 
data show that the HDAC inhibitor, TSA, reduced LPS-stimulated NO production 
in a concentration dependent manner. 
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While TSA did inhibit LPS-stimulated NO production, it had no effect on RAW 
cell viability either alone or in conjunction with LPS (Fig 5.37). These results 
indicate that TSA is able to inhibit NFKB mediated gene transcription. 
0.7 

0.6 
w_ 0.5mE 
~&:
:0 0.4
.or-­mil)
.-­>w 0.3Q)~(,) 
0.2 
0.1 
0 
control 1 10 0 1 10 
I 
+ 1 /J.g/ml LPS 
TSA (nglml) 
Figure 5.37 Effect of HDAC inhibition on RAW cell viability 
RAW cells were stimulated for 24 hrs with either medium + vehicle (control), 
TSA (lor 10 nglml), LPS (1 ).lg/ml) or LPS + TSA (l or 10 nglml). Data (n= 6) 
plotted as mean ± SEM. The data show that TSA had no effect on RAW cell 
viabiliy, either when used alone or in combination with LPS. 
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5.4. Discussion 
The overall aim of this chapter was to better characterise the cell signalling 
pathway(s) involved in LPS-stimulated NFK'B activation in macrophages. To this 
end NFKB activation was measured directly, through Western blotting and ICC 
techniques, and indirectly, through the assay of NO production that was used as 
an indicator of NFKB activity. 
5.4. 1 LPS induction of RAW cell NO production and associated cell toxiCity 
Initially, the ability of LPS to stimulate NOS dependent NO production in the 
RAW cells was established. In common with the work of others, NO production 
was measured through the assay of nitrite, its stable breakdown product (Paul et 
a!., 1997; Patel et ai., 1999; Tsai et ai., 1999). LPS was shown to induce NO 
production in a concentration dependent manner (Fig 5.2). This NO production 
was inhibited by the NOS inhibitor L-NAME (Fig 5.5), thereby demonstrating the 
role of NOS in LPS-stimulated RAW cell NO production and confirming the 
results of Paul et aI., (1997) who demonstrated L-NAME inhibition of LPS (l 
Ilglml) stimulated RAW cell NO production. 
The majority of LPS-stimulated NO production occurred during the first 24 hours 
of stimulation (Fig 5.4). After this period only small amounts of NO were 
produced, even when the medium was replaced with fresh medium that contained 
fresh LPS. This indicates that the lack of NO production was not due to the 
depletion of an essential element in the culture medium. It may instead be caused 
by the development of hypo-responsiveness to LPS, as previously reported by 
others (Virca et al., 1989). Such hypo-responsiveness may be caused by the 
ability of NO to directly inhibit NFKB DNA-binding activity (Sekkai et al., 1998; 
Matthews et al., 1996) and the formation of stable iNOS dimers (Albakri and 
Stuehr, 1996). These auto-regulatory inhibitory functions of NO would result in 
the increasing inhibition of further NO production as levels of NO in the media 
rise through LPS-stimulation. 
The negative feedback of NO on its own production may be important as results 
presented here demonstrate an association between NO levels and RAW cell 
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viability. Approximately 35 J.LM nitrite was required to induce a decrease in the 
number of viable RAW cells, as measured by MTT assay (Fig 5.6, 5.15 & 5.28). 
This is unfortunate since the LPS concentration of 1 J..lg/ml initially chosen for this 
work induces NO production which fluctuates around 35 J...LM and therefore in 
some experiments LPS-stimulation induces a decrease in cell viability whilst in 
others it does not. At NO concentrations above 35 J..lM the decrease in cell 
viability was marked with a >50% decrease in cell viability often recorded (Fig 
5.6). This decrease in cell viability correlates with visual observations in which a 
lower cell number was observed with remaining cells appearing shrunken (section 
5.3.1). That the cell toxicity observed in response to LPS-stimulation was reduced 
by L-NAME demonstrates the NO dependency of this effect. Indeed, high levels 
of NO have previously been shown to induce an apoptotic response mediated, at 
least in part, through the inhibition of the mitochondrial electron transport chain 
(Nishikawa et ai., 1998; Brown, 1995). 
5.4.2 LPS-mediated NFlCB activation in RAW cells 
NFKB activity has been previously reported to be essential in iNOS up-regulation 
(Kim et ai., 1997; Xie et al., 1994) acting through the KB element located in the 
iNOS promoter (Xie et at., 1993). Thus, it was not unexpected to find that LPS­
stimulated RAW cell NO production was associated with NFKB activation. The 
nuclear translocation of p65, which indicates NFKB activation, was demonstrated 
in LPS-stimulated cells by both Western blotting (Fig 5.9)and ICC (Fig 5.10). 
Furthermore, ICC was also used to demonstrate nuclear translocation of p50 (Fig 
5.22). The translocation of both p65 and p50 suggests the possible presence of 
both p65 & p50 in the NFKB dimer activated by LPS. This correlates with a 
previous study in which both p65 and p50 were shown to be present in the LPS­
activated NFKB complex in RAW cells, as measured by EMSA supershift assay 
(Xie et ai., 1994). The presence of p65 and p50 in the nucleus further suggests 
that the classic p50/p65 NFKB heterodimer or the p50 homodimer may be the 
form of NFKB activated. This hypothesis is supported by previous work in which 
both dimers have been suggested to be activated by LPS in RAW cells (Xie et ai., 
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1994; Tsai et al., 1999), as well as in inflamed CD tissue (RogIer et ai., 1998; 
Ardite et ai., 1998), demonstrating that these dimers are also activated during 
inflammatory responses in vivo. 
Whilst NFld3 activation occurred in response to LPS, no associated degradation of 
IlCBa was observed, as measured by Western blot (Table 5.2) and ICC (Fig 5.11). 
This is unusual due to the dominant role that IKBa has in the inhibition of NFKB 
dimers containing the p65 subunit (Bohuslav et ai., 1998 & Algarte et aI., 1999). 
However, the mechanisms that regulate hd3a levels are complex. Whilst 
phosphorylation of the IKK dependent sites, Ser 32 and Ser 36, has been shown to 
induce IKBa degradation, this degradation is dependent, at least in part, on casein 
kinase-II (CKll) phosphorylation. 
CKll acts on the carboxy-terminal PEST sites of IKBa and inadequate CKII 
mediated phosphorylation leads to an increase in IlCBa half-life during IKK 
dependent NFKB activation (Pando and Verma, 2000). Also, IKBa degradation 
has been shown to be dependent on both whole cell IlCBa. levels and its 
cytoplasmic/nuclear distribution (Yang et al., 2001), with high IKBa expression 
and consequent nuclear localisation of IKBa associated with resistance to 
degradation (Yang et al., 2001). Indeed, high levels of nuclear IKBa were evident 
in the RAW cells as demonstrated by both ICC (Fig 5.11) and Western blot (Table 
5.2) analysis. Furthermore, phosphorylation induced dissociation of IKBa without 
its concomitant degradation can occur through tyrosine phosphorylation (Imbert et 
aI., 1996) and PKC-mediated. NFKB activation (Wilson et at., 1999). Thus, in the 
results presented here, the high levels of nuclear 11d3a observed indicate that 
IleBa may be resistant to IKK degradation and therefore an alternative mechanism 
of NF1d3 activation may be occurring which may require only the dissociation of 
IleBa and not its degradation. 
Whilst LPS had no effect on IKEa levels, it was associated with a decrease in the 
nuclear levels of Bcl-3 (Fig 5.12 & 5.13), another IKE family member. This 
finding suggests that Bcl-3 may be involved in LPS-stimulated NF1d3 activation. 
This correlates with the only other published work in which Bc1-3 levels have 
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been studied in macrophages during an inflammatory response. In the work of 
Moine et ai., (2000) total Bcl-3 levels were found to be significantly decreased in 
alveolar macrophages from patients with acute respiratory distress syndrome 
compared to those from control patients. As described earlier (Chapter Three), 
Bcl-3 is involved in modulating the function of pSO homodimers that are likely to 
be present in LPS-stimulated RAW cells (Xie et at., 1994; Tsai et aI., 1999). 
Indeed, nuclear Bcl-3 has been suggested to mediate increased p5G homodimer 
nuclear translocation (Richard et ai., 1999; Wanatabe et aI., 1997) which may 
compete with p65/p50 leading to a reduction in transcription from certain genes 
(Richard et ai., 1999). 
Thus, the decreased nuclear levels of Bcl-3 observed here may lead to the 
preferential nuclear translocation of p6S/pSO heterodimers and therefore increased 
expression of the inflammatory genes targeted by this heterodimer (Tak and 
Firestein, 2001; Baldwin, 2001). Alternatively, Bcl-3 has also been suggested to 
inhibit the binding of p50 homodimers to DNA (Franzoso et aI., 1997), thus the 
loss of nuclear Bc1-3 might allow the increased DNA-binding ofpSO homodimers. 
As such, whilst the work presented here does indicate that Bcl-3 is degraded in 
response to LPS-stimulation, no firm conclusions can be drawn on the function of 
this activity. 
5.4.3 The role of PKC-e in LPS-stimulated NF1CB activation 
PKC activation has been identified as an early response in LPS-stimulated 
macrophages (Paul et aI., 1995) and as essential for the up-regulation of NO 
production (Severn et ai., 1993; Sodhi and Kumar, 1994; Paul et aI., 1995). 
However the PKC isoforms involved and their function remain to be determined. , 
Thus, PMA, a direct activator of the PKC family of kinases, was used to 
investigate the role of PKC in LPS-stimulated NO production and NFKB 
activation in RAW cells. 
A PMA concentration response curve demonstrated that PMA did not stimulate 
NO production (Table 5.4) or effect RAW cell viability (Table 5.S) indicating that 
PKC activation alone is not sufficient to induce NO production in RAW cells. 
However, when used in combination with LPS, PMA inhibited NO production by 
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>50% (Fig 5.14), with a corresponding reduction in the deleterious effects of LPS 
on cell viability (Fig 5.15). The earlier work presented here indicates that the 
reduction by PMA of the negative effects of LPS-stimulation on RAW cell 
viability is directly attributable to the inhibition of NO production (see 5.4.1). 
The fact that PMA can inhibit LPS-stimulated RAW cell NO production indicates 
that either PKC activation inhibits LPS-stimulated NO production, or that the high 
levels of PMA used, induced the over activation of PKC, thereby causing the 
inhibition of PKC. Indeed, this later hypothesis is supported by recent work that 
showed that chronic PMA-stimulation of >5 ng/ml causes the down-regulation of 
PKC expression (0'Angelo et aI., 1997; Dom et al., 2000). Also, PMA (100 nM) 
has previously been shown to inhibit LPS-stimulated RAW cell NO production, 
an ability attributed to the fact that chronic PMA-stimulation causes the 
degradation of PKC a, ~, and E isoforrns (Paul et al., 1997). 
To further investigate the effect of PMA on LPS-stimulated NO production, the 
effects of PMA on LPS-stimulated NO production with time, were studied. This 
showed that in the presence of PMA, the onset of significant NO production was 
inhibited by two hours as compared to LPS alone (Fig 5.16). Also, consistently 
higher cell viability was observed in the cells stimulated with LPS and PMA (Fig 
5.17), a finding likely to be a direct consequence of the inhibition of LPS­
stimulated NO production by PMA. However, whilst LPS-stimulated NO 
production was partially inhibited by PMA, total inhibition was not achieved. This 
suggests that PKC is a non-essential signalling pathway that normally contributes 
to the rapid up-regulation of iNOS expression. Thus, its inhibition does not cause 
the complete abrogation of NO production. 
It was hypothesised that the negative effects of PMA on LPS-stimulated NO 
production were mediated through the inhibition of PKC function by PMA. To 
investigate this hypothesis the activity of a range of PKC isoforrns were 
specifically inhibited using the PKC inhibitors, Go 6983 (Go) and 
Bisindolymalemide I (Bis). These inhibitors act on over-lapping PKC isoforms, 
with Go inhibiting PKC a, ~, 'Y, S, and ~, whilst Bis inhibits PKC a, ~, 'Y. 0 and E. 
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Whilst Go had no effect on LPS-stimulated NO production, Bis almost completely 
suppressed it (Fig 5.18) mimicking the effect of PMA and thereby demonstrating 
a role for PKC in the LPS-stimulated cell signalling pathway that leads to NO 
production. From the different sets of isoforms inhibited by each of these 
compounds, it can be concluded that the PKCc isoform is specifically involved in 
LPS-stimulated NO production, as this is the only isoform inhibited by Bis but not 
Go. Thus, as LPS-induced NO production is mediated predominantly through 
NFKB modulated iNOS expression (Kim et al., 1997; Xie et al., 1994) it seems 
likely that PKCE is involved in the NFKB activation pathway. 
PKC has been previously shown to be involved in NFKB activation for a range of 
stimuli including, IL-l ~ stimulated NFKB activation in T cells (Steffan et al., 
1995). More recently PKC has been shown to be involved in LPS-stimulated 
NFld3 activation in alveolar macrophages (Greenberg et al., 1998) and DLD-l 
enterocytes (Wilson et al., 1999). Furthermore, a putative PMA responsive IKK 
complex named IKKE in T cells has been recently discovered (Peters et al., 2000). 
Moreover, in RAW cells, LPS-stimulation has been recently shown to induce 
NFKB via PKC activity, although the PKC isoforrn involved has not been defined 
(Chen et al., 1998a; St-Denis et aI., 1998). 
In fact, there are at least 11 isoforms of PKC that exist in RAW cells, which differ 
in sensitivity, stimuli, cellular location, and tissue expression (Hug and Sarre, 
1993). However, when over-expressed, PKCE has been previously demonstrated 
to induce NFKB activation in macrophages (Dfaz-Guerra et ai., 1996; Tojima et 
ai., 2000) and PKCE has been suggested to be required for NFKB activation in 
thymocytes (Simon et at., 20(0). Currently, no in vivo role has been ascribed to 
PKCE in LPS-stimulated NFld3 activation. 
To determine whether PKCe was involved in LPS-stimulated NFKB activation 
directly, the effect of PMA and the PKC inhibitor Bis, on LPS-stimulated NFKB 
activation was assessed via Western blotting for the cellular localisation of p65. 
PMA wac,,; found to decrease the period over which LPS was able to induce 
nuclear translocation of NFKB (Fig 5.20). Nuclear levels of p65 peaked far higher 
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in LPS and PMA-stimulated cells compared to LPS alone. The high nuclear p65 
levels in LPS and PMA-stimulated cells corresponded with a drop in cytoplasmic 
levels (Fig 5.21). A similar effect could be seen for p50 where LPS + PMA­
stimulation was associated with a visibly more intense nuclear staining than either 
LPS or PMA alone at one hour stimulation (Fig 5.22). 
Unlike PMA, Bis had no effect on p65 nuclear translocation (Fig 5.23). This 
finding has been confirmed recently by others, who demonstrated Bis to have no 
effect on LPS-stimulated NFKB DNA-binding in peripheral blood monocytes 
(Shames et al., 1999). This indicates that PKCE is not involved in the nuclear 
translocation or DNA-binding of NF1d3. However, ICC carried out for PKCE 
I demonstrated that it is expressed predominantly in the nucleus of RAW cells (Fig 
I 5.24), a localisation which correlates with that in U937 monocytic cells (Kiley and 
Parker, 1995) and in rat aortic vascular smooth muscle cells (Li et al., 1999b). It is 
.. 
therefore not unexpected that the inhibition of PKCE translocation by a TAT­
.•.•...•.••....,: 
:~i linked MALY inhibitor that prevents binding of PKC to RACK proteins, had no 
effect on LPS-induced NO production (Table 5.7). 
This indicates that PKCE mediates its effects on NFKB-regulated iNOS 
expression, in the nucleus. If PKCE functions in this manner it need not affect the 
nuclear translocation of p65. Instead, PKCE might directly phosphorylate the 
NFlCB p65 subunit once it reaches the nucleus. Indeed, a PKC phosphorylation 
site exists on the p65 subunit (PROSITE search http://www. 
www.expasy.chlprosite) and p65 phosphorylation is known to increase the 
transactivation potential of NFKB, without affecting its DNA-binding or nuclear 
translocation (Wang et al., 2000; Zhong et al., 1997 & 1998). 
In support of a role for PKO:: in NFlCB transcriptional activity is the work of 
others which shows a link between PKCE, NFK'B and iNOS expression in RAW 
cells (Diaz-Guerra et al., 1996 & Chen et al., 1998). The reason that these groups 
did not conclude that PKCE acts on NFKB in vivo was the fact that they could not 
detect the presence of PKCE in their RAW cell cultures. In contrast, the work 
presented here and that of others (Larsen et ai., 2000; Paul et aI., 1997) 
demonstrates the existence of PKO:: in this cell line. 
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Thus, while PKC£ is involved in NFKB-mediated iNOS gene expression possibly 
through its phosphorylation of p65, it does not appear to be involved in the 
nuclear translocation of NFKB. Instead, it is more likely to affect the ability of the 
activated NFKB dimer to recruit transcriptional co-activators, such as the histone 
acetyl-transferase p300lCBP (Perkins et al., 1997; Zhong et ai., 1998; Berghe et 
ai., 1999), to the iNOS promoter site. 
5.4.4 The role of the MAP kinase pathways in LPS-stimulated NFI(B 
activation. 
To determine the role of the ERK signalling pathway in LPS-stimulated NFKB 
activation in RAW cells, the MEK inhibitor PD98059 (PD) was used. PD was 
found to induce a small increase in LPS-stimulated RAW cell NO expression (Fig 
5.25). This was associated with an increase in mitochondrial respiration (Fig 
5.26), indicating that the increased NO levels detected may be due to the presence 
of increased cell numbers. Recently, others have shown PD to have no effect on 
LPS-stimulated RAW cell NO production (Paul et al., 1999; Chen and Wang, 
1999), even at much higher concentrations (Jeon et al., 2000). Thus, while the 
ERK signalling pathway may be involved in the mediation of cell survival, it does 
not appear to playa role in LPS-stimulated NFKB activation in RAW cells. 
In contrast, when the role of the p38 MAP kinase pathway was investigated using 
the p38 MAP kinase inhibitor SB203580 (SB), at a concentration of 10 ~M, LPS· 
stimulated RAW cell NO production was significantly inhibited (Fig 5.27). This 
finding has been confirmed recently by others who concluded a role for the 
MAPK p38 in this activation pathway (Patel et al., 1999; Paul et al., 1999). 
However, more recently, work by Lali et al., (2000) has indicated that, at a 10 ~ 
concentration, SB is not specific for p38 as was previously believed. Instead, the 
10 JlM concentration of SB is now known to inhibit phosphoinositide-dependent 
protein kinase 1 (PDKl) as well as the p38 MAP kinase family (Lali et al., 2000). 
PDK1 is responsible for activating protein kinase B (PKBIAkt) which has recently 
been implicated in NFlCB activation (Fig 5.28; Kane et al., 1999; Scheid and 
Woodgett, 2000 & Madrid et al., 2001). Indeed Ozes et al., (1999) have 
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demonstrated a requirement for the PI-3K1PKB pathway in TNFa induced NFKB 
activation. Thus, it seems plausible that SB mediated inhibition of PDKI and not 
p38 MAP kinase, is responsible for the drop in LPS-stimulated RAW cell NO 
production observed at the 10 /-lM SB concentration. 
IPI-3·k:irras~ 
Figure 5.38: PKB mediated NFlCB activation (adapted from Scheid and 
Woodgett,2000) 
The p38 MAP kinase specific 1 JlM concentration of SB (Lali et aI., 2000) had no 
effect on LPS-stimulated NO production in the RAW cells, suggesting the 
absence of a role for p38 MAPK in NFtcB activation. However, it did significantly 
increase RAW cell viability (Fig 5.28), preventing the LPS-induced, NO 
associated, decrease in cell viability. This may be due to the important role that 
the p38 MAP kinase pathway has in inducing apoptosis (Xia et at., 1995; Pelech, 
1996). The inhibition of this pathway might therefore prevent, at least partially, 
the LPS-stimulated, NO associated decrease in RAW cell viability, since, as 
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previously discussed (section 5.4.1), NO appears to induce cell death via apoptotic 
pathways. 
When PD and SB were used together to inhibit LPS-stimulated NO production the 
level of inhibition achieved was identical to that for SB alone (Fig 5.29). Also, no 
change in cell viability was observed compared to when SB was used alone (Fig 
5.30), demonstrating the independent manner in which these two pathways 
operate in LPS-stimulated RAW cell NO production. 
5.4.5 The role of Src kinases in LPS-stimulated NO production 
The determine the role of the Src tyrosine kinase family in LPS-stimulated NFKB 
activation, the Src kinase inhibitor PP2 was used to inhibit LPS-induced NO 
production in RA W cells. At a 5 ~ concentration it significantly inhibited LPS­
stimulated RAW cell NO production (Fig 5.31), a fact that might reflect the 
previously postulated role of Src kinases in NFKB activation (Abu-Arner et al., 
1998). However, PP2 also significantly reduced RAW cell viability (Fig 5.32) and 
therefore the reduction in LPS-stimulated NO production may be due to the 
decrease in the number of viable cells. Also, others have demonstrated that the 
deletion of the Src kinase genes, Hck, Fgr, and Lyn, in macrophages, has no 
significant effect on LPS-induced NFKB activation and NO production (Meng and 
Lowell, 1997). 
At 50 ~ concentration PP2 almost completely abolished LPS-induced NO 
production (Fig 5.31) whilst cell viability levels were only reduced by 50% (fig 
5.32). At this concentration PP2 is no longer specific for Src kinases and has been 
shown to effectively inhibit JAK2 instead (Hanke et ai., 1996; Salazar and 
Rozengurt, 1999). Thus, the fact that 50 j.tM PP2 appears to inhibit LPS­
stimulated NO production beyond an effect that can be explained by a decrease in 
the number of viable cells, suggests that JAK2 may be involved in LPS-stimulated 
NFKB activation in the RAW cells. 
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5.4.6 The role of JAK2 in LPS-stimulated NO production. 
To determine the role of JAK2 in the LPS-induced iNOS expression pathway the 
JAK2 inhibitor AG-490 was used. This significantly inhibited LPS-stimulated NO 
production in RAW cells at a concentration of 10 J1M (Fig 5.33) without inducing 
decreased cell viability (Table 5.9). This indicates that JAK2 is involved in LPS­
stimulated RAW cell NO production and therefore NFKB activation. Indeed, there 
is growing evidence for cross-talk between the JAK2 signalling pathway and the 
NFKB signalling pathway. 
AG-490 has been recently demonstrated to inhibit LPS-stimulated iNOS induction 
in a skin dendritic cell line apparently through an NFKB mediated mechanism 
(Cruz et ai., 2001). Also, JAK2 has recently been demonstrated to phosphorylate 
IKB directly, thereby facilitating NFKB activation (Digicaylioglu and Lipton, 
2001). Alternatively, JAK2 has been shown to act on PI3K (Nguyen et ai., 2001), 
that in turn activates the PKB pathway (as discussed above; 5.4.4; Fig 5.39). 
However, JAK2 is also known to phosphorylate and thereby activate the 
transcription factor STAT1 (Winston and Hunter, 1996; Thle, 1995 & Briscoe et 
al., 1994), for which a complementary enhancer element has been found within 
the iNOS promoter site (GAS). This GAS site has been shown to playa role in 
LPS-induced iNOS expression (Gao et aI., 1997). It is therefore equally possible 
that inhibition of JAK2 mediated STATl activation is responsible for the 
inhibition of LPS-induced NO production by AG-490. 
The mechanism by which LPS may stimulate JAK2 activation remains unclear. 
JAK2 is predominantly activated by IFNy (Delgado et ai., 2000) with a role 
having been demonstrated for JAK2 in LPSIIFNy stimulated iNOS expression in 
rat mesangial cells (Nakashima et aI., 1999). Whilst LPS might induce IFNy 
expression in RAW cells this has not yet been shown to occur. However, it is 
known that at high levels (>10 nglml) LPS can induce IFNB production in 
macrophages and that the autocrine/paracrine stimulation by this mediator is 
critical in LPS-mediated NO production (Zhang et al., 1994; Fujihara et al., 
1994). Indeed LPS-induced STATlex. binding of the iN OS GAS has been shown 
to take two hours, much longer than the 30 min required when IFNy is the 
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stimulant and suggestive of an autocrinel paracrine IFN~ function (Gao et aI., 
1997). IFN~ is not as effective as IFNyat activating GAS sites because IFN~ 
stimulation induces the formation of STATla into complexes that bind the IFN­
stimulated response elements (IS REs) in preference to GAS sites (Seegert et aI., 
1994). Thus, whilst it is possible that LPS-stimulated IPNB production may be 
responsible for the activation of JAK.2, as this leads to the preferential activation 
of ISRE sites, it seems likely that either JAK2 is acting on the NFKB activation 
pathway, or that some other form of JAK.2 activation is taking place. 
When AG-490 was combined with 1 J.lM SB a synergistic effect was observed 
leading to the reduction of LPS-stimulated NO production inhibition (Fig 5.35), 
without a decrease in cell viability (Fig 5.36). This synergistic effect implies that 
both JAK.2 and p38 MAP kinase are involved in the LPS-induced signalling 
pathway that leads to NO production. 
5.4.7 The role of histone deacetylases in NFKB activity 
The binding of NFld3 to histone acetyl-transferases (HATs), such as p300/CBP, 
has been shown to be essential for the full transactivation of NFKB driven 
promoters (Perkins et al., 1997; Berghe et al., 1999). HATs, together with histone 
deacetylases (HDACs), are responsible for regUlating chromatin structure, with 
histone acetylation leading to the partial unwinding of the nuc1eosome complex 
thereby allowing access of transcription factors to the DNA. It was therefore 
hypothesised that TSA, a HDAC inhibitor, would induce the up-regUlation of 
LPS-stimulated iNOS expression and consequent NO production. Instead TSA 
inhibited this response (Fig 5.36) whilst at the same time having no significant 
effect on cell viability (Fig 5.37). 
TSA has previously been shown to decrease p57KIP expreSSIOn, a cyclin­
dependent kinase (cdk) inhibitor (CKI) (Yan et al., 1997). This is important 
because Cdk inhibition is known to activate NFKB (Perkins et al., 1997). Thus a 
TSA induced down-regulation of CKIs may in turn inhibit NFtd3 activation. Also, 
TSA is known to up-regulate HDAC1, 2 and 3 expression during an initial six 
hour period (Dagond and Gullans, 1998), a situation that may lead to an early 
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increase in HDAC activity. It is shortly after this period LPS-stimulated NO 
production begins. Alternatively cell treatment with TSA may lead to an up­
regulation of an inhibitor of LPS-stimulated NO production, although this 
inhibitor is not likely to include 11d3a since earlier work in this chapter (section 
5.4.2) has shown that its degradation is not involved in LPS-stimulated NFKB 
activation in the RAW cells. 
In addition, the paradoxical down regulation of gene expression by TSA has been 
recently reported by others. Nair et al., (2001) demonstrated that TSA treatment of 
HeLa cells led to the down-regulation of cyclin Bland cyelin A, and that this 
down-regulation was not dependent on de novo protein synthesis. This suggests 
that TSA is also able to inhibit the activity of certain HATs and therefore the 
transcription of genes acetylated by these HATs. 
5.4.8 Summary 
In summary the aim of this chapter was to better characterise the cell signalling 
pathways involved in LPS-stimulated NFKB activation in macrophages due to the 
relevance this has to NFId3 activation in the inflamed intestine. The work 
presented here demonstrates a complex network of pathways involved in the 
modulating NFKB-mediated gene transcription (Fig 5.39). 
Initially, the PKC, p38 MAP kinase, ERK, and Src kinase pathways were 
hypothesised to be involved in LPS-stimulated NFKB activation, and that HATs 
were involved in modulating NFKB-mediated gene transcription. Subsequently, 
PKCe was shown to be involved in modulating the transactivation potential of 
NFlcB, probably, through the ability of NFKB to recruit transcriptional co­
activators such as HATs. The p38 MAPK pathway was shown not to be involved 
in LPS-stimulated NFKB activation, but that the PKB pathway might instead be 
responsible for the inhibitory effects of SB, when SB was used at high 
concentrations (10 J..LM). In addition, neither the ERK or Src kinase pathways were 
shown to be involved in LPS-stimulated, NFKB-mediated, gene transcription. 
However, the inhibitory effect of high doses of the Src inhibitor PP2 indicated that 
JAK2 might be involved instead. Use of the specific JAK2 inhibitor confirmed 
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this hypothesis although it is not possible to determine whether the inhibition of 
JAK2 led to a decrease in NO production due to an effect on transactivation 
through the KB or GAS response elements. Finally, use of the HDAC inhibitor 
TSA demonstrated that when histone deacetylation was blocked, NO production 
was actually inhibited. This result is perhaps indicative of the broad ranging action 
of TSA on gene transcription, as it seems likely that TSA treatment leads to the 
up-regulation of an inhibitor, either of NFKB activity, or of iNOS activity. 
Thus, in intestinal inflammation, PKCe, PKB, JAK2 and HATslHDACs may all 
be important in mediating the NFKB-mediated gene transcription of macrophages. 
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Fig 5.39 LPS-stimulated cell signalling pathways leading to iNOS expression 
and subsequent NO production 
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The NFKB signalling pathway in rat TNBS..colitis 
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6.1 Introduction 
Experimentally induced 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis, 
originally established by Morris et ai., (1989) is a commonly used experimental 
model that shares many of its characteristics with Crohn's disease. For example, 
TNBS induces an acute inflammation of the classic delayed-type hypersensitivity 
reaction with a T H 1 type profile (Neurath et al., 1995), resulting in a transmural 
granulomatous colitis (Neurath et al., 1996b). Similarly, CD is characterised by a 
prevailing TH1 cytokine profile (Niessner and Volk, 1995; Parronchi et al., 1997) 
as well as transmural granuloma (Crohn et al., 1933; Present et ai., 1966). 
In TNBS-induced colitis inflammation is induced primarily through the activation 
of T cells by TNBS, a contact sensitising hapten. However, TNBS-induced colitis 
is not purely T-cell mediated. The initial mode of TNBS action is through direct 
toxicity at the site of administration, with the severity of the inflammation 
dependent upon the magnitude of the initial injury (Yamada et aI., 1992). Also, 
colonocytes can metabolise TNBS to form reactive oxygen species that are 
themselves pro-inflammatory due to their mediation of tissue injury 
(Keshavarzian et ai., 1992). Furthermore, for TNBS to enter the mucosal tissue it 
must be administered in an ethanol vehicle that itself degrades the mucus 
protecting the mucosal epithelium, thereby inducing inflammation (Wallace et al., 
1985). 
Currently, only two studies have been published on the role NFKB in TNBS­
colitis. In both these studies, p65 antisense phosphorothioate oligonucleotides 
were used to suppress TNBS induced colitis (Neurath et aI., 1996; Neurath and 
Pettersson, 1997), providing direct evidence of the central importance of the p65 
subunit to the inflammation generated in this model. 
More recently, De Plaen et ai., (1998) have demonstrated the activation of NFKB 
associated with inflammation in the small intestine of rats injected intra-Iumenally 
with platelet-activating factor (PAF). Also, NFK::B activation has been 
demonstrated in passive anaphylaxis in the rat small intestine induced by intra­
venous challenge with the cognate antigen following intra-peritoneal sensitisation 
with 19B anti-dinitrophenyl monoclonal antibody (Tavares et aI., 1998). Thus the 
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importance of NFKB activation in experimentally induced colitis has been firmly 
established. 
As previously discussed, evidence from chapter three, and work predating this 
study (Ellis et aI., 1998), suggesting the existence of increased NFKB activity 
(chapter three) and IKBa expression (chapter three) in the non-inflamed intestinal 
tissue of CD patients. Moreover, in the previous work, neither NFKB activity nor 
IKBa protein expression was assessed in non-CD intestinal inflammation. Thus it 
remains unknown whether increased NFKB activation in inflamed and non-
inflamed tissue are traits specific to CD. As such it is important to determine 
whether the same increases occur during intestinal inflammation in a nonnal 
individual. 
In addition, whilst NFKB activation has been demonstrated in the inflamed tissue 
of experimentally induced colitis, no attempt has been made to examine the effect 
of this inflammation on other members of the NFJd3 signalling pathway. For 
example neither IKBa nor Bcl-3, which were examined in chapter three, have 
been examined in experimentally induced colitis. Furthermore, evidence in 
chapter three indicated that IKBa may be unable to inhibit NFKB activation in the 
inflamed intestine. Instead, NFKB activation might be occurring through the 
alternate route such as IKBB degradation and therefore, IKBB protein levels may 
be important in the inflamed intestine. Indeed, IKB~ is preferentially degraded in 
response to stimuli that induce long-term inflammatory responses (Verma et aI., 
1995; Thompson et al., 1995), such as TNBS. In addition, PKCe, identified in 
chapter five as having a role in LPS stimulated NFKB activation in macrophages, 
has yet to be examined in an experimentally induced colitis. This is important, 
because an increase in PKCe expression may in tum increase NFlcB-mediated 
gene expression. 
As such the aims of this chapter were as follows. Firstly, to confirm that NFKB 
activation occurs in the TNBS induced inflammation of the intestine and whether 
there are differences in activation in inflamed and non-inflamed intestinal tissue. 
Secondly, to detennine whether an increase in NF'ICB activity in the TNBS treated 
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intestinal tissue is associated with increased PKCe protein expression. Thirdly, to 
detennine whether the inhibitors of NFKB are degraded, namely lK:Ba, IKBP and 
Bcl-3, in inflamed tissue compared to non-inflamed. 
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6.2 Methods 
6.2. 1 Approach 
Both inflamed and non-inflamed intestinal tissues from TNBS-treated rats were 
examined and these tissues compared to those from identical intestinal regions in 
a control (Sham operated) group of animals. To determine whether inflammation 
in one section of the intestine was able to affect the NFtd3 signalling pathway in 
another non-inflamed section, NFKB activation was assessed by EMSA. To 
confirm that changes in NFKB activity did not simply reflect changes in NFKB 
expression, Western blotting was used to assess the protein levels of p65 and p50. 
Both p65 and p50 have previously been shown to be constituents in the NFKB 
dimer activated in both TNBS-induced colitis (Neurath et al., 1996) and in CD 
(Schreiber et ai., 1998; RogIer et al., 1998). Western blotting was also used to 
assess the protein levels of PKCE, IKBa, lKl3~ and Bcl-3, in both inflamed and 
non-inflamed TNBS treated tissue, and in Sham operated, control tissue. 
6.2.2 Rat intestinal tissue 
Full details of the rat intestinal tissue are given in section 2.2. Briefly, in TNBS­
treated animals only the distal colon was inflamed. The proximal colon thus 
represents non-inflamed tissue. After sacrifice, 2 cm long sections of the proximal 
and distal colon were dissected from the Sham-operated and TNBS-treated 
animals (see section 2.2). This resection tissue was lysed using an identical 
method to that used in chapter three for the human intestinal tissue (see section 
2.7.1). Aliquots of the original lysate were used for all EMSA and Western blot 
assays. 
6.2.3 EMSA of rat intestinal tissue 
NF1d3 activity in the samples was measured by EMSA as previously described 
(see section 2.7) with samples loaded to yield equal protein content in each lane. 
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6.2.4 Western blotting for p65, pSG, hcBa, BcJ-3, and PKCe 
The protein expression of specific proteins in the samples was accomplished by 
Western blotting. Western blotting was carried out as previously described (see 
section 2.8) with samples loaded to yield equal protein content. The samples used 
in these experiments were derived from the same lysates that were used in the 
EMSA. 
6.2.5 Statistics 
A tissue sample from one animal represents a sample number of one (n=1). If two 
animals were sampled this constitutes a sample number of two (n=2). The sample 
number used is stated in the figure and table legends. Results are expressed as 
mean ± standard error of the mean (SEM). To determine statistical significance, 
results were analysed using a Mann-Whitney V-test (Wardlaw, 1985) with the 
critical threshold value of p<O.05 considered to be significant. 
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6.3 Results 
6.3.1 Visual obsewation of the intestine in rat TNBS-induced colitis 
Visual observation of the samples revealed the distal colon to be inflamed in the 
TNBS treated animal group (Fig 6.lb) when compared to the Sham treated group 
(Fig 6.1a). Distal intestinal tissue from the TNBS-treated group was much thicker 
than the Sham operated controls or the tissue from the proximal region of the 
colon in the TNBS-treated group. Also, the tissue colour of the distal samples 
from the TNBS group appeared much a darker red colour indicating well­
advanced inflammation and necrosis. 
a b 
Figure 6.1 Sham-operated and TNBS-treated rat large intestine 
Mice were Sham operated (a) or TNBS (b) treated for 7 days before sacrifice. 
The large intestine was removed and photographed. Arrows indicate the distal and 
proximal regions from which tissue was taken. The distal region of the TNBS 
treated colon appears much thicker and red compared to the Sham operated 
(control) tissue, whilst the proximal region of the TNBS treated colon more 
closely resembles that of the control tissue. 
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6.3.2 NF1(B activity in inflamed and non~inflamed regions of the colon in 
the rat TNBS-induced colitis 
To determine whether NFKl3 activity was increased in inflamed and non-inflamed 
intestinal tissue from TNBS-treated rats when compared to Sham operated 
(control) tissue, levels were measured by EMSA. In the TNBS-treated group 
NFKB activity was found to be significantly higher in the inflamed distal large 
intestine (TNBS-distal) than both the non-inflamed proximal tissue (TNBS­
proximal) from the same animal and the control tissue (Sham-distal) (Fig 6.2). In 
the Sham operated intestine, there was no significant difference in NFKB activity 
between the distal and proximal regions, suggesting that such changes were due to 
inflammation alone, and not the region of intestine being studied. 
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Figure 6.2 NFKB DNA-binding activity in TNBS-colitis 
EMSA for NF1d3 DNA-binding activity: a) image of EMSA film, b) Optical 
density (OD) data plotted as mean en = 9) ± SEM. Results show significantly 
increased NFKB activity in the distal TNBS tissue compared to all other tissue 
types (* = p<0.05). 
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6.3.3 Levels of NFICB subunits in rat TNBS-induced colitis 
To assess the protein levels of the NFlcB subunits p65 and p50, Western blotting 
was used on the same intestinal tissue in which NFKB DNA-binding activity had 
been measured. Neither p65 (Table 6.1) nor p50 (Table 6.2) levels were found to 
significantly differ between either the TNBS and Sham groups or between 
proximal and distal intestinal tissue. This indicates that the increase in NFKB 
DNA-binding observed in the TNBS-Distal tissue (Fig 6.2) is as a result of 
increased NFKB activation and not constant activation but with increased 
expression of the subunits and hence DNA-binding levels. 
Table 6.1 p65 levels in distal and proximal regions of rat colon after Sham or 
TNBS treatment. 
CdCd S
......a) Cd 
.-<
SCd ..... K 
...... CIl P< 
r/,l .,..., 0
..... l-IQ Q £ I Po. iI (/l I C/'J 
~ g t=Q~ 
..c Z ~ 
C/'J ~ (/l ~ 
b) 
Mean 417 235 352 115 
SEM 151 63 112 41 
Protein levels of p65 were assessed by Western blotting. a) image of Western blot 
film; lane 1 =Sham-Distal, lane 2 =TNBS-Distal, lane 3 =Sham-Proximal, lane 
4 = TNBS-Proximal. b) Data expressed as mean (n = 9) and SEM. No significant 
difference in the relative protein levels of p65 was found between any of the four 
groups of tissues. 
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Table 6.2 p50 levels in distal and proximal regions of rat colon after Sham or 
TNBS treatment. 
a) 
b) 
pSO levels (arbitrary units) 
Mean 222 594 231 230 

SEM 75 234 111 46 

Protein levels ofp50 were assessed by Western blotting: a) image of Western blot 
film, b) Data expressed as mean (n = 9) and SEM. No significant differences in 
relative p50 levels were found between any of the four groups of tissues. 
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6.3.4 PKC£ expression in rat TNBS-induced colitis 
To determine whether changes in the expression of PKCe were associated with 
increased NFKB activity, levels of PKCe protein were assessed in inflamed 
intestinal tissue, by Western blotting. A significant increase in PKC£ protein 
expression was observed in TNBS-Distal (inflamed) tissue compared to Sham­
Distal (control) or TNBS-Proximal (non-inflamed). No significant difference was 
observed between the proximal and distal regions in the Sham treated animals 
(Fig 6.3). This indicates that PKCe expression is up-regulated in the inflamed 
intestine, and that there are no differences in the expression of PKCe between 
different regions of the intestine. 
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Figure 6.3 PKCE levels in distal and proximal regions of rat colon after Sham 
or TNBS treatment. 
Relative protein levels of PKCE, assessed by Western blotting: a) image of 
Western blot film, b) Optical density (OD) data plotted as mean (n =5) ± SEM. 
Results show significantly increased PKCE protein levels activity in the TNBS­
Distal tissue compared to all other tissue types (* =p<O.05). 
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6.3.5 Levels of ITcB family members in a rat TNBS model of colitis 
To determine the levels of the IKE family members, IleBa, IKBB, and Bc1-3 in the 
rat intestinal tissue they were measured by Western blotting. Levels of IKBa were 
found to be signicantly (p<O.05) higher in the inflamed (TNBS-distal) tissue 
compared to the control (Sham-distal) tissue (Fig 6.4). Also, within the Sham 
treated animals IKBa levels were found to be significantly higher (p<O.05) in 
proximal tissue compared to distal. However, this difference was lost in the TNBS 
treated tissue (Fig 6.4). This indicates that not only are IleBa levels increased in 
inflamed tissue compared to non-inflamed tissue from the control animals, but 
also that IKBa levels vary with intestinal region with IKBa expression being 
higher in the proximal tissue than the distal. 
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Figure 6.4 I lCBa levels in distal and proximal regions of rat colon after Sham 
or TNBS treatment. 
Relative protein levels of IKBa, assessed by Western blotting: a) image of 
Western blot film, b) Optical density (OD) data plotted as mean en = 9) ± SEM (* 
= p<O.05 as compared to Sham-Distal). Results show significantly increased 
IlCBa protein levels in the TNBS-Distal tissue compared to Sham-Distal tissues, 
and significantly increased IKBa protein levels in Sham-Proximal and TNBS­
Proximal tissue compared to Sham-Distal. 
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Levels of IKBP did not differ significantly between the Sham and TNBS treated 
groups or between the distal and proximal regions (Table 6.3), indicating that its 
expression did not change in inflamed tissue or alter with the intestinal regions 
studied. However, it must be noted that the high level of error associated with 
these mean values might mask differences that could be revealed if higher sample 
numbers were measured. 
Table 6.3 IKB~ levels in distal and proximal regions of rat colon after Sham 
or TNBS treatment. 
';3
'"@ S
'"@ S .....
.....';3 ..... ><
...... ell ><
......
..... 0 8'" I-<0 0...Cl 0...I I 
I en I IZla) ~ ~ 
..c:: ~ ..c:: ~ 
r/.l Eo-< iZl ~ 
b) 
Sham- Sham- TNBS­ TNBS-
Distal Proximal Distal Proximal 
M~rul·. 
(OD) 
SEM 67 140 191 299 
Relative protein level of IKBP, assessed by Western blotting: a) image of Western 
blot film, b) Optical density (OD) data expressed as mean (n = 9) and SEM. 
Results show no significant difference in IKBP protein levels between any of the 
four sets of tissue. 
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Bcl-3 levels were not found to significantly differ between TNBS-treated and 
Sham-operated tissue. However, as for IKBa, a significant difference was seen 
between the proximal and distal regions of the colon. However, in this case, Bcl-3 
levels were significantly (p<O.05) higher in the distal colon compared to the 
proximal colon (Fig 6.5), the reverse of the findings for 11d3a (Fig 6.4). This 
indicates that Bcl-3 expression varies with intestinal region but not with 
inflammation.. 
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Figure 6.S Bel-3 levels in distal and proximal regions of rat colon after Sham 
or TNBS treatment. 
Relative protein levels of Bc1-3 measured by Western blotting: a) image of 
Western blot film, b) Optical density (OD) data plotted as mean (n = 5) ±SEM 
(+++ =p<O.OOl as compared to Distal tissue). The data show that Bcl-31evels do 
not differ significantly between the TNBS-treated and Sham-operated tissues. 
However, levels of Bcl-3 protein are significantly lower in the Proximal tissues 
than in the Distal tissues. 
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6.4 Discussion 
The work undertaken here set out to compare the results already gathered on 
NFKB activity in CD (Chapter 3), with those from an animal model of colitis. For 
this purpose, the rat TNBS model of colitis was used which is both well 
characterised and shares a number of characteristics in common with CD. Both 
the activity of NFKB, and the expression of Ilc13 family members were measured. 
This was accomplished by using tissue taken from both the non-inflamed 
proximal colon (appearance similar to Sham treated animals; Fig 6.1a) and the 
inflamed distal colon (dark red, enlarged tissue; Fig 6.1 b) of the TNBS treated 
animals, as well as non-inflamed tissue from corresponding locations in Sharn­
operated animals (Fig 6.1a). 
In common with the results for CD tissue, NFKB activation was demonstrated in 
inflamed TNBS-distal tissue (Fig 6.2). However, NFKB activation in the non­
inflamed tissue from the TNBS treated animals (TNBS-proximal) was found not 
to significantly differ from NFKB activity levels in the Sharn-operated animals 
indicating that NFlCB activation in inflamed tissue need not be associated with 
NFld3 activation in non-inflamed tissue. Also, the observed increase in NFKB 
activity in TNBS-distal tissue cannot be attributed to increased p65 or p50 
expression as the levels of these subunits were shown to remain stable (Tables 6.1 
& 6.2). However, the levels of the other potential NFKB subunits such as c-rel, 
have not been assessed here. This might prove important because whilst p65 and 
p50 are essential in the initiation phase of inflammation, there is some evidence to 
suggest that c-Rel may become more prevalent in the activated NFKB complex as 
the duration of an inflammatory response progresses. For example, it has been 
recently shown that administration of p65 antisense in the murine DSS model of 
colitis effectively reduces the level of intestinal inflammation only when 
administered early on in the DSS treatment regime (Murano et al., 2000). This 
suggests that p65 has a less important role in an established inflammatory 
response. 
In chapter five PKC€ was identified as a potential component in the pathways that 
induce NFld3 activation. To further examine its role in NFKB activation protein 
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levels of PKC€ were assessed. Expression of PKC€ was found to be significantly 
increased in the inflamed Distal-TNBS tissue when compared to the Distal-Sham 
tissue (Fig 6.3) and increased PKC€ protein levels are therefore associated with 
increased NFlCB activation (Fig 6.2). Recently, confirmatory work by others has 
demonstrated increased levels of PKC€ in the particulate fraction of the inflamed 
intestinal tissue of TNBS treated mice (Chang et al., 2000). The fact that PKC€ is 
up-regulated in inflamed intestinal tissue lends further weight to the hypothesis 
that PKC€ is involved in NFKB activation since both increased PKC€ protein 
expression and NF1d3 activity appear to occur together. 
To expand on the previous work done on the NFlCB signalling pathway in the 
TNBS model of colitis and to allow comparisons to be made with chapter three, 
the work carried out here examined the protein levels of the IKB family members, 
IlCBa, 11(B~ and Bc1-3. 
Both p65 and c-Rel containing NFKB dimers are inhibited by IKBa (Henkel et al., 
1993 & Pando et ai., 2000), and as such this IKE family member is likely to have 
an important role in colitis. Assessment of IlCBa levels in the TNBS model of 
colitis revealed a significant (p<0.05) increase in the inflamed TNBS-distal tissue 
compared to the control, Sham-distal tissue (Fig 6.4). Thus increased b:Ba 
expression was observed in the same tissue as increased NFlCB activity. Whilst 
IlCBa levels have not been previously assessed in an animal model of colitis, this 
finding is in agreement with that presented in chapter three, where increased IKBa 
levels were detected in inflamed CD tissue (Fig 3.7). 
As discussed in chapter three, the concomitant increase in IlCBa levels and NFKB 
activity seem, at first, contradictory. However, they can be explained as follows. 
NFKB activity can upregulate IKBa expression through the presence of a KB 
enhancer element in the llCBa gene promoter (Ito et al., 1994). As it is unlikely 
that all cells within the inflamed tissue will have been activated at the same time, 
it is possible that some cells may have only recently undergone NFKB activation, 
while NFKB activation in other cells may have taken place some time ago. In the 
cells that have recently undergone NFlCB activation, 11d3a levels will not yet have 
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been up-regulated, whilst in cells in which NFKB has been activated for longer, 
IKBa expression will have been induced. Thus, at the level of whole tissue, 
increased IKBa expression and NFKB activation can occur at the same time. As an 
alternative to this theory, the NFKB activity observed may have escaped the 
regulatory control of IKBa, and hence produced the inflanunation seen. 
IKBa primarily inhibits the p6S/pSO NFKB dimer. However, the composition of 
the dimer activated in the distal TNBS group has not been elucidated. Therefore, a 
different dimer composition may be involved that is not inhibited by IKBa, 
although this seems unlikely due to the recently demonstrated role for p65 
(Neurath et al., 1996; Murano et aI., 2000) and pSO (Seganin et ai., 2000) in 
experimental colitis. Furthermore, as discussed in both chapters three and five, 
IKBa degradation need not be required for NFKB activation, particularly in 
macrophages/monocytes (chapter five) which are one of the prevalent cell types in 
which NFKB activation occurs in CD (RogIer et at., 1998; Ellis et aI., 1998). 
Instead, post-transcriptional modification of IKBa itself, i.e. via phosphorylation, 
has been postulated to limit the ability of IKBa to inhibit NFKB activity (Bourke 
et al., 2000). Also, the phosphorylation ofNFKB during long-term activation (>72 
hours) has been shown to prevent its inhibition by IKBa (Thompson et at., 1995). 
Thus, during long-term activation, the inhibitory control of IKBa over NFKB 
activity can be lost. 
To explore the possibility that other IKB subunits may play a role in TNBS­
induced colitis, the levels of IKB~ and Bcl-3 were examined. Unlike IKBa, IJCB~ 
levels were not found to significantly differ between the TNBS treated and Sham 
operated animals or between the distal and proximal regions of the colon (Table 
6.3). The lack of any change in IKB~ protein levels in the TNBS treated tissues as 
compared to the Sham operated tissues suggests that h:B~ is not involved in the 
NFKB activation that occurs in TNBS-induced inflammation. If it were, its 
degradation would be detected because, due to the lack of a KB response element 
in the IKB~ promoter (Baldwin, 1996; Johnson et ai., 1996), IKB~ expression is 
not up-regulated by NF'KB activity and therefore its degradation is long-lived. 
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Also, a further reason to reject the idea that IKB~ plays a major role in TNBS­
induced colitis is that Itd3~ is expressed predominantly in the intestinal epithelial 
cells (Wu et ai., 1999) which make up only a small proportion of the tissue 
involved in the TNBS-induced inflammation. 
In addition to the expression of IKB~, the protein levels of the Itd3 family member 
Bc1-3 were ~lso assessed. Bc1-3 is believed to interact with pSO and/or pS2 
containing NFKB dimers (Dechend et ai., 1999). Of these, the pSO homodimer has 
been found in both the normal intestine (De Plaen et aI., 1998) and in the inflamed 
CD intestine (Ardite et ai., 1998). The function of Bcl-3 appears to be the 
modulation of the transactivation of NFKB dimers (Dechend et al., 1999). In the 
present study Bcl-3 protein levels were not found to significantly differ between 
the TNBS treated and Sham operated tissues (Table 6.4). This is in contrast to the 
findings in chapter five in which nuclear levels of Bc1-3 were shown to decrease 
in RAW cells in response to LPS stimulation, although this loss of Bcl-3 was 
short lived. 
Currently, no other in vivo work has looked at the changes in Bcl-3 protein 
expression that occur during an inflammatory response. However, Bc1-3 levels in 
alveolar macrophages from patients with acute respiratory distress syndrome have 
been shown to decrease via a proteolytic mechanism (Moine et ai., 2000). The 
work presented in this chapter does not support a role for the modulation of Bc1-3 
protein levels in TNBS induced colitis. However, this may be due to the analysis 
of Bc1-3 expression at a whole tissue level rather than within specific cell types 
such as macrophages. As such, the Western blotting technique used here may not 
be sensitive enough to detect the small changes that may be occurring in Bcl-3 
protein levels. 
Also, the decreased Bcl-3 levels in macrophages (as demonstrated in chapter five), 
whilst potentially important, might be masked be a lack of change in the rest of 
the tissue. Furthermore, the Bcl-3 degradation observed in chapter five may occur 
only in response to transitory NFKB activation, whilst Bcl-3 degradation may 
have no part to play in the long-term activation of NFKB which occurs in the 
TNBS model of colitis. 
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Interestingly, the work presented here demonstrates that Bcl-3 protein levels are 
higher in the distal colon compared to the proximal. This is in contrast to IKBa 
levels, which were significantly higher in the proximal colon compared to the 
distal in the Sham operated animals. This distribution pattern will undoubtedly 
have consequences on the pattern of gene expression in these intestinal regions, 
and seems likely to reflect the differing environment of the intestine in the 
proximal and distal regions. 
However, while IKBa. and Bcl-3 protein levels differed with colonic region, 
neither p50 or p65 subunit levels changed nor was overall NFKE activity affected. 
As such, these changing IKE levels may affect the way in which NFlCB is 
activated, and/or the genes that are targeted by activated NFKE. 
IKBa is down-regulated in the distal colon (Fig 6.4) where there is a particularly 
high bacterial load and hence a greater inflammatory stimulus. This might be 
because IKEa. is less effective at inhibiting NFld3 activation in the inflamed 
intestine, a situation s,¥ggested by the data from chapter three and six (as 
discussed earlier). The role of IKBa in these distal tissues may be replaced by 
another IKE family that is more resistant to degradation. 
Bc1-3, on the other hand, is known to modulate the activity of pSO homodimers, 
and may help repress transcription from pro-inflammatory genes (Franzoso et at., 
1997) and induce transcription from others (Dechand et al., 1999). The higher 
expression of Bc1-3 in the distal colon may therefore help suppress inflammation 
triggered by the high bacterial load present there. 
6.4. 1 Summary 
In summary, while NFKE activity was increased in inflamed intestinal tissue, this 
was not the case for non-inflamed tissue and therefore the increased NFKB 
activity found in the non-inflamed tissue from CD patients (chapter three) may be 
specific to CD. In addition, associated with the increased NFlCB activity in the 
inflamed intestine was an increase in the protein levels of PKCE, strengthening the 
hypothesis that PKCE is involved in mediating NFKB activity as was suggested in 
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chapter five. In confirmation of the finding from chapter three (fig 3.7), IKBa. 
protein levels were increased in the inflamed TNBS intestinal tissue, suggesting 
that 11d3a may have lost its inhibitory control of NFKB activity in the inflamed 
intestine. Finally, levels of the other IKE family members, IKB~ and Bcl-3, were 
unchanged in the inflamed tissue indicating that they are not involved in TNBS­
induced intestinal inflammation and NFKB activation. However, both IKBa. and 
Bcl-3 protein levels were shown to vary with intestinal location, and thus are 
likely to effect NF1d3-mediated gene expression in these regions, probably due to 
normal inflammatory/immuno-regulatory functions in these areas. 
-
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The overall mm of this thesis has been to investigate NFlCB activation in 
inflammatory processes, focusing on intestinal inflammation. To this end, in 
chapter three, NFKB activity was investigated in CD, a chronic inflammatory 
disease of the intestine. NFKE activity was found to be increased in inflamed CD 
tissue confirming the results of Ellis et aI., (1998) and confirmed by the results of 
others (Schreiber et al., 1998; RogIer et ai., 1998; Theile et ai., 1999). This 
increased activity was not reflected in a change in p65 or p50 subunit expression, 
indicating that the underlying expression of NFKB does not change, only its 
activation. Associated with this increased NFKB activity was an increase in IKBa 
protein levels in the inflamed CD tissue, although this finding disagrees with that 
of another study in which lower sample numbers were used (Schreiber et al., 
1998). Levels of another IKE family member, Bc1-3, did non significantly differ 
between inflamed CD, non-inflamed CD, and control tissue. 
In non-inflamed CD tissue, NFKB activity was increased in submucosal tissue, 
confirming the findings of previous work from this laboratory. Increased IlCBa. 
protein expression was also demonstrated in non-inflamed tissue. Interestingly 
this increase was found in biopsy tissue in which no increase in NFrd3 activity 
was observed. 
In chapter four, NFlCB activation was investigated in intestinal epithelial cells 
(IECs) since they are known to be one of the predominant cell types in which 
NFlCB activation occurs in the intestine. Initially, the potential stimuli of NFKB 
activation in IECs were determined in the human mucosal epithelial cell line, 
HeLa Ohio. In HeLa Ohio's, IL-IB, LPS, and PMA were shown to induce NFKB 
activation. Interestingly, both IL-l ~ and LPS induced activation of NFKB dimers 
containing the p65 subunit, and to a lesser extent p50, whilst PMA-induced the 
activation of dimers containing p50 but not p65. When these same stimuli were 
used in the human IEC line, Caco-2, only LPS was found to stimulate the up­
regulation of an NFld3-mediated gene, namely TNFa.. To assess whether a 
combination of stimuli would be a more potent stimulus of NFKB-mediated gene 
expression, IL-l B, LPS, and TNFa., were used together, and were found to induce 
increased NO production from Caco-2 cells, indicating NFKB-mediated up­
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regulation of iNOS expression. As previously discussed (chapter four), mc are 
relatively unresponsive to pro-inflammatory stimuli, a situation which may reflect 
a requirement for a combination of stimuli for an inflammatory response to be 
induced. 
In chapter five, LPS-stimulated NFKB activation was assessed in the murine 
macrophage cell line, RAW 264.7. LPS was shown to induce the activation of 
NFKB dimers containing both the p65 and p50 subunits. This activation was not 
associated with 11C8a degradation. To better characterise the intra-cellular 
signalling pathways which mediate LPS-stimulated NFKB activation, the role of 
the PKC family, Src kinases, p38 MAPK, ERK, JAK2, and histone acetylation, 
were investigated. Through this work it was established that PKC£ is able to 
modulate LPS-induced NFKB activity, a finding that has been subsequently 
supported by other studies. Furthermore, JAK2 and PKB were both suggested to,! , be involved in the LPS-induced NFKB activation pathway, a hypothesis, 
subsequently supported by the work of others. Work in chapter five also 
demonstrated a possible role for the lK:B family member Bc1-3 in LPS-induced 
NFKB activation, as nuclear Bcl-3 levels were found to drop in response to LPS­
stimulation, although this work had a low number of observations (n=2). 
Currently no other studies are present in the scientific literature in which a role for 
Bcl-3 in inflammation has been investigated. 
In chapter six the NFKB activation pathway was examined in rat TNBS-colitis so 
that comparisons with the events occurring in CD could be made. Concurrent with 
the findings from chapter three, both NFKB activity and IKBa protein levels were 
found to be increased in inflamed tissue from the TNBS-treated rats. However, 
neither NFKB activity nor IKBa expression were increased in non-inflamed TNBS 
tissue. In contrast, neither Bc1-3 nor IKB~ protein levels were significantly 
different between inflamed and non-inflamed tissue, although their levels were 
shown to differ with intestinal region. Currently, the protein levels of IlCBa, 
IKBPO, and Bcl-3 have yet to be studied in any other published work, although 
NFKB activation in inflamed tissue from TNBS-treated rats has been previously 
demonstrated (Neurath et al., 1996). 
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Findings from chapter six also supported a role for PKCE in NFKB activation, as 
increased protein levels of PKC8 were associated with increased NFKB activity in 
inflamed intestinal tissue from TNBS-treated rats. This finding corresponds with 
the more recent finding of others, which demonstrated increased PKC£ levels in 
the particulate (nuclear) fraction of intestinal tissue from TNBS-treated animals as 
compared to controls. 
As discussed in chapters three and six, the increased NFKB activation in non­
inflamed CD tissue as compared to non-inflamed control tissue is suggestive of an 
underlying increase in the NFKB activity of the intestine in CD patients. Also, 
increased IKBa. protein expression was found to occur in non-inflamed tissue 
from CD patients as compared to non-inflamed controls, indicating that NFKB 
activity may be abnormally regulated in CD. To confirm that increased NFKB 
activity and IKBa protein levels were not normal manifestations of intestinal 
inflammation the NFKB signalling pathway was studied in experimentally induced 
TNBS-colitis in rats. NFKB activity and IKBa protein levels were found to be no 
different between non-inflamed tissue from TNBS-treated animals and non­
inflamed tissue from the identical intestinal region in Sham operated animals. This 
confirms that increased NFKB activity and IKBa protein levels in non-inflamed 
CD tissue is not a normal consequence of the presence of intestinal inflammation 
elsewhere in the intestine, and instead that in CD these increases may be 
indicative of some underlying abnormality. 
However, recent work by others casts doubt on the ability to sample unaffected 
non-inflamed tissue. In TNBS-induced colitis in the rat both iNOS and COX-2 
activities have been shown to be elevated four weeks after the macroscopic and 
histologic resolution of colitis (Asfaha et al., 2001; Warriner and Wallace, 2001). 
Since the expression of both iNOS (Xie et al., 1994) and COX-2 (Newton et al., 
1997) are mediated by NFKB, the presence of iNOS and COX-2 activity in non­
inflamed tissues may indicate that NFKB activity is also increased. 
Thus, the increased NFKB activity and IKBa protein levels detected in non­
inflamed CD tissue may be a residual effect of a previous episode of 
226 

.. 

Chapter 7 
inflammation. However, it seems unlikely that all of the non-inflamed CD tissue 
sampled will have been previously inflamed, and, furthermore, there is at present 
no evidence to suggest that these underlying changes in NFICB activity persist 
beyond four weeks. 
While reasons may exist to discount the presence of increased NFKB activity and 
IKBa expression in non-inflamed CD tissue, there are also a number of lines of 
evidence that suggest these findings are valid and represent an underlying detect 
in the intestine of CD patients. For example, there is strong evidence for a genetic 
element to CD (see section 1.5.5) with the inheritance of CD calculated to be 
equivalent to that of insulin-dependent diabetes mellitus (Parkes et aI., 1997). 
Moreover, a mutation of the leucine-rich region (LRR) of the NOD2 gene has 
recently been associated with CD (Hampe et al., 2001; Hugot et ai., 2001 & 
Ogura et al., 2001a). 
NOD2 is involved in LPS-stimulated NFKB activation (Ogura et al., 2001a & 
Ogura et at., 2001h) and is expressed exclusively in cells of monocytic lineage 
(Ogura et ai., 2001h). Macrophages, a differentiated form of monocytes, are one 
of the predominant cell types in which NFlCB activation is known to occur in CD 
(RogIer et al., 1998; Ellis et al., 1998). mterestingly, macrophages have also been 
shown to spontaneously secrete higher levels of TNFa in CD (Zareie et al., 2001), 
the gene promoter of which is regulated by NFlcB (Malin in et al., 1997 & Shames 
et aI., 1999). Thus, abnormal LPS-stimulated NFKB activation in macrophages, 
may lead to increased TNFa production that has been observed in CD. 
Although there is strong evidence for abnormal regulation of NFld3 activity in 
CD, this does not mean that CD is the only disease in which this might occur. 
Increased NFKB activity has also been demonstrated in non-inflamed tissue in UC 
(RogIer et ai., 1998). Furthermore, in rheumatoid arthritis (RA) which, in 
common with CD, has a disease pathology involving chronic inflammation, an 
increased level of NFKB activity has been demonstrated in quiescent tissue 
(Marok et ai., 1996). It is, therefore, possible that abnormal NFx:B activation may 
form part of the aetiology of many diseases in which chronic inflammation 
occurs. 
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In contrast to this hypothesis, others have suggested that increased NFKB activity 
in non-inflamed tissue is a general attribute of the inflamed intestine (RogIer et 
al., 1998). The authors based this conclusion on work which showed an increase 
in the number of cells which stain positive for the active form of p65, not only in 
CD, but also in UC and non-specific colitis (RogIer et at., 1998). However, both 
CD and UC have genetic components to their aetiology that may involve the 
abnormal activation of NFKB (Hampe et aI., 2001; VanHeel et aI., 2002). Also, 
non-specific colitis is a term commonly used by clinicians when the intestinal 
inflammation observed can not be easily categorised into a more specific disease 
type e.g. CD. As such, an alternative interpretation of the results of RogIer et al., 
(1998) is that an underlying increase in NFKB activity can occur in a number of 
forms of intestinal inflammation, but that this occurrence may still be central to 
the disease aetiology. 
While abnormal NFKB activation may be involved in the aetiology of a broad 
range of chronic inflammatory diseases, it seems unlikely that a mutation directly 
affecting the NFKB or IKB family members would be involved, due to the far­
reaching implications that such mutations would likely have. For example, in 
IKBa -/- mice death occurs due to widespread inflammation (Klement et ai., 
1996). Also, in p65 -/- mice death occurs in utero at days 14-15 due to massive 
liver degeneration associated with hepatocyte apoptosis (Beg et aI., 1995a). 
Instead, mutations may affect signalling pathway components that are involved in 
the activation of NFKB in response to specific stimuli. 
Equally, mutations might occur in the leB elements of specific gene promoters, 
leading to the abnoffi1a1 expression of certain genes. Indeed, just such a mutation 
has recently been associated with both CD and DC, in which polymorphisms in 
the TNF promoter lead to increased TNPa expression through NFKB and Oct-l 
activity (Van Heel et al., 2002). Though the mutation itself does not directly 
induce increased NFKB activity, the production of TNFa, a potent activator of 
NFKB (Zhang et al., 2000b), would lead to increased NFKB activity throughout 
the intestine. 
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Also, the abnormalities in the NFlCB signalling pathway in non-inflamed CD 
tissue presented here need not solely be generated as a result of mutations present 
in the patient's genome. Instead, environmental factors may also play an 
important role. Indeed super-antigens, pathogens, and diet have all been 
implicated in the aetiology of CD. For example, a recent paper has shown an 
increase in the occurrence of CD in spouses after co-habitation (Laharie et ai., 
2001) suggesting a role for environmental factors in the development of CD. Also, 
diversion of the faecal stream is known to abolish intestinal inflammation in CD 
(Winslet et at., 1994), demonstrating that at least some constituent ofthe luminal 
contents is essential in perpetuating the pathology of CD. The inability to induce 
experimental colitis in abiotic animal models (Podolsky, 1997) further 
demonstrates a requirement for the presence of endogenous intestinal micro-flora 
for intestinal inflammation to occur. 
Another, previously unreported, finding presented here is the increase in IKBa 
protein levels found in the inflamed intestine of CD patients (chapter three) as 
well as inflamed tissue from TNBS-treated rats (chapter six). As discussed 
previously, this finding seems likely to represent the escape of NFKB activity 
from the inhibitory control of IKBa. in these tissues. This theory is supported by 
growing evidence in the literature which suggests that IKBa. is not the most 
important IKB member in the suppression of pro-longed NF1d3 activation. 
However, to confirm this hypothesis it would be necessary to study IlCBex. 
expression and NFKB activity at a cellular level to determine whether increases in 
both occur within the same or separate cells. Thus it is not possible to discount the 
alternate hypothesis in which increased IlCBa expression occurs in cells in which 
NFlCB activation has returned to control levels through up-regulated IKEex. protein 
levels. 
Interestingly, there are only two other studies which IKBa levels have been 
measured in the inflamed intestine. In the ftrst, IKBa. levels were measured in CD 
and DC tissue and compared to non-inflamed controls. Although IlCBa. levels 
were slightly increased in inflamed versus control tissue, this difference was not 
significantly different, probably due to the lower sample number used in this 
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study (Schreiber et al., 1998). In the second study, IKBa levels were measured in 
experimentally induced endotoxemia in mice. In this acute intestinal 
inflammation, IKBa and IKB~ proteins levels were reduced after 60 minutes and 
remained lower over the four hour period studied (Pritts et al., 2000). The 
difference between the results of Pritts et al., (2000) and the results presented here 
on inflamed tissue from CD patients and TNBS-colitis, is the period over which 
the inflammation examined occurs. The inflammation in both TNBS and CD 
occurs over days (TNBS), months or years, a much longer time period than that 
examined by Pritts et al., (2000). Indeed, the work of Pritts et al., (2000) which is 
carried out in the first hours of endotoxemia is more likely to share common 
characteristics with the situation observed in vitro e.g. rapid IKBa degradation 
following by IKBa up-regulation and decreased NFKB activity. 
In chapter five, PKCe, amongst other pathways, was shown to have a role in 
modulating NFKB activity in the murine macrophage cell line RAW 264.7. 
Furthermore, in chapter six, an increase in PKCe protein levels was associated 
with increased NFKB activation in rat TNBS-colitis, supporting the hypothesis 
that PKCe modulates NFKB activity. This hypothesis has recently been confirmed 
in macrophages taken from PKCE -/- mice in which LPS-stimulated NO 
production and NFKB activity was severely reduced (Castrillo et al., 2001). 
However, in contrast to the hypothesis presented in chapter five, where PKCe was 
postulated to improve the transactivation potential of NFKB through the 
phosphorylation of the p65 subunit, Castrillo et al., demonstrate that in PKCe -/­
macrophages, LPS-induced IKK activation is decreased compared to controls. 
This suggests that PKCe is directly involved in NFtcB activation and not just the 
modulation of its transactivation potential. This contrasts with the work presented 
here in which a non-specific PKCe inhibitor, bisindolymalemide (Bis), had no 
effect on LPS-stimulated p65 nuclear translocation. These different findings can 
be attributed to the fact that, in the present study, a murine tumour cell line was 
used, which is by definition abnormal and may not give an accurate representation 
of cellular function in vivo. The different findings may also reflect the fact that 
macrophages were stimulated with a higher concentration of LPS in the work 
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presented here than used in the study of Castrillo et al., (2001). The higher level 
of LPS used in the present study may stimulate NFKB activation through other 
non-specific pathways. Thus, the inhibition of PKC£ by Bis would have no effect 
on the nuclear translocation of NFKB as this may be mediated by other pathways 
activated through by the high concentration of LPS used. However, Bis may still 
block the LPS-stimulated increase in NFKB transactivation potential if this 
process is PKC£ specific. 
In chapter four, different stimuli were found to activate NF1d3 dimers of different 
compositions in the human epithelial cell lines HeLa Ohio and Caco-2, 
demonstrating that the p65 subunit is not always involved during NFKB activation 
in response to inflammatory stimuli. To date the most conclusive study completed 
to identify the cell types in which NF1d3 activation occurs in the inflamed 
intestine, has been carried out using co-staining for the active form of the p65 
subunit (RogIer et al., 1998). However, in the present study, the finding that 
NFKB dimer composition can vary in response to different stimuli indicates that 
the identification of cells containing active p65 may not give a fully representative 
picture of NFKB activation in the intestine. Not only does this suggest that the 
activation of other NFK:B subunits should be examined in the inflamed intestine to 
determine whether other cell types are involved, but it also vindicates the 
experimental approach taken here, in which total NFlCB activity has been assessed 
in intestinal tissue by EMSA as opposed to the measurement of a single subunit. 
Comparison of results from chapter four and five indicate that lECs are far less 
responsive to stimulation than macrophages. The level of p65 nuclear 
translocation observed in response to LPS was far high in the RAW cells than the 
HeLa Ohio ceUs, and the induction of NFICB-mediated gene expression was far 
higher in RAW cells than Caco-2 cells. As discussed in chapter four, the 
unresponsiveness of Caco-2 cells is likely to reflect an essential part of IEC 
function since in vivo IECs must remain in a non-inflamed state despite their 
continuous challenge with the pro-inflammatory stimuli of the intestinal lumen. In 
contrast, macrophages, which are shielded from the luminal contents behind the 
epithelial barrier, can afford a far high level of sensitivity to pro-inflammatory 
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stimuli so that they can react quickly if the epithelial barrier is breached. 
Interestingly, these differing sensitivities indicate that, for NFKB activation to 
occur in macrophages in CD (RogIer et ai., 1998), minimal stimulation is 
required. In contrast, for NFKB activation to occur in IEe in CD (RogIer et ai., 
1998) a combination of stimuli is required. Thus the NFKB activation that has 
been reported in IEC in the inflamed intestine (RogIer et al., 1998) may be due to 
the presence of numerous pro-inflammatory mediators produced from nearby 
cells, or the presence of an invading pathogen, or both. 
Evidence presented in chapter five demonstrates an LPS-induced down-regulation 
of Bc1-3 expression in RAW 264.7 macrophages. This finding is in agreement 
with previous work by Moine et al. (2000), where Bc1-3 levels were found to be 
decreased in macrophages from patients suffering from respiratory inflammation 
as compared to controls. However, in CD (chapter three) and TNBS induced 
colitis (chapter six), whole tissue levels of Bcl-3 were unchanged in inflamed 
tissue. As such, whilst Bcl-3 may be important in the regulation of gene 
expression during inflammatory responses in the intestine, its role is probably 
highly cell specific and may not solely involve regulation through its 
expression/degradation. 
In summary the findings from this thesis have produced several key conclusions 
about NFKB activation in relation to the inflamed intestine. Firstly, both NFKB 
activation and 11d3a protein are abnormally increased in non-inflamed intestinal 
tissue from CD patients, whilst in intestinal tissue from TNBS-treated rats this 
was not the case. This suggests the presence of an underlying abnormality in CD, 
which, as discussed, may have both a genetic and environmental component. 
Secondly, increased NF1d3 activation and IKBa protein levels can occur 
concomitantly in the inflamed intestine. As discussed, this may indicate that 
NF1d3 can escape the inhibitory control of IKBa. However, it is also possible that 
these increases occur in different cells and therefore for this hypothesis to be 
confirmed additional experiments would be required (described below). 
Thirdly, in IECs, pro-inflammatory stimuli common to the intestine, used in 
isolation, are relatively poor activators of NFKB or NFKB-mediated gene 
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expression. However, when used in combination, these stimuli are more effective. 
As already discussed, this may represent the fact that, in vivo, IECs are 
continuously exposed to pro-inflammatory stimuli yet must remain in a non­
inflamed state to maintain the epithelial barrier. It is for this reason that they are 
adapted to be relatively umesponsive to pro-inflammatory stimulation, perhaps 
mediated by an abnormal NFlCB activation pathway, and/or low cell surface 
receptor numbers. 
Lastly, in macrophages, PKCc appears to be involved in NF1d3-mediated iNOS 
expression and hence NO production. The data presented here suggests that PKCc 
acts on the transactivation potential of NFKB, although, in contrast, a more recent 
study suggests that PKCc is involved in IKK mediated NFlCB activation. As such, 
further experiments are required to clarify this issue (as described below). In 
addition, in the present study, JAK2 and PKB were suggested to be involved in 
LPS-stimulated NFKB expression, hypotheses later confinued by others. 
In conclusion, while this study has made a novel contribution to our 
understanding of the role of the NFKB signalling pathway in intestinal 
I 
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inflammation, due to the complexity of the pathways involved, many more 
experiments are now required to expand on these findings. 
7. 1 Future Work 
To further examine the role that genetics might play in the increased NFKB 
activation observed in CD, it would be interesting to generate a genetically 
modified murine model of colitis in which the NOD2 gene has been mutated to 
replicate the mutations associated with CD. Sensitivity of the intestine to pro­
inflammatory challenge could then be measured. Also, isolated macrophages 
could be studied to detennine the specific cell-type effect that these NOD2 
mutations have on LPS-stimulated NFKB activation. 
While p65, p50 and c-Rel have all been suggested to be present in the NFKB 
dimer activated in the inflamed intestine through the use of EMSA supershift 
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assays, all of these studies have used only a single KB oligonucleotide probe to 
make this assessment. However, different KB sequences are known to have 
different NFKB dimer binding affinities. Thus, the use of a range of KB probes to 
detect NFKB activity in both inflamed and non-inflamed CD tissue would yield 
more reliable information on the NFKB dimers involved and the extent of their 
activation in intestinal inflammation. 
The finding that NFKB activation may have escaped the inhibitory control of 
IKBa in the inflamed intestine is both novel and functionally significant. Thus it is 
important to confirm this finding. One means of doing so would be to utilise an 
ICC approach to identify, both the cells in which increased IKBa protein levels 
occurs, and the cells in which NFKB activation is occurring. This would allow the 
concomitant increase, within individual cells, of IKBa expression and NFKB 
activation, to be confirmed. In addition, the phosphorylation state of IKBa could 
be examined using antibodies specific for the phosphorylated form of IKBa, 
particularly to the CKII phosphorylation site, to determine whether post­
transcriptional modification of IKBa might be occurring in the inflamed intestine. 
Such modification may be responsible for the inability of IKBa to inhibit NFKB 
activation. Subsequently, the cell types identified as containing increased NFKB 
activation and IKBa protein levels, could be investigated in vitro, utilising long­
term stimulation (days) to determine whether this leads to the loss of NFKB 
inhibition by IKBcc 
To confirm the role of PKC£ in LPS-stimulated NFKB activation in macrophages, 
immuno-precipitation studies could be used to determine whether PKCc: is 
physically associated with NFKB during LPS-stimulation. Also, antibodies to the 
phosphorylated form of p65 have recently become available and it should be 
possible to use these to determine whether LPS-stimulation induces p65­
phosphorylation, and also whether use of the PKC inhibitor Bis is able to prevent 
this. In addition, the use of interference RNA to knockout specific PKC isoforms 
and then determine their effect on LPS-stimulated NO production, could confirm 
the role of PKCe in NFKB activation. 
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To investigate the possibility of a phasic shift in NFKB dimer composition in 
intestinal inflammation, a time point analysis of TNBS-colitis could be carried 
out. Indeed, this model is known to enter a more chronic stage after 14 days (the 
time point examined in this study) when T cell numbers are seen to dramatically 
increase in the lamina propria (Van Rees et al., 1997). It would therefore be 
interesting to map NFKB activation and dimer composition over a number of time 
points in the TNBS-induced colitis, up to and beyond the 14 day time point. 
Currently we understand only a fraction of the mechanisms and functions of 
NFKB activation in the inflamed intestine and there are innumerable possible 
approaches available to answer the questions left out-standing. However, the 
continued investigation of this complex signalling pathway is likely to yield yet 
more important insights into intestinal inflammation that may prove to be crucial 
in our ability to understand and control intestinal inflammatory events. 
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Figure 8.1 A nitrite standard curve used for NO measurement by Greiss 
assay 
A typical nitrite standard curve. Mean (n=3) ± SD (but too small to discriminate). 
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Figure 8.2 A protein standard curve used for the BioRad™ protein assay 
A typical BioRad assay standard curve. Data plotted as mean (n=3) ± SD. 
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measurement by ELISA 
TNFa. standard curve. Data plotted as mean (n=2) ±SD. 
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Figure 8.5 NFKB activity adjusted for Oct-l activity in intestinal biopsy tissue 
from CD and control patients 
Intestinal biopsy tissues (n= 7) were assessed for NFKB (Fig 3.3) and Oct-l (Fig 
3.4) activity by EMSA. NFld3 activity was then adjusted for Oct-l activity and 
plotted as mean ±SEM. The data show that, when adjusted for Oct-l loading, 
NFKB activity was not significantly different between any of the three tissue 
types. 
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Proximal Colon 
2 F 30 CD Proximal Colon Terminal Ileum 
3 F 42 CD Terminal Ileum Proximal Colon 
4 F 30 CD Proximal Colon Terminal Ileum 
5 M 31 CD Proximal Colon Terminal Ileum 
6 M 32 CD Distal colon Terminal Ileum 
7 M 39 CD Distal colon Proximal colon 
8 F 32 Control NA Proximal Colon 
9 F 20 Control NA Proximal Colon 
10 F 59 Control NA Terminal Ileum 
11 F 21 Control NA Distal Colon 
12 M 40 Control NA Terminal Ileum 
13 M 38 Control NA Terminal Ileum 
]4 M 40 Control NA Proximal Colon 
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Table 8.1 Human intestinal biopsy tissue, patient details; age, sex, and disease 
location 
Patient details for biopsy tissue. Analysis of data using Students t test showed that 
there was no significant difference between CD patients and controls with regards 
to age, sex and the intestinal location of tissues examined. 
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